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Introduction and objectives 
 
 
 
The history of insulin as a therapeutic drug dates back to 1922 when it was successfully 
administered in the treatment of diabetic mellitus (Brange, 1987). Until now, insulin is 
indispensable in the treatment of insulin-dependent diabetes mellitus (IDDM) and it is 
frequently indicated for non-insulin-dependent diabetes mellitus (NIDDM) as well. 
 
Although the peroral route is considered to be the most convenient way of drug 
administration, it is not suitable for the delivery of peptides and proteins due to chemical or 
enzymatic degradation in the gastro-intestinal tract and epithelium and to the limited 
membrane permeability of the gastro-intestinal epithelium. In addition, peptides that have 
passed the gastro-intestinal barriers are exposed to a high first-pass metabolism in the liver. 
Furthermore, the gastro-intestinal transit time of pharmaceutical dosage forms shows a high 
intra- and intersubject variability. Consequently, it is difficult to develop a safe and reliable 
peroral delivery system for peptides having a narrow therapeutic range. This explains why 
most peptides are currently delivered via the parenteral route (Lee et al., 1991a; Carino and 
Mathiowitz, 1999). 
 
Currently, systemic delivery of insulin is achieved by subcutaneous or intramuscular 
administration. Since adequate metabolic control in diabetics is essential to avoid chronic 
diabetes complications in IDDM patients (as shown in the Diabetes Control Complication 
Trial), glucose control requires an intensive insulin therapy with multiple injections a day 
(Jeandidier and Boivin, 1999) or by continuous infusion using an insulin pump attached to an 
indwelling needle inserted under the skin. However, the specific disadvantages related to the 
latter system limit its widespread use (Reynolds, 2000). In addition there are numerous 
disadvantages associated with parenteral administration: patient compliance is poor due to 
pain and discomfort during self-injection; absorption of subcutaneous-delivered insulin is 
slow and sustained and fails to mimic the physiological pulsatile pattern of endogenous-
released insulin observed in non-diabetics; large intra- and interindividual variation in 
glycaemic control; infections may occur at the injection site (Hinchcliffe and Illum, 1999; 
Jeandidier and Boivin, 1999).  
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The disadvantages of parenteral administration have stimulated investigations of alternative 
routes for systemic insulin delivery such as the buccal, pulmonal, ocular, transdermal, rectal, 
vaginal and nasal route (Zhou and Li Wan Po, 1991; Sayani and Chien, 1996). 
Among these, the nasal route has been widely investigated for peptide and protein delivery as 
its accessibility facilitates self-medication. The nasal cavity has a relatively large absorptive 
surface area due to the presence of microvilli. In addition, the endothelial basement 
membrane is porous and the nasal mucosa is highly vascularised ensuring rapid systemic 
distribution of absorbed compounds. As venous blood from the nose immediately flows into 
the systemic circulation the first-pass metabolism is also avoided (Cornaz and Buri, 1994; 
Arora et al., 2002). Furthermore, the plasma pharmacokinetic profile after nasal delivery is 
for some drugs similar to that of an intravenous bolus injection. For the treatment of 
diabetics, some studies indicated that the nasal route might allow mimicking the endogenous 
pulsatile secretion pattern of insulin (Hinchcliffe and Illum, 1999). 
 
Currently, three classes of nasally administered drugs are marketed. The first class includes 
low molecular weight drugs for treatment of local inflammations of the nasal mucosa 
(sinusitis and rhinitis): e.g. naphazolin nitrate (Vasocedine®), budenoside (Rhinocort®) and 
beclomethasone dipropionate (Beconase Aqua®). The second class comprises low molecular 
weight drugs used in the treatment of migraine and intended for systemic delivery:             
e.g. sumatriptan (Imitrex®) and zolmatriptan (Zomig®). The third class includes a few peptide 
drugs like desmopressin (Minirin®), LHRH (Kryptocur®) and analogues (Suprefact® and 
Synarel®), and calcitonin (Miacalcic®). These peptides have sufficient nasal absorption to 
induce a systemic effect or have a higher stability (Verhoef et al., 1992;                        
Behl et al., 1998). 
 
However, nasally administered drugs (especially in the case of peptides and proteins) 
encounter several barriers before reaching the systemic circulation. These barriers include the 
mucus and epithelium (a physical barrier), the mucociliary clearance (a temporal barrier) and 
the enzymatic activity (a chemical barrier), resulting in a low bioavailability of peptides and 
proteins (Cornaz and Buri, 1994). To achieve sufficient absorption via the nasal route, 
simultaneous administration of peptides, absorption enhancers and/or enzyme inhibitors has 
been extensively investigated. Another approach to increase the nasal bioavailability has been 
to prolong the residence time of the formulation in the nasal cavity. 
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This research project will focus on powder formulations as carriers for the nasal delivery of 
peptides, aiming to improve the nasal bioavailability of the drug by enhancing the residence 
time of the drug in the nasal cavity due to the incorporation of viscosity-enhancing excipients 
in the formulation. Nasal powder formulations are preferred to liquid formulations as the 
chemical stability of the drug is increased (Lee et al., 1991b; Schipper et al., 1993). As the 
small volume of the nasal cavity limits the amount that can be administered, it is only suitable 
for the administration of low-dose or high solubility drugs via a simple liquid formulation 
(Ugwoke et al., 2001). In contrast, powder formulations allow to administer a larger amount 
of drug and excipients, increasing the residence time of the drug in the nasal cavity and 
possibly saturating the enzymatic degradation processes due the high drug concentrations 
obtained at the nasal mucosa (Illum et al., 1987). Furthermore, no preservatives are required 
in dry powder formulations. 
 
The powder formulations used in this doctoral thesis are composed of a physical mixture or a 
spray-dried mixture of starch and poly(acrylic acid) (Carbopol®).  
 
As a previous study (Callens, 2002) demonstrated that the spray pattern of a powder 
formulation from the device was influenced by the density of the formulation, the aim of the 
first experiment was to investigate the influence of the bulk density of the powder on the 
nasal bioavailability of insulin (used as model peptide) after administration to rabbits. Rabbits 
were selected as animal model as they are easy to handle, inexpensive and well suited for 
clinical trials (Gizurarson, 1990). These animals do not need to be anaesthetised and repeated 
blood sampling is possible due to the large total blood volume (Ugwoke et al., 2001). The 
blood samples can easily be collected from the ear veins (Illum, 1996) and larger amounts 
can be administered in comparison with smaller animal models (Gizurarson, 1993). 
 
The influence of the addition of divalent cations to a spray-dried mixture of starch and 
Carbopol® on the absolute bioavailability of peptides (insulin and salmon calcitonin) in 
rabbits was also tested. The irritating potential of those powder formulations was evaluated 
using a non-invasive washing technique in rabbits and using the Slug Mucosal Irritation 
assay.  
 
Stability testing of the spray-dried starch and Carbopol® stored as bulk powder was also 
performed. 
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Finally, the spray-dried mixture of starch and Carbopol® was evaluated as platform for the 
nasal delivery of oxymetazoline hydrochloride to healthy volunteers. 
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Chapter 1 The nasal musoca as absorption barrier 
 
 
1.1 The nasal cavity 
 
The inhaled air is conditioned in the nasal cavity by cleaning, warming and humidifying 
before reaching the fragile alveolar tissue in the lungs. The nasal cavity is divided into two 
approximately equal halves by the nasal septum. Each half is beginning anteriorly at the 
nostrils and extending posteriorly to the nasopharynx where the two halves join together. The 
total volume of the nasal cavity is about 15 - 20 ml and the total surface area about 150 cm2 
(Hinchcliffe and Illum, 1999). A cross-sectional view of the nasal cavity is shown in     
Figure 1. 
 
 
 
Figure 1. Anatomy of the nasal cavity (A = vestibular region, B = atrium, C = respiratory region, c1 = inferior 
turbinate, c2 = middle turbinate, c3 = superior turbinate, D = olfactory region). (Cornaz and Buri, 1994) 
 
 
The nasal cavity can be divided into three functional regions: the vestibular (10 - 20 cm2), the 
respiratory (about 130 cm2) and the olfactory region (10 - 20 cm2) (Hinchcliffe and        
Illum, 1999). 
 
The nasal vestibule, situated just inside the nostrils, is covered with stratified, keratinised and 
squamous epithelium. The atrium forms a transepithelial region between the nasal vestibule 
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and the respiratory region and is anteriorly composed of stratified squamous cells and 
posteriorly of pseudostratified cells with microvilli (Cornaz and Buri, 1994; Mygind and 
Dahl, 1998; Arora et al., 2002). 
 
The respiratory region occupies the majority of the nasal cavity and three turbinates (inferior, 
middle and superior) projecting down from the lateral wall considerably increase its surface 
area. The respiratory mucosa is pseudostratified having four different cell types: basal cells, 
ciliated and non-ciliated columnar cells and goblet cells. The basal cells, which are lying on 
the basement membrane, are precursor cells of the other cell types (Figure 2). 
 
 
 
Figure 2. Nasal epithelium cells (ML = mucus layer, SL = sol layer, BM = basement membrane, CC = ciliated 
columnar cell, MC = non-ciliated columnar cell, BC = basal cell, GC = goblet cell, UC = undifferentiated cell). 
(Cornaz and Buri, 1994) 
 
 
The columnar cells (ciliated as well as non-ciliated) are covered with microvilli 
(approximately 400 per cell), thus providing a large absorption surface to transfer nasally 
administered drugs from the nasal cavity into the systemic circulation. The apically located 
cells exhibit a high metabolic activity due to an abundance of mitochondria and have an 
important role in the transport of fluids. 
Goblet cells, having many secretory vesicles in the cytoplasm, produce together with the 
submucosal glands the mucus layer on the surface of the epithelium. However, the 
contribution of the goblet cells to the volume of nasal secretion is probably small compared 
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to the submucosal glands. Their release mechanism is unclear and is probably in response to 
physical and chemical irritants in the microenvironments (Mygind and Dahl, 1998; Morita 
and Yamahara, 2004). 
 
The olfactory mucosa, which is located in the roof of the nasal cavity and on the upper part of 
the nasal septum, contains the receptors for the sense of smell (Hinchcliffe and Illum, 1999). 
 
The basement membrane, consisting of a layer of collagen fibrils, separates the epithelium 
from the lamina propria (or submucosa). The lamina propria (containing mast cells, T cells,  
B cells, nerves and glands) is highly vascularised and permeable, thus providing a rapid 
passage of fluid and dissolved substances from the tissue to the blood vessels and vice versa 
(Cornaz and Buri, 1994; Mygind and Dahl, 1998). 
 
 
1.2 Barriers to nasal absorption 
1.2.1 Mucociliary clearance 
 
The interaction between cilia (fine contractile projections on the apical surface of most nasal 
epithelial cells) and mucus (a thin layer of clear nasal fluid covering the apical epithelial 
surface) is called the mucociliary clearance and facilitates the removal of deposited particles 
from the nasal cavity to the nasopharynx (Hinchcliffe and Illum, 1999). Approximately      
1.5 - 2 l mucus is daily delivered by serous and seromucus glands, goblet cells, tissue fluid 
transudate and condensed water from expired air. Mucus is composed of water (95 - 97 %), 
glycoproteins (mucin) (2.5 - 3 %), electrolytes, proteins, immunoglobulins and lipids  
(Marttin et al., 1998). The glycoproteins give mucus its visco-elastic characteristics to 
provide a protective coating on the nasal epithelium and to ensure the proper functioning of 
the mucociliary transport. Mucus consists of two fluid layers: a viscous sol layer (periciliary 
fluid layer) and a viscous gel layer (mucus). The viscous sol layer containing water and 
soluble proteins is immediately adjacent to the epithelial surface and is covered by the 
viscous gel layer which is composed of water and mucins. Whereas the periciliary layer 
remains relatively stationairy, the cilia propel the mucus at a beat frequency of about 10 Hz 
towards the nasopharynx where it is removed by swallowing. The mucus turnover is about  
15 - 30 min (Hinchcliffe and Illum, 1999). The efficiency of the mucociliary clearance is 
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determined by the length and density of the cilia and their ciliary beat frequency, by the 
amount of mucus and the depth of the periciliary layer and by the visco-elastic properties of 
the mucus (Marttin et al., 1998). 
 
 
1.2.2 Permeability of the nasal epithelium 
 
To reach their site of pharmacological activity via the blood stream, nasal administered drugs 
need to pass the mucus and epithelial cell layer, drug transfer across the membrane occuring 
via the transcellular or paracellular route.  
In the transcellular route molecules permeate across the apical cell membrane, the 
intercellular space and the basolateral membrane by passive (diffusion, pH partition theory) 
or active transport (facilitated and carrier-mediated diffusion, specific transcellular transport 
mechanism, endocytosis). Lipophilic molecules or molecules having a specific recognition of 
a membrane site will preferentially be absorbed by this route. Different lipophilic drugs, such 
as propranolol, naloxone, buprenorphine, testosterone and 17α-ethinyloestradiol, have 
already shown complete absorption via the nasal route in animal models (Hinchcliffe and 
Illum, 1999). In case of transcellular uptake of peptides and proteins proteolytic degradation 
during cytoplasmatic passage can occur (Cornaz and Buri, 1994).  
The paracellular route involves passive diffusion of molecules through the intercellular tight 
junctions and the spaces between adjacent cells. Tight junctions hold the epithelial cells 
together at their apical surface and are dynamic structures consisting of plasma membranes 
which assemble and disassemble in response to various physiological stimuli such as a 
decrease in extracellular calcium. As the connections between a ciliated cell and a goblet cell 
or between two goblet cells are relatively weak and the connections between two ciliated 
cells are tight, the nasal epithelium can be considered as relatively leaky. Hydrophilic, polar 
compounds with molecular weight up to about 1000 Dalton can cross the membrane 
paracellular (Cornaz and Buri, 1994). In contrast, the absorption of proteins and peptides is 
restricted due to their hydrophilic nature but in particular due to their high molecular weight, 
resulting in a low nasal bioavailability of 1 – 2 % when administered as a solution 
(Hinchcliffe and Illum, 1999). 
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1.2.3 Enzymatic degradation 
 
The metabolic enzymes present in the nasal secretions, cytosol and lamina propria create a 
pseudo-first-pass effect after nasal absorption of drugs. Monooxygenases, reductases, 
transferases, esterases and peptidases have been identified in the nasal cavity, cytochrome    
P-450-dependent monooxygenase being important for the detoxification of inhaled 
xenobiotics. Peptides and proteins are susceptible to degradation by exo- and endopeptidases. 
Although Lee and Robinson (1988) reported that endopeptidases are involved in the 
degradation of insulin, the contribution of proteolytic activity on the low nasal bioavailability 
of insulin is probably minimal as insulin degradation in human nasal washing was less than 
0.5 % during the period of drug absorption according to Gizurarson and Bechgaard (1991). 
 
 
1.3 Strategies for improving drug absorption 
 
Due to the low bioavailability observed after nasal delivery of peptides and proteins, several 
strategies have been investigated in order to improve their membrane permeability. 
 
 
1.3.1 Modification of peptides 
 
A first approach to improve nasal absorption of peptides is to modify the structure of peptides 
by increasing their lipophilicity in order to increase membrane permeability or to improve 
their stability due to a reduction of enzymatic degradation. This can be achieved by 
substituting specific amino acids by their equivalent D-amino acids, by derivatisation of the 
N-terminus or C-terminus and by cyclisation (Verhoef et al., 1992). However, this approach 
can affect the affinity of the molecule for the target receptors. Using this approach, the nasal 
bioavailability of LHRH analogues (buserelin, leuprolide and nafarelin) remained very low  
(2 – 3 %), but these analogues were 50 – 200 times more potent compared to native LHRH 
(Anik et al., 1984; Sandow and Petri, 1985). 
Hashimoto et al. (1989) synthesised lipophilic palmitoyl derivatives of insulin which were 
less effective in reducing the glucose plasma concentrations after intramuscular injection. 
Asada et al. (1995) observed that chemical modification of insulin with fatty acids increased 
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the transport across membranes. However, the higher lipophilicity generally resulted in a 
lower pharmacological activity, although several derivatives had a similar pharmacological 
activity as native insulin. 
 
 
1.3.2 Incorporation of absorption enhancers 
 
Several studies illustrated that the incorporation of absorption enhancers like bile salts (e.g. 
glycocholate, taurocholate, cholate, deoxycholate, chenodeoxycholate, taurodihydrofusidate), 
surfactants (e.g. Laureth-9), chelating compounds (e.g. EDTA), fatty acids (e.g. sodium 
caprylate), phospholipids (e.g. lysophosphatidylcholine, didecanoyl-L-α-phosphatidyl-
choline) and miscellanous compounds (e.g. dimethyl-β-cyclodextrin (DM-β-CD)) in a 
formulation enhanced the nasal absorption of insulin in animal models as well as in healthy 
and diabetic humans (Behl et al., 1998; Hinchcliffe and Illum, 1999; Davis and Illum, 2003). 
The addition of 1 % sodium taurodihydrofusidate increased the nasal bioavailability of 
insulin from 0.9 % to 5.2 % in rabbits and from 0.3 to 18.0 % in rats (Deurloo et al., 1989) 
and resulted in a bioavailability of 16.2 % in sheep (Longenecker et al., 1987). Salzman        
et al. (1985) described that nasal delivery of an insulin spray containing 1 % Laureth-9 
lowered the plasma glucose levels to 50 % of the basal values after 45 and 120 min in healthy 
subjects and IDDM diabetics, respectively. Nasal delivery of insulin formulated in a liquid 
formulation containing DM-β-CD resulted in an absolute bioavailability of 100 % in rats, 
while in rabbits and humans no absorption was observed. DM-β-CD appeared to be more 
effective when administered in a powder formulation. An absolute nasal bioavailability of   
13 %, 3.1 % and 5.1 % was found in rabbits, healthy subjects and diabetic patients, 
respectively (Merkus et al., 1991, 1996; Schipper et al., 1993). 
 
The mechanism of absorption enhancement is assumed to be a combination of several effects: 
formation of aqueous pores in the cell membrane, disrupting the membrane integrity by their 
solubilising properties, increasing drug lipophilicity by ion-pairing between absorption 
enhancer and peptide, opening the tight junctions by chelation of extracellular divalent 
cations, enzyme inhibition, mucolytic activity and/or dissociation of peptides (Hinchcliffe 
and Illum, 1999). 
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Unfortunately, many absorption enhancers caused damage to nasal and other biological 
membranes. Laureth-9 induced a rapid and irreversible ciliostasis of human nasal cilia at a 
concentration of 0.3 % (Hermens et al., 1990) and 30 min after nasal administration of 1 % 
Laureth-9 to rats the nasal epithelium was partially disrupted showing necrosis, inflammation 
and exudation (Daugherty et al., 1988). Chandler et al. (1995) reported that the haemolytic 
activity of three lysophosphatidylcholine homologues increased with decreasing chain length 
of the fatty acid. EDTA, on the other hand, was well tolerated after administration to human 
volunteers in a concentration of 0.1 % (Batts et al., 1991). Unfortunately, its absorption 
promoting effect was limited as EDTA alone was not able to increase the nasal absorption of 
insulin (Aungst and Roger, 1988). 
 
 
1.3.3 Administration of enzyme inhibitors 
 
To protect peptides from degradation by proteases and peptidases present in the mucus, on 
the membrane surface and in the intercellular space enzyme inhibitors can be incorporated in 
the formulation. The aminopeptidase inhibitor bestatin improved the nasal absorption of 
desmopressin in rats, while it was ineffective in enhancing the absorption of human growth 
hormone and salmon calcitonin (O’Hagan et al., 1990; Morimoto et al., 1995). Another 
aminopeptidase inhibitor amastatin was able to increase the absorption of human growth 
hormone upon nasal administration to rats (O’Hagan et al., 1990). Morimoto et al. (1995) 
found an enhanced hypocalcemic effect in rats when the trypsin inhibitor camostat mesilate 
or aprotinin was administered with salmon calcitonin.  
Despite the enzyme inhibiting potential of these compounds, the degree of absorption 
enhancement remained lower compared to other absorption enhancing strategies, as the 
addition of an enzyme inhibitor alone is not sufficient to obtain efficient drug absorption.  
 
 
1.3.4 Formulation approach 
 
In order to prolong the residence time of a nasal formulation in the nasal cavity (15 to 30 min 
due to the mucociliary clearance) and to improve the absorption efficiency a fourth approach 
consisted of modifying the formulation.  
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The simplest and most convenient way to deliver drugs nasally is via drops. However, the 
exact volume of dosing is difficult to determine and there is a fast drainage from the nose to 
the nasopharynx due to posterior deposition in the nasal cavity. Harris et al. (1986) 
demonstrated that reducing the droplet size using a spray device resulted in an anterior 
deposition and hence a slower clearance and higher extent of absorption of desmopressin.  
 
The clearance rate of a nasal spray can be reduced by incorporation of polymers in the 
formulation, which increase the viscosity and/or have bio- or mucoadhesive properties 
(Pennington et al., 1988). A bioadhesive agent is defined as a component that interacts with 
biological materials through interfacial forces and is retained on them for a prolonged time 
period. If the biological material is a mucous membrane, the bioadhesive material is 
classified as a mucoadhesive (Ahuja et al., 1997). Critchley (1989) demonstrated that nasal 
solutions containing methyl cellulose, hydroxypropylmethyl cellulose and poly(acrylic acid) 
(Carbopol 934) were able to increase the nasal bioavailability of desmopressin in rats to    
27 %, 50 % and 77 %, respectively, compared to 15 % for an aqueous solution of 
desmopressin. 
 
Enhanced nasal absorption can also be obtained using powder formulations instead of liquid 
formulations. Nagai et al. (1984) was the first to use dry powder formulations for nasal 
delivery of insulin. A formulation containing hydroxypropyl cellulose or neutralised 
Carbopol 934 as viscosity-enhancing agent resulted in a pronounced decrease of the plasma 
glucose levels in rabbits after nasal administration. Callens et al. (2000, 2003) used powder 
blends of starch and Carbopol®, obtaining the highest nasal bioavailability (18 %) in rabbits 
using a spray-dried mixture of Amioca® starch/Carbopol® 974P 25/75. 
 
Bioadhesive microsphere systems based on albumin, starch and diethylaminoethyl-dextran 
reduced the mucociliary clearance in human volunteers (Illum et al., 1987). Compared to a 
solution an improved nasal bioavailability in sheep was obtained for gentamicin (Illum et al., 
1988), insulin (Farraj et al., 1990), human growth hormone (Illum et al., 1990) and 
desmopressin (Critchley et al., 1994) using starch microspheres. Addition of 
lysophosphatidylcholine to these formulations resulted in a further increase of bioavailability. 
Combining other absorption enhancing agents (sodium glycodeoxycholate and sodium 
taurodihydroxyfusidate) with starch microspheres also had a synergistic effect on the nasal 
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absorption of insulin, whereby the absorption of insulin and hence its biological effect was 
more pronounced for the powder formulation compared to a solution (Illum et al., 2001).  
Pereswetoff-Morath and Edman (1995) demonstrated that dextran microspheres coated with 
insulin were more effective than insulin-loaded microspheres. For the latter, water had to 
penetrate into the core of the microsphere to obtain complete swelling of the dextran matrix 
prior to dissolution and diffusion of insulin out of the sphere. Furthermore, poly(acrylic acid) 
and hyaluronic acid microspheres have also been investigated for the nasal delivery of 
peptides (Vidgren et al., 1992; Illum et al., 1994a). 
 
Several mechanisms of absorption enhancement have been proposed for powder formulations 
containing viscosity-enhancing and/or bioadhesive agents. They absorb water and swell to 
form a gel after contact with the nasal mucosa, thus increasing the residence time of the drug 
in the nasal cavity. The water absorption from the nasal mucosa could also shrink the 
epithelial cells, resulting in a transient opening of the tight junctions (Pereswetoff-       
Morath, 1998). Some authors suggested that the calcium-binding capacity of polymers such 
as starch microspheres, dextran microspheres and Carbopol® may be involved in the drug 
absorption enhancement as in-vitro studies revealed that depletion of extracellular calcium 
resulted in the opening of the tight junctions (Junginger, 1990; Oechslein et al., 1996). 
 
Chitosan, derived from chitin by partial deacetylation, is a linear cationic polysaccharide 
consisting of copolymers of β-1,4-linked monomers of glucosamine and N-acetyl 
glucosamine and is able to enhance the nasal delivery of insulin. Illum (1999) reported that 
liquid formulations containing 0.5 % chitosan resulted in a rapid and reproducible increase of 
serum insulin after nasal application in human volunteers, obtaining an absolute 
bioavailability of 7 %. Studies in sheep indicated that the bioavailability might be improved 
by administering a chitosan powder formulation instead of a liquid formulation. Human 
growth hormone formulated in chitosan powder or granules resulted in a nasal bioavailability 
of 14 % and 15 %, respectively, relative to a subcutaneous injection (Cheng et al., 2005). 
Nasal administration of nanoparticles of chitosan induced significantly lower plasma glucose 
levels in rabbits in comparison with a liquid chitosan formulation (Fernandez-Urrusuno et al., 
1999). However, following the study of Dyer et al. (2002) similar nanoparticles were not 
effective in decreasing the plasma glucose levels what was contributed to the lower dose of 
insulin in the nanoparticles. In-vitro measurements revealed that the bioadhesive properties of 
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chitosan-ethylcellulose microparticles were higher compared to pure chitosan (Martinac et 
al., 2005). Also microparticles consisting of chitosan and sodium alginate exhibited good 
mucoadhesive properties with an improved drug permeation ex-vivo compared to 
microparticles without sodium alginate (Gavini et al., 2005). The absorption enhancing 
potential of chitosan is contributed to interactions between the positive charges of the 
polymer and the negatively charged sialic acid residues in the mucus layer (Illum et al., 
1994b). This results in a reduced mucociliary clearance and in structural changes of the tight 
junctions with a transient opening of the paracellular pathway (Artursson et al., 1994). 
 
Besides viscosity-enhancing or bioadhesive polymers water-insoluble powders can also be 
used as carrier for the nasal delivery of peptides. Ishikawa et al. (2001, 2002) increased the 
nasal bioavailability of (Asu1,7)-eel calcitonin using water-insoluble calcium carbonate 
(CaCO3) as a carrier. Haruta et al. (2003) demonstrated that porous CaCO3 spheres were even 
more effective in enhancing the nasal bioavailability of insulin than conventional CaCO3 
powder. Teshima et al. (2002) increased the maximum plasma concentrations of glucagon in 
healthy volunteers from 111 ± 59.3 to 358 ± 68.0 pg/ml following nasal administration of 
powder formulations without and with microcrystalline cellulose as carrier, respectively. 
Suzuki and Makino (1999) observed the highest absorption of calcitonin and leuprolide in 
rabbits when a powder mixture of microcrystalline cellulose and hydroxypropyl cellulose was 
used. It has been shown that insoluble powders exhibit a longer residence time in the nasal 
cavity compared to liquid formulations, which may result in an enhanced absorption. 
On the other hand, powder formulations containing water-soluble compounds such as lactose 
did not succeed in enhancing the nasal absorption of peptides (Nagai et al., 1984; El-Shafy et 
al., 2000). 
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Chapter 2 Composition of powder formulations 
 
 
2.1 Starch/Carbopol® 974P mixtures 
2.1.1 Drum Dried Waxy Maize starch/Carbopol® 974P mixtures 
 
Starch is a polysaccharide composed of α-D-glucopyranosyl units. Two types of                  
D-glucopyranose polymers can be distinguished: amylose and amylopectin (Figure 1). 
 
 
 
AMYLOSE 
 
 
 
AMYLOPECTIN 
 
Figure 1. Chemical structure of starch components. 
 
 
Amylose is a linear polymer wherein the glucopyranosyl units are linked by                        
α-D-(1,4) glucosidic bonds. These molecules can consist of 100 - 2000 glucose units 
(Newman et al., 2002). Aqueous solutions of amylose are very unstable due to intermolecular 
attractions and associations of neighbouring amylose molecules. This leads to viscosity 
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increase, retrogradation and, under specific conditions, precipitation of amylose particles 
(Young, 1984).  
 
Amylopectin has a branched structure, each branch being composed of 12 to 25 
glucopyranosyl units connected with α-D-(1,4) linkages, the different branches linked by    
α-D-(1,6) glucosidic bonds (Newman et al., 2002). Aqueous solutions of amylopectin are 
characterised by a high viscosity, clarity, stability and resistance to gelling (Young, 1984).  
 
Depending on their origin the amylose/amylopectin ratio of the starches will vary, most 
naturally occurring starches containing ± 30 % amylose. ‘Waxy’ maize starch is a genetically 
modified starch containing ± 100 % amylopectin (Whistler and Daniel, 1984). 
 
Drum Dried Waxy Maize starch (DDWM) (Eridiana-Béghin Say Cerestar, Vilvoorde, 
Belgium) is a thermally modified starch formed by simultaneous cooking and drying of 
native maize starch on heated rolls (‘drums’) in order to obtain a pregelatinised starch (Wade 
and Weller, 1994).  
 
 
Carbopol® 974P (C 974P) (Noveon, Cleveland, Ohio, USA) is a synthetic, water swellable, 
high molecular weight, cross-linked acrylic acid-based polymer (Figure 2). Carbopol® 974P 
is cross-linked with allyl pentaerythritol and is polymerised in ethyl acetate (Ahuja                 
et al., 1997). After dispersion in water, Carbopol® partially swells, increasing the viscosity of 
the dispersion. The viscosity is pH dependent: the lowest viscosity is obtained in acid media 
and a maximum is reached at pH 7.4. Above their pKa-value (6.0 ± 0.5) the carboxyl groups 
become ionised and electrostatic repulsion between the negative charges causes uncoiling and 
expansion of the molecule, resulting in swelling of the polymer and gel formation. 
Carbopol® 974P is a pharmaceutical grade polymer used as controlled release agent in tablets, 
as bioadhesive, as thickener, as suspending agent and emulsion stabiliser (Singla et al., 2000). 
 
Nasal powder formulations based on a physical mixture of Drum Dried Waxy Maize starch/ 
Carbopol® 974P (DDWM/C 974P) at a ratio 95/5 were used. 
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Figure 2. Structure of Carbopol® 974P (R = allyl pentaerythritol) 
 
 
2.1.2 Spray-dried Amioca® starch/Carbopol® 974P mixtures 
 
Amioca® starch (National Starch and Chemical Company, Bridgewater, New Jersey, USA) is 
a maize starch mainly consisting of amylopectin (waxy maize). Amioca® starch is frequently 
used as native thickener and texturising agent in the food industry. 
 
Prior to spray-drying, the Amioca® starch was pregelatinised by jet cooking in a custom-
made jet cooker. The temperature was set at 138 °C, the pressure at 3.1 – 3.2 bar and the flow 
rate at 1.2 – 1.5 l/min. Steam jet cooking is an effective manner to rapidly form an aqueous 
starch solution: a slurry of granular starch is brought in contact with high pressure steam, 
leading to gelatinisation, disruption and solubilisation of the granules (Byars, 2003). Phase 
contrast optical microscopy (Olympus BH2-UMA, Olympus, New York, USA) was used to 
verify that pregelatinisation was complete and no granules remained.  
To produce the spray-dried mixtures, an aqueous mixture of the jet cooked/pregelatinised 
Amioca® starch and Carbopol 974P was spray-dried in a Bowen spray-dryer model         
BE-1393 (Arnold Equipment Company, Cleveland, Ohio, USA). Mixtures were spray-dried 
at a ratio 25/75 and 85/15 (w/w) (Ameye et al., 2003). 
 
 
2.2 Insulin 
 
Insulin is a polypeptide hormone secreted by the β-cells of the islets of Langerhans of the 
endocrine pancreas in response to increased blood glucose levels. Insulin is synthesised by 
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the ribosomes bound to the rough endoplasmatic reticulum. The first precursor of insulin is 
preproinsulin. It contains a hydrophobic signal peptide at the amino terminus, which 
facilitates the transport of preproinsulin through the cell membranes of the endoplasmatic 
reticulum. Within the lumen of the endoplasmatic reticulum the signal peptide is cleaved by 
proteases to produce proinsulin. Proinsulin is transported to the Golgi complex where it is 
converted to insulin. Proinsulin consists of three segments: the A chain and B chain which are 
linked to each other with a ‘connecting-peptide’ or C chain. Also two disulfide bonds connect 
the A and B chain and there is a third disulfide bond connecting 2 cystein residuals on the    
A chain. Through proteolytic cleavage of the C chain insulin is formed consisting of            
51 amino acids and having a molecular weight of 5808 Da (Figure 3) (Rawn, 1989). 
The insulin molecule contains many ionisable groups, due to the presence of 6 amino acid 
residues capable of attaining a positive charge and 10 amino acid residues capable of 
attaining a negative charge. Its isoelectric point is at pH 5.4 (Brange, 1987). 
 
 
A-chain                         S            S                                                
Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn
 
                                           S     S  
              S                                                                                      S
Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr   
B-chain    
                     
                                                           
1      2      3      4      5      6       7      8      9   10    11    12    13    14   15    16    17    18    19      20    21
 1      2      3       4      5      6      7       8     9     10    11    12    13    14    15    16    17    18    19    20     21    22    23    24    25    26    27    28   29    30  
 
 
Figure 3. Amino acid sequence of human insulin. (Hoffman and Ziv, 1997) 
 
 
The basal insulin secretion from the β-cells of the islets of Langerhans is approximately        
1 IU/h. Stimulation of the insulin secretion as consequence of the digestion of food results in 
a release of 25-50 IU a day. Inadequate insulin secretion results in diabetes mellitus 
(Hoffman and Ziv, 1997). Two different types can be distinguished (Rawn, 1989): 
Type I diabetes or insulin-dependent diabetes mellitus (IDDM) occurs as a consequence of 
inadequate insulin production due to the inability to cleave proinsulin or to a genetic 
predisposition to an autoimmune destruction of the insulin-producing β-cells of the islets of 
Langerhans. The onset of IDDM usually occurs in early childhood and before the age of 20 
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and is characterised by hyperglycemia and ketoacidosis. Patients suffering from IDDM can 
effectively be treated with insulin. 
Type II diabetes or non-insulin-dependent diabetes mellitus (NIDDM) generally appears in 
adults over the age of 40. NIDDM is characterised by a decreased production of insulin in the 
β-cells as well as by insulin resistance of various tissues. Diet control and physical exercise 
can usually control NIDDM and treatment with insulin is only required in extreme cases.  
 
For 60 years, insulin was obtained by extraction from the pancreas of cows, pigs or sheep in 
sufficient quantities to cover the therapeutic needs. Bovine and porcine insulin were very 
impure and purification by repeated crystallisation, HPLC or ion-exchange chromatography 
was required. Insufficient purification resulted in immunological reactions to the impurities 
or the insulin molecule itself, limiting the use of these compounds. From an immunogenetic 
point of view, significant progress was made with the production of human insulin in the 
early 1980s using recombinant DNA technology or using an enzymatic reaction whereby the 
alanine residue at position B30 of pork insulin was replaced with a threonine residue (Trehan 
and Ali, 1998; Brange and Vølund, 1999). 
 
 
2.3 Calcitonin 
 
A second polypeptide hormone used in the research project was calcitonin consisting of       
32 amino acids and having a molecular weight of approximately 3500 Da. It is characterised 
by a disulfide bridge between the cysteine residues at position 1 and 7 and a proline amide 
moiety at the C-terminus (Figure 4). The number of amino acid residues and the structure of 
the chain ends are identical in all calcitonins and appear to be essential for the biological 
activity. Salmon calcitonin and eel calcitonin are more potent in mammals, especially in man, 
in comparison with human or other mammalian calcitonins (Azria, 1989).  
 
Calcitonin is secreted by the parafollicular (C) cells of the thyroid gland and its major 
physiological role is to control the calcium concentration as well as its metabolism in the 
body. It is responsible for the reduction of the amount of calcium in the blood stream as it 
increases the rate of calcium clearance from the kidneys. It also reduces the amount of 
calcium excreted by the bone, by inhibiting the osteoclast activity (decreased bone 
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resorption). Finally, it decreases the amount of calcium that can be absorbed from the small 
intestines. Its production is inhibited when the calcium concentration is decreased beyond 
normal levels and the parathyroid hormone is then secreted to promote the opposite reactions 
in the body of calcitonin. Both hormones act to maintain a normal concentration of calcium in 
the blood stream.  
 
 
 
 
Figure 4. Amino acid sequence of salmon calcitonin. (Torres-Lugo and Peppas, 2000) 
 
 
Due to their ability to reduce osteoclast activity, calcitonins are commonly used in the 
treatment of bone diseases such as Paget’s disease, hypercalcemia and osteoporosis (Torres-
Lugo and Peppas, 2000). 
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Chapter 3 Influence of bulk density on nasal 
bioavailability of insulin 
 
 
3.1 Introduction 
 
After nasal delivery of powder formulations based on a physical mixture of Drum Dried 
Waxy Maize starch and Carbopol 974P (ratio: 90/10) (DDWM/C 974P 90/10) and on a 
spray-dried mixture of Amioca starch and Carbopol 974P (ratio: 25/75) (SD 25/75) an 
absolute nasal bioavailability of 14 % and 18 %, respectively, was found in rabbits (Callens 
et al., 2000, 2003a). The higher bioavailability of the latter was related to the higher viscosity 
and elasticity of the powder after dispersion in nasal mucus (Callens et al., 2003b).  
Besides the powder characteristics the nasal bioavailability will depend on the deposition 
pattern of the powder formulation in the nasal cavity: anterior deposition of a formulation 
promotes the absolute bioavailability (Harris et al., 1986; Illum et al., 1987; Ridley               
et al., 1995; Callens, 2002). 
The aim of the next experiment was to evaluate if the nasal bioavailability depended on the 
spray pattern of the powder. Callens (2002) determined the spray pattern of powder 
formulations based on DDWM/C 974P 90/10 and SD 25/75. For the latter a longer spray time 
was required to completely empty the powder from the nasal delivery device. The angle at 
which the particles were sprayed and the mean maximum and minimum width of the cross-
section of the powder cloud were larger compared to the DDWM/C 974P powder. These 
differences were due to the higher bulk density and smaller particle size of SD 25/75, 
resulting in a compact powder having a higher resistance to airflow. 
Bond et al. (1985) and Newman et al. (1987) showed that the cone angle of a nasal adaptor 
determined the width of the spray pattern and hence the deposition area in the nasal cavity. 
Changing the cone angle from 60 to 35 or 30° resulted in a posterior deposition in the nasal 
cavity and in a faster clearance rate of the formulation because of the higher deposition in the 
ciliated area. The smaller spray angle of the DDWM/C 974P 90/10 particles resulted in a 
narrow cross-section of the particle cloud (Callens, 2002) and might contribute to a posterior 
deposition in the nasal cavity and hence to the lower bioavailability obtained after nasal 
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delivery. On the other hand due to its lower bulk density and larger powder volume a larger 
area of the nasal epithelium might be covered with powder. 
As the density of the formulation determined the spray pattern from the delivery device, the 
objective of the following experiment was to investigate the relation between the powder 
bulk density and nasal bioavailability of insulin using the rabbit as an animal model. The 
powder bulk density of the powder formulation was modified by changing the solid fraction 
of the dispersion (prior to freeze-drying) and by changing the freezing rate during the freeze-
drying cycle. 
 
 
3.2 Materials and methods 
 3.2.1 Materials 
 
Actrapid HM 100 (100 IU/ml) (human monocomponent insulin) was obtained from     
Novo-Nordisk (Bagsvaerd, Denmark). The spray-dried mixture of Amioca starch and 
Carbopol 974P (ratio: 25/75, w/w) (SD 25/75) (batch number: 10851: 141-1) was prepared 
by National Starch and Chemical Company (Bridgewater, New Jersey, USA). Drum Dried 
Waxy Maize starch (DDWM) and Carbopol 974P (C 974P) were supplied by Eridania-
Béghin Say Cerestar (Vilvoorde, Belgium) and Noveon (Cleveland, Ohio, USA), 
respectively. All other chemicals were of analytical grade. 
 
 
3.2.2 Insulin formulations 
3.2.2.1 Insulin solution for intravenous administration 
 
An insulin solution of 0.8 IU/ml was prepared by diluting Actrapid HM 100 in a phosphate 
buffered saline solution (PBS, pH 7.4) (2.38 g Na2HPO4.2H2O, 0.19 g KH2PO4 and 8.0 g 
NaCl per liter distilled water) of which 0.5 ml was administered intravenously to rabbits       
(n = 10). 
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3.2.2.2 Nasal powder formulations 
 
Dispersions containing a physical mixture of DDWM and C 974P (ratio: 95/5, w/w) 
(DDWM/C 974P 95/5) were prepared in a concentration of 2.0, 5.0 and 8.5 % (w/w), whereas 
dispersions containing a spray-dried mixture of Amioca starch and C 974P                     
(ratio: 25/75, w/w) (SD 25/75) were prepared in a concentration of 1.0, 2.5 and 7.0 % (w/w). 
To prepare the dispersions containing 2.0 and 5.0 % DDWM/C 974P 95/5, 1.0 g powder was 
dispersed in 10.0 ml distilled water and to prepare the dispersions containing 1.0 and 2.5 % 
SD 25/75, 1.0 g powder was dispersed in 30.0 ml distilled water. To prepare the dispersions 
containing 8.5 % DDWM/C 974P 95/5 and 7.0 % SD 25/75, 1.0 g powder was hydrated with 
1.0 and 2.0 ml distilled water, respectively. After neutralisation of the dispersions containing 
DDWM/C 974P 95/5 and SD 25/75 to pH 7.4 with 0.2 M and 2.0 M NaOH, respectively, the 
insulin solution (Actrapid® HM 100) was added to obtain a final concentration of 1 IU insulin 
per mg powder. Finally distilled water was added until the desired concentration was 
obtained. The selection of the solid fractions of the dispersions was based on the consistency 
of the dispersions: dispersions having the lowest solid fraction had a liquid-like structure, 
dispersions with the intermediate solid fraction had a gel-like structure and dispersions with 
the highest solid fraction was the highest which could be prepared. 
The dispersions were freeze-dried in vials using an Amsco-Finn Aqua GT4 freeze-dryer 
(Amsco, Germany). The dispersions were frozen to 228 K within 175 min at 1000 mbar. 
Additionally, the dispersions containing 5.0 % DDWM/C 974P 95/5 and 2.5 % SD 25/75 
were frozen to 228 K within 30 min and 350 min. Primary drying was performed at 258 K 
and at a pressure varying between 0.8 and 1 mbar during 13 h, followed by secondary drying 
at elevated temperature (283 K) and reduced pressure (0.1 - 0.2 mbar) for 7 h. After freeze-
drying the powder was sieved (63 µm) at low relative humidity (20 %) and ambient 
temperature. The fraction below 63 µm was stored in a desiccator at 4 - 8 °C until use.  
 
 
3.2.3 Nasal delivery device 
 
The powders were nasally administered using an experimental device (Figure 1) composed of 
a polyethylene tube (inner diameter: 1.5 mm, length: 5.5 cm) (Medisize, Hillegom, The 
Netherlands), valve and polypropylene syringe (10 ml with Luer-Lok® needle holder). After 
closing the valve 7.8 ml air was compressed to 1 ml (generating an internal pressure of          
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± 2.5 bar). Then, a polyethylene tube filled with the powder formulation was connected to the 
syringe. The powder formulation was sprayed into the nostrils of the rabbits by opening the 
valve, releasing the compressed air. This experimental device was based on the system 
developed by Sørensen (1991). 
 
 
  
 
Figure 1. Picture of experimental delivery device and of nasal powder delivery to rabbits. 
 
 
3.2.4 Nasal bioavailability  
 
New Zealand white rabbits (3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was 
available ad libitum. They were sedated with an intramuscular injection of 0.05 ml/kg 
Combistress (Kela Laboratoria, Hoogstraten, Belgium). The rabbits received 0.4 IU insulin 
intravenously. The powder was administered intranasally using polyethylene tubes filled with 
5.0 mg of the DDWM/C 974P 95/5 powder formulation or 10.0 mg of the SD 25/75 powder 
formulation. 10 mg powder (equivalent to 10 IU insulin) was administered in each nostril. In 
case of DDWM/C 974P 95/5 2 tubes filled with 5.0 mg powder were delivered into each 
nostril. The delivery device was filled under conditions of low relative humidity (20 %) and 
ambient temperature. Blood samples were collected from the ear veins at -5, 1, 5, 10, 15, 20, 
30, 40, 50 and 60 min after intravenous administration and at -5, 2, 5, 10, 15, 20, 25, 30, 35, 
45, 60, 90, 120, 150 and 180 min after nasal delivery of the powders. The samples were 
centrifuged (700g, 5 min) and the sera were frozen at –20 °C until RIA-analysis             
(Coat-A-Count kit, DPC, Humbeek, Belgium). The radioactivity of the samples was 
quantified using a Cobra gamma counter (Canberra Packard Benelux, Zellik, Belgium). The 
individual serum concentration-time profiles were analysed using MW/Pharm version 3.15 
(Medi-ware, Utrecht, The Netherlands). For calculation of the absolute biovailability (BA) 
the weight of the rabbits and the concentration of insulin in the powder formulations were 
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taken into account. The maximum serum insulin concentrations (Cmax) and tmax values were 
determined from the individual serum concentration-time profiles. 
 
¾  Statistical analysis 
 
The influence of the solid fraction and the freezing rate on absolute nasal bioavailability, Cmax 
and tmax of insulin was analysed using a one-way ANOVA. The data and residuals were 
tested for normal distribution using the Kolmogorov-Smirnov test and the homogeneity of 
variances was tested using the Levene’s test. Multiple comparisons were performed by a 
Scheffé test using P < 0.05 as significance level. The computer software SPSS version 11.0 
was used for statistical analysis of the data. 
 
 
3.2.5 Determination of bulk density 
 
The apparent powder bulk density (defined as the ratio of the powder weight over its bulk 
volume) was determined in the polyethylene tubes of the nasal delivery device filled with   
5.0 mg of the freeze-dried DDWM/C 974P 95/5 mixture or 10.0 mg of the freeze-dried       
SD 25/75 mixture. Results are presented as a mean value ± standard deviation (n = 10). 
 
¾  Statistical analysis  
 
The influence of the solid fraction and the freezing rate on the powder bulk density was 
analysed using a one-way ANOVA followed by a Scheffé test using P < 0.05 as significance 
level. The data and residuals were tested for normal distribution using the Kolmogorov-
Smirnov test and the homogeneity of variances was tested using the Levene’s test. If the 
distribution of the data or residuals was not normal or the variances were not homogeneous, 
the data were transformed to their logarithm. The computer software SPSS version 11.0 was 
used for statistical analysis of the data. 
 
 
3.2.6 Determination of particle size 
 
The particle size of the powder formulations was determined by laser diffraction  
(Mastersizer S, Malvern Instruments, Worcestershire, UK), using Miglyol 812N 
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(caprylic/capric acid triglycerides) (Sasol, Witten, Germany) as dispersion medium. The 
volume median diameter (VMD) was calculated. 
 
 
3.2.7 Moisture content 
 
The moisture content was determined using a Mettler DL 35 Karl Fischer titrator (Mettler-
Toledo, Beersel, Belgium). Hydranal-Composite 2 (Riedel-de Haën Laborchemicalien, 
Seelze, Germany) was used as titrant and anhydrous methanol (Riedel-de Haën 
Laborchemicalien, Seelze, Germany) as reaction medium. Calibration and verification of the 
titrant (theoretical 2 mg H2O/ml) was performed with distilled water. Results are presented as 
a mean value ± standard deviation (n = 3). 
 
 
3.3 Results and discussion 
 
To investigate the influence of powder bulk density on the nasal bioavailability of insulin 
using rabbits as animal model, the density of DDWM/C 974P 95/5 and SD 25/75 was 
modified by varying the solid fraction of the dispersion (prior to freeze-drying) and by 
changing the freezing rate. 
 
The bulk density, particle size and moisture content of the powder formulations having 
different solid fractions are shown in Table 1. Significantly higher bulk densities (P ≤ 0.01) 
were obtained when the solid fraction of the freeze-dried dispersion was increased. This 
increase in bulk density was not related to the volume median diameter as the different 
powders had a similar particle size. The differences in bulk density can be explained by the 
formation of smaller ice crystals during freezing. When processing a dispersion with a higher 
solid fraction, smaller ice crystals are formed, yielding a freeze-dried cake with smaller pores 
after sublimation of the ice (Pikal, 1991). 
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Table 1. Influence of the solid fraction of the dispersion (prior to freeze-drying) on powder bulk 
density, volume median diameter (VMD) and residual moisture content of powders containing 
DDWM/C 974P 95/5 or SD 25/75. The dispersions were frozen to 228 K within 175 min. 
Solid fraction (w/w) Bulk density 
(mg/µl) 
VMD 
(µm) 
Residual moisture 
(%) 
DDWM/C 974P 95/5 
2.0 %  
5.0 %  
8.5 %  
 
 
0.028 ± 0.002 
  0.058 ± 0.004 a 
    0.083 ± 0.008 a,b 
 
69.0 
62.1 
49.2 
 
5.8 ± 0.2 
5.0 ± 0.1 
3.6 ± 0.3 
SD 25/75 
1.0 % 
2.5 %  
7.0 %  
 
0.116 ± 0.009 
  0.165 ± 0.016 c 
    0.184 ± 0.015 c,d 
 
55.8 
51.9 
41.9 
 
9.9 ± 0.9 
7.5 ± 1.0 
6.8 ± 1.0 
a Significantly higher than 2.0 % (w/w) dispersion (P ≤ 0.001) 
b Significantly higher than 5.0 % (w/w) dispersion (P ≤  0.001) 
c Significantly higher than 1.0 % (w/w) dispersion (P ≤ 0.001) 
d Significantly higher than 2.5 % (w/w) dispersion (0.01 ≥ P > 0.001) 
 
 
The powder bulk density, particle size and moisture content of the different powder 
formulations frozen at different freezing rates are shown in Table 2. Varying the freezing rate 
had a limited effect on the powder bulk density. Only freezing at the highest freezing rate 
resulted in a significantly higher bulk density (P ≤ 0.001) of the SD 25/75 powder compared 
to slower freezing rates. Fast freezing resulted in the formation of smaller ice crystals due to a 
higher degree of supercooling (Dawson and Hockley, 1991) resulting in smaller pores of the 
freeze-dried cake after sublimation. Possibly the effect of the size of the ice crystals on the 
powder bulk density is more pronounced at a lower solid fraction because of the higher water 
content. 
 
The solid fractions of the dispersions and freezing rates used are production limits, hence the 
powder bulk densities obtained can also be considered as the limits. Although the bulk 
density varied within a small range, these differences could be essential as the nasal cavity of 
rabbits has only a small volume (6 ml) and a limited surface area (61 cm2) (Gizurarson, 
1990). As a result small changes of the powder density might result in significant differences  
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Table 2. Influence of freezing rate on powder bulk density, volume median diameter (VMD) and 
residual moisture content of powder formulations prepared by freeze-drying dispersions containing 
5.0 % DDWM/C 974P 95/5 or 2.5 % SD 25/75. 
Freezing rate to 228 K within Bulk density 
(mg/µl) 
VMD 
(µm) 
Residual moisture 
(%) 
DDWM/C 974P 95/5 
30 min 
175 min 
350 min 
 
 
0.060 ± 0.004 
0.058 ± 0.004 
0.063 ± 0.006 
 
71.2 
62.1 
47.7 
 
6.41 ± 0.21 
5.04 ± 0.12 
4.72 ± 0.15 
SD 25/75 
30 min 
175 min 
350 min 
 
0.202 ± 0.010 
  0.165 ± 0.016 a 
  0.160 ± 0.014 a 
 
61.3 
51.9 
48.5 
 
3.55 ± 0.24 
7.54 ± 0.99 
3.72 ± 0.22 
a Significantly lower than freezing to 228 K within 30 min (P ≤ 0.001) 
 
 
in the area of nasal epithelium covered with powder particles. A larger fraction of the nasal 
epithelium covered with particles will occur after administration of low bulk density powders 
(because of their larger volume) and could contribute to a higher nasal bioavailability. 
Comparison of two nasal sprays, each containing 2 % didecanoyl-L-α-phosphatidylcholine 
and 200 IU or 500 IU insulin/ml, in healthy volunteers demonstrated that a higher absolute 
bioavailability was obtained after nasal administration of the 200 IU/ml formulation (13.2 % 
versus 8.8 % for the 500 IU/ml formulation). This was related to the greater surface area, 
which was covered by the 200 IU/ml formulation due to its larger dose volume (0.25 ml 
versus 0.1 ml for the 500 IU/ml formulation) (Jacobs et al., 1993). However, it must be 
emphasised that a more extensive spreading over the nasal epithelium does not guarantee a 
higher bioavailability as the distribution of the formulation between anterior and posterior 
part of the nose remains an important parameter for absorption (Kublik and Vidgren, 1998). 
 
The results of the absolute bioavailability, Cmax and tmax obtained after nasal delivery of 
DDWM/C 974P 95/5 and SD 25/75 powder formulations to rabbits are shown in Table 3   
and 4.  
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Table 3. Absolute bioavailability, Cmax and tmax (mean ± SD) after nasal delivery to rabbits of powder 
formulations (1 IU insulin/mg) obtained by freeze-drying DDWM/C 974P 95/5 or SD 25/75 dispersions 
at different solid fractions. The dispersions were frozen to 228 K within 175 min. 
Solid fraction (w/w) BA 
(%) 
Cmax 
(µIU/ml) 
tmax 
(min) 
n 
DDWM/C 974P 95/5 
2.0 %  
5.0 %  
8.5 %  
 
 
6.8 ± 1.7 
9.2 ± 3.0 
 5.8 ± 1.9 a 
 
449.8 ± 166.9 
497.1 ± 184.6 
353.0 ± 144.6 
 
22.1 ± 4.3 
23.3 ± 5.5 
23.7 ± 6.8 
 
7 
8 
8 
SD 25/75 
1.0 %  
2.5 % 
7.0 %  
 
17.4 ± 5.3 
19.2 ± 5.3 
   11.1 ± 3.0 b 
 
588.6 ± 112.5 
681.4 ± 246.6 
455.5 ± 99.4 
 
44.4 ± 13.4 
50.9 ± 7.4 
39.9 ± 6.5 
 
7 
8 
7 
a Significantly lower than 5.0 % (w/w) dispersion (0.05 ≥ P > 0.01) 
b Significantly lower than 2.5 % (w/w) dispersion (0.05 ≥ P > 0.01) 
 
 
Table 4. Absolute bioavailability, Cmax and tmax (mean ± SD) after nasal delivery to rabbits of powder 
formulations (1 IU insulin/mg) obtained by freeze-drying dispersions containing 5.0 % DDWM/C 974P 
95/5 or 2.5 % SD 25/75 at different freezing rates. 
Freezing to 228 K within BA 
(%) 
Cmax 
(µIU/ml) 
tmax 
(min) 
n 
DDWM/C 974P 95/5 
30 min 
175 min 
350 min 
 
 
5.4 ± 2.6 
9.2 ± 3.0 
8.2 ± 3.0 
 
281.1 ± 192.8 
497.1 ± 184.6 
478.7 ± 163.0 
 
29.9 ± 5.3 
23.3 ± 5.5 
22.4 ± 4.4 
 
7 
8
8 
SD 25/75 
30 min 
175 min 
350 min 
 
18.2 ± 3.7 
19.2 ± 5.3 
22.4 ± 3.3 
 
708.4 ± 210.2 
681.4 ± 246.6 
852.4 ± 84.0 
 
41.5 ± 9.3 
50.9 ± 7.4 
40.9 ± 11.7 
 
7 
8
6 
 
 
Although significant differences in absolute bioavailability were observed after nasal delivery 
to rabbits, no influence of powder bulk density on the absolute bioavailability of insulin was 
found. When increasing the solid fraction of the dispersion an increase in powder bulk 
density was seen (Table 1). However, the bioavailability after nasal delivery was similar. 
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Only for powders prepared by freeze-drying the dispersions containing                        
8.5 % DDWM/C 974P 95/5 and 7.0 % SD 25/75 a significant decrease in area under the 
curve (P < 0.05) was seen, although their Cmax and tmax values were not significantly             
(P > 0.05) different. 
 
Based on these data, it was indirectly demonstrated that differences in the spray pattern of 
nasal powders due to variations in the powder bulk density have no influence on the nasal 
insulin bioavailability in rabbits. 
 
 
3.4 Conclusions 
 
The bulk density was mainly influenced by the solid fraction of the dispersion prepared prior 
to freeze-drying. The bulk density of the powder formulations had no influence on the nasal 
bioavailability of insulin in rabbits. 
From this study, it was concluded that the procedure for preparation of the nasal powder 
formulations was a robust production method. 
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Chapter 4 Addition of divalent cations to       
spray-dried Amioca® starch/Carbopol® 
 
 
Chapter 4.1  Influence of addition of divalent cations to 
spray-dried Amioca® starch/Carbopol® on 
nasal absorption of peptides  
 
 
4.1.1 Introduction 
 
To enhance the nasal absorption of peptides Callens et al. (2000, 2003) used powder 
formulations based on neutralised mixtures of starch and poly(acrylic acid). With a 
formulation composed of spray-dried Amioca starch/Carbopol® 974P (ratio: 25/75) and 
containing 1 IU insulin/mg an absolute bioavailability of 18 % was obtained in rabbits 
(Callens, 2003). The aim of the present study was to investigate if the neutralising agent had 
an influence on the absorption of peptides. Whereas Callens et al. (2000, 2003) only used 
sodium hydroxide to neutralise the polymer, metal inorganic compounds (calcium hydroxide 
or calcium carbonate) will also be evaluated in this study as neutralising agents. 
In literature it has been described that divalent ions affected the drug release and 
mucoadhesion of poly(acrylic acid) polymers (Lee and Chien, 1996). Tablets composed of 
starch-acrylic acid graft copolymers partially neutralised with calcium or magnesium 
exhibited a slower theophylline release, a better mucoadhesion and a longer adhesion time to 
the gingiva of dogs compared to the sodium-neutralised formulation (Geresh et al., 2004). 
Adding calcium or magnesium ions to a polymethylmethacrylate sodium salt used as carrier 
for buccal drug delivery reduced the dissolution rate of the polymer without influencing the 
bioadhesive properties, thus prolonging the adhesion time in human volunteers          
(Cilurzo, 2005). 
In the present study the influence of calcium incorporated in sodium salts of starch/Carbopol® 
mixtures was investigated on the nasal absorption of insulin and salmon calcitonin in rabbits.  
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4.1.2 Materials and methods 
4.1.2.1 Materials 
 
Actrapid HM 100 (100 IU/ml) (human monocomponent insulin) and Miacalcic             
(100 IU/ml) were obtained from Novo-Nordisk (Bagsvaerd, Denmark) and Novartis Pharma 
(Brussels, Belgium), respectively. Spray-dried Amioca starch and a spray-dried mixture of 
Amioca starch and Carbopol 974P (ratio: 25/75, w/w) (SD 25/75) (batch number:      
10851: 141-1) were prepared by National Starch and Chemical Company (Bridgewater, New 
Jersey, USA). Carbopol 974P was supplied by Noveon (Cleveland, Ohio, USA). Calcium 
hydroxide (Ca(OH)2) and calcium carbonate (CaCO3) (density: 0.30 g/ml) were obtained 
from Sigma-Aldrich (Bornem, Belgium) and Federa (Brussels, Belgium), respectively. All 
other chemicals were of analytical grade. 
 
 
4.1.2.2 Preparation of formulations 
4.1.2.2.1 Insulin solution for intravenous administration 
 
An insulin solution of 0.8 IU/ml was prepared by diluting Actrapid HM 100 in a phosphate 
buffered saline solution (PBS, pH 7.4) (2.38 g Na2HPO4.2H2O, 0.19 g KH2PO4 and 8.0 g 
NaCl per liter distilled water) of which 0.5 ml was administered intravenously to rabbits       
(n = 10). 
 
 
4.1.2.2.2 Calcitonin solution for intravenous administration 
 
A salmon calcitonin solution of 20 IU/ml was prepared by diluting Miacalcic (100 IU/ml) in 
a phosphate buffered saline solution (pH 7.4) of which 0.5 ml was administered intravenously 
to rabbits (n = 2). 
 
 
4.1.2.2.3 Nasal powder formulations 
 
Physical mixtures of SD 25/75 combined with Ca(OH)2 or CaCO3 were made in a           
90/10 (w/w) ratio. To investigate the influence of the Amioca starch/Carbopol 974P versus 
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Ca(OH)2 ratio on the absorption of insulin, physical mixtures at a ratio of 90/1, 90/20 and 
90/30 (w/w) were also prepared. To investigate the influence of spray-drying, a physical 
mixture of Amioca starch (spray-dried), Carbopol® 974P (ratio: 25/75, w/w) (PM 25/75) 
and Ca(OH)2 was made, at a ratio of 90/10 (w/w) between PM 25/75 and Ca(OH)2. The 
mixtures of SD 25/75 and PM 25/75 were used as reference.  
A 500 mg powder blend was dispersed in 15 ml distilled water followed by neutralisation 
until pH 7.4 with 2.0 M NaOH (Table 1). Then the insulin solution (Actrapid® HM 100) or 
salmon calcitonin solution (Miacalcic®) was added in order to obtain a final concentration of             
1 IU insulin or 2 IU salmon calcitonin per mg powder, respectively. 
 
 
Table 1. Amount of NaOH 2.0 M required to reach pH 7.4 
after dispersion of 500 mg powder formulation into distilled 
water. 
Formulation ml NaOH 2.0M 
 
SD 25/75 
 
2.15 
(SD 25/75)/Ca(OH)2 90/1 2.0 
(SD 25/75)/Ca(OH)2 90/10 1.30 
(SD 25/75)/Ca(OH)2 90/20 0.7 
(SD 25/75)/Ca(OH)2 90/30 0.1 
(SD 25/75)/CaCO3 90/10 1.50 
PM 25/75 2.0 
(PM 25/75)/Ca(OH)2 90/10 1.35 
 
 
To obtain a powder, the aqueous dispersion was freeze-dried using an Amsco-Finn Aqua 
GT4 freeze-dryer (Amsco, Germany). The dispersion was frozen to 228 K within 175 min at 
1000 mbar. Primary drying was performed at 258 K and at a pressure varying between 0.8 
and 1 mbar during 13 h, followed by secondary drying at elevated temperature (283 K) and 
reduced pressure (0.1 - 0.2 mbar) for 7 h. After freeze-drying the powder was sieved (63 µm) 
at low relative humidity (20 %) and ambient temperature. The fraction below 63 µm was 
stored in a desiccator at 4 - 8 °C until use. 
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4.1.2.3 Nasal bioavailability study 
 
New Zealand white rabbits (3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was 
available ad libitum. They were sedated with an intramuscular injection of 0.05 ml/kg 
Placivet (Codifar, Florida, USA). The rabbits received 0.4 IU insulin or 10 IU salmon 
calcitonin intravenously. 10 mg powder (equivalent to 10 IU insulin or 20 IU salmon 
calcitonin) was administered in each nostril using polyethylene tubes (Medisize, Hillegom, 
The Netherlands). The powder was released from the tubes using a syringe containing 1 ml 
compressed air (2.5 bar). This device was based on a system developed by Sørensen (1991). 
The tubes were filled under conditions of low relative humidity (20 %) and ambient 
temperature. Blood samples were collected from the ear veins at -5, 1, 5, 10, 15, 20, 30, 40, 
50 and 60 min after intravenous administration and at -5, 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 
90, 120, 150 and 180 min after nasal delivery of the powder formulations. The samples were 
centrifuged (700g, 5 min) and the sera were frozen at –20 °C until analysis. The samples 
containing insulin were analysed using RIA (Coat-A-Count kit, DPC, Humbeek, Belgium). 
The radioactivity of the samples was quantified using a Cobra gamma counter (Canberra 
Packard Benelux, Zellik, Belgium). The samples with calcitonin were analysed using an 
Enzyme-Linked Immunosorbent kit (Active® Ultra-sensitive salmon calcitonin, Diagnostic 
Systems Laboratories, Texas, USA). The fluorescence measurements were carried out on a 
fluorometer (Wallac 1420 multilabel counter, PerkinElmer, Turku, Finland) at 450 nm. 
The basal levels of calcitonin were determined by collecting blood samples from the ear veins 
at -5, 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 90, 120, 150 and 180 min from an untreated rabbit  
(n = 1). 
The individual serum concentration-time profiles were analysed using MW/Pharm       
version 3.15 (Medi-ware, Utrecht, The Netherlands). For calculation of the absolute 
biovailability (BA) the weight of the rabbits and the concentration of insulin or salmon 
calcitonin in the powder formulations were taken into account. For salmon calcitonin the 
basal levels were also taken into account. The maximum serum insulin concentrations (Cmax) 
and tmax values were determined from the individual serum concentration-time profiles. 
 
¾ Statistical analysis 
 
The influence of the powder formulations on the absolute nasal bioavailability, Cmax and tmax 
of insulin or salmon calcitonin was analysed using One-way ANOVA. The data and residuals 
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were tested for normal distribution using the Kolmogorov-Smirnov test and the homogeneity 
of variances was tested using the Levene’s test. If the distribution of the data or residuals was 
not normal or the variances were not homogeneous, the data were transformed (logarithm, 
square root or power). Specific sets were compared using Contrast Analysis (P < 0.05). The 
software program SPSS version 11.0 was used for statistical analysis. 
 
 
4.1.2.4 Rheological properties 
 
The elasticity (G’) and viscosity (G”) of the powders were determined on a TA Instruments 
AR 1000-N Rheometer (Zellik, Belgium) after dispersion (10 %, w/w) in simulated nasal 
fluid (7.45 mg/ml NaCl, 1.29 mg/ml KCl and 0.32 mg/ml CaCl2, Melon, 1968). The 
measurements were performed at 32 ± 0.5 °C using a cone of 4 cm with an angle of 1° and 
applying an oscillation stress of 1.4 Pa and a frequency of 0.1 Hz. The measurements were 
performed on SD 25/75 powders mixed with different concentrations of Ca(OH)2, but 
without insulin. 
 
 
4.1.2.5 Physical analysis 
 
The physical analysis of the powder formulations was performed by Prof. Dr. Ronald 
Verbeeck (Department of Dental Materials Science, Faculty of Medicine and Health 
Sciences, Ghent University). 
 
The neutralised (SD 25/75)/Ca(OH)2 powders were characterised by IR spectroscopy and    
X-ray diffractometry. IR spectra of the samples dispersed in KBr tablets were recorded 
between 400 and 4000 cm-1 with a resolution of 1 cm-1 using a Galaxy 6030 Fourier 
transform IR spectrophotometer (Mattson, Madison, WI, USA). X-ray powder diffraction 
patterns were recorded between 2 and 60° 2θ by step-scanning with a microprocessor-
controlled diffractometer system (PW 1830, Philips, Almelo, The Netherlands). Ni-filtered 
copper Kα radiation was used with an automatic divergence slit (PW 1836) and a graphite 
monochromator. The step scanning was performed with an integration time of 4 sec at 
intervals of 0.02° (2θ). The measurements were performed on the nasal powder formulations 
without insulin. 
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4.1.2.6 TEER experiment 
 
The TEER experiments were performed by Raf Mols and Prof. Dr. Patrick Augustijns 
(Laboratory for Pharmacotechnology and Biopharmacy, Faculty of Pharmaceutical 
Sciences, Katholieke Universiteit Leuven). 
 
4.1.2.6.1 Materials 
 
All chemicals used for culturing the Caco-2 cells were purchased from Cambrex (Verviers, 
Belgium). Cell culture medium consisted of Dulbecco’s modified Eagle’s medium 
supplemented with 10 % fetal bovine serum, 1 % MEM non-essential amino acids solution 
and 100 IU/ml penicillin-streptomycin. Transport medium (TM) consisted of Hanks’ 
balanced salt solution (HBSS) containing 25 mM D-(+)-glucose (Sigma, St. Louis, MO) and 
10 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES); pH was adjusted to 
7.4 at 37 °C with NaOH 2.0 M (BDH, Poole, UK). 
 
 
4.1.2.6.2 Cell culture 
 
Caco-2 cells originating from a human colon adenocarcinoma were purchased from Cambrex 
Biosciences (Walkersville, MD). Caco-2 cells were cultivated in 75 cm2 culture flasks at     
37 °C in an atmosphere of 5 % CO2 and 90 % relative humidity. Cells were passaged every   
3 - 4 days (at 70 - 80 % confluence) at a split ratio of 1 - 7. Cells were negative for 
mycoplasma infection. 
 
 
4.1.2.6.3 TEER experiments 
 
For transport experiments, Caco-2 cells were plated at a density of 40 000 cells/cm2 on 
Costar® Transwell membrane inserts (3 µm pore diameter, 12 mm diameter) (Corning, New 
York, USA). Confluence was reached within 3 - 4 days after seeding and the monolayers 
were used for the experiments 17 days post-seeding. Cell passage 42 was used in the 
experiments. Transepithelial electrical resistance-values (TEER values) were measured with 
an EndOhm Voltohmmeter (WPI, Aston, UK). TEER measurements are a means to check the 
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integrity of the monolayer and can reveal toxicity or an opening of tight junctions induced by 
the drug or excipients. Only monolayers with initial TEER values higher than 200 Ω.cm2 
were used. 
After rinsing the monolayers three times with calcium-free transport medium, the apical 
medium was removed and the cell culture inserts were transferred into wells containing      
1.5 ml transport medium. 1 mg (target amount) of the powder formulation SD 25/75 or           
(SD 25/75)/Ca(OH)2 90/10 was spread over the cell surface. After incubation of the cells 
during 2 or 5 min, 500 µl calcium-free transport medium was added to the apical side of the 
cell monolayer. TEER values were recorded immediately after adding the calcium-free 
transport medium and also 15, 30, 45 and 60 min after having added the powders. 
 
 
4.1.2.7 Liquid uptake rate 
 
The liquid uptake was studied hydrodynamically. 50 mg powder was placed on the upper side 
of a filter connected to a reservoir filled with simulated nasal fluid (SNF) (7.45 mg/ml NaCl, 
1.29 mg/ml KCl and 0.32 mg/ml CaCl2, Melon, 1968). The measurements were performed at 
32 ± 0.5 °C. The amount of SNF absorbed was determined volumetrically in function of time. 
 
 
4.1.2.8 Transmission electron microscopy study of the nasal epithelium  
 
The transmission electron microscopy was performed by Dorothea Van Limbergen and Prof. 
Dr. Claude Cuvelier (Department of Pathology, Faculty of Medicine and Health Sciences, 
Ghent University). 
 
10 mg powder composed of SD 25/75 and (SD 25/75)/CaCO3 90/10 was sprayed into each 
nostril of New Zealand white rabbits (3.0 ± 0.5 kg). 15 min after nasal administration the 
rabbits were sacrificed by exsanguination of the femoral arteries. Immediately after 
exsanguination the nasal cavity was excised and fixed in a 4 % paraformaldehyde/5 % 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.5). After fixation the tissue was cut 
in small slices and washed during 12 h in a 0.1 M sodium cacodylate buffer (pH 7.5). 
Postfixation was performed in 1 % osmium tetroxide in 0.1 M sodium cacodylate buffer. 
Then the tissue slices were dehydrated and embedded in Epon 812. Semi-thin (1 µm) 
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sections, stained with toluidin blue, were used for orientation of the tissue. Ultra-thin sections 
(60 nm) were stained with uranylacetate and lead nitrate and examined with a Zeiss TEM 
900. Digital pictures were taken with a Camera JENOPTIC JENA laser optic system.  
 
 
4.1.3 Results and discussion 
4.1.3.1 Addition of divalent cations to spray-dried Amioca®/Carbopol®  
 
Callens et al. (2003) demonstrated that nasal delivery of a powder formulation consisting of a 
neutralised mixture of spray-dried Amioca® starch/Carbopol® 974P (ratio: 25/75) resulted in 
an absolute bioavailability of 18 % in rabbits. Sodium hydroxide was used to neutralise the 
poly(acrylic acid) fraction, forming a sodium poly(acrylate). The aim of this study was to 
evaluate if Ca2+-poly(acrylates) were able to enhance the nasal absorption of insulin. Calcium 
poly(acrylates) were produced in situ by dispersing a physical mixture of spray-dried 
Amioca® starch/Carbopol® 974P (ratio: 25/75) and Ca(OH)2 (ratios: 90/1, 90/10, 90/20 and 
90/30) into distilled water. The interaction between the carboxylate groups of poly(acrylic 
acid) (≈ pH 3.1) and Ca(OH)2 and the neutralisation to pH 7.4 with NaOH resulted in a 
mixture of Na+- and Ca2+-carboxylate. The SD 25/75 formulation contained exclusively   
Na+-carboxylate, while the (SD 25/75)/Ca(OH)2 90/30 formulation was mainly composed of 
Ca2+-carboxylate. 
 
The different nasal formulations were analysed by X-ray diffractometry to confirm the in situ 
formation of Ca2+-carboxylates (Figure 1). The XRD patterns of the (SD 25/75)/Ca(OH)2 
powder formulations showed some broad bands comparable to the XRD pattern of the        
SD 25/75 mixture without Ca(OH)2. Diffraction peaks corresponding to the most intense 
diffraction peaks characteristic of crystalline Ca(OH)2 could not be detected. As the intense 
and sharp absorption peak of OH stretching vibration around 3643 cm-1, which is typical for 
Ca(OH)2, could also not be detected in the IR spectra of the (SD 25/75)/Ca(OH)2 powder 
formulation, the physical analyses indicated that the entire Ca(OH)2 content interacted with 
poly(acrylic acid). The IR spectra of the SD 25/75 powder formulations with and without 
Ca(OH)2 showed an intense and relative broad band centred at about 1560 cm-1 and a less 
intense absorption at 1454 cm-1 from the asymmetric and symmetric carbonyl stretching  
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Figure 1. IR spectra (at the top) and X-ray diffraction patterns (at the bottom) of powder formulations 
containing (SD 25/75)/Ca(OH)2 at different ratios. 
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vibration in poly(acrylate) salts (Crisp et al., 1974; Nicholson et al., 1988; Deb and 
Nicholson, 1999). Whereas the position of the absorption peak at 1454 cm-1 was 
independent of the amount of Ca(OH)2 added, the centre of the band at 1560 cm-1 shifted 
with increasing Ca(OH)2 concentration from 1575 cm-1 for the SD 25/75 mixture without 
Ca(OH)2 (containing only sodium poly(acrylate)) to 1552 cm-1 for (SD 25/75)/Ca(OH) 
90/30 (containing mainly calcium poly(acrylate)) (Figure 1). This indicated a gradual 
transition from an ionic structure to a chelating bidentate structure typical for calcium 
poly(acrylate) (Nicholson et al., 1988; Deb and Nicholson, 1999). In all spectra a weak but 
distinct absorption at 1680 cm-1 was observed which appeared as a shoulder on the 1560 
cm-1 band. This absorption is due to the carbonyl vibration in carboxyl groups, indicating 
that some COOH-groups of poly(acrylic acid) were not neutralised (Crisp et al., 1974; 
Nicholson et al., 1988). 
 
The fact that nearly all Ca(OH)2 in the powder formulations participated in the 
neutralisation of Carbopol® was observed indirectly during the preparation of the nasal 
powders. Aqueous dispersions of powder blends containing more Ca(OH)2 required less 
NaOH to reach pH 7.4, indicating that partial neutralisation of the carboxylic acid functions 
of Carbopol® occurred by Ca(OH)2. Furthermore, from the amount of Ca(OH)2 in the 
formulation and the amount of NaOH required to obtain pH 7.4, the free Ca2+-ion 
concentration could be estimated and was found to be minimal (Table 2). 
 
 
Table 2. Amount of Na+ and Ca2+ bound to Carbopol® 974P and amount of free Ca2+-ions in             
(SD 25/75)/Ca(OH)2 powders calculated from the amount of Ca(OH)2 present in the formulation and the 
amount of NaOH required to reach pH 7.4. 
Formulation mg Na+ bound/ 
g polymer 
mg Ca2+ bound/ 
g polymer 
mg free Ca2+/ 
g polymer 
 
SD 25/75 
 
263.1 
 
- 
 
- 
(SD 25/75)/Ca(OH)2 90/1 252.1 9.5 -1.5 
(SD 25/75)/Ca(OH)2 90/10 174.5 77.1 3.0 
(SD 25/75)/Ca(OH)2 90/20 106.3 136.1 23.8 
(SD 25/75)/Ca(OH)2 90/30 18.4 212.8 27.4 
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In the next experiment the absolute nasal bioavailability of insulin after administration of   
SD 25/75 physically mixed with Ca(OH)2 at a ratio 90/10 was determined in rabbits. The 
addition of Ca(OH)2 significantly increased the absolute nasal bioavailability (P < 0.001) and 
Cmax (P < 0.001), while tmax significantly (P < 0.001) decreased (Table 3). 
 
 
Table 3. Absolute bioavailability, Cmax and tmax (mean ± SD) after nasal delivery to rabbits of 
powders (1 IU insulin/mg) containing SD 25/75 physically mixed with Ca(OH)2 at different ratios.  
Formulation BA 
(%) 
Cmax 
(µIU/ml) 
tmax 
(min) 
n 
 
b SD 25/75 
 
19.2 ± 5.3 
 
681 ± 247 
 
50.9 ± 7.4 
 
8 
b (SD 25/75)/Ca(OH)2 90/1 24.6 ± 9.2 958 ± 484 44.5 ± 9.6 6 
a (SD 25/75)/Ca(OH)2 90/10      29.0 ± 11.4***  1813 ± 828*** 27.3 ± 3.4 8 
b (SD 25/75)/Ca(OH)2 90/20  9.6 ± 2.5 956 ± 225 15.1 ± 2.9 7 
b (SD 25/75)/Ca(OH)2 90/30 2.2 ± 0.7       181 ± 51 10.2 ± 4.6 8 
The BA and Cmax of  seta was compared to setb using Contrast Analysis (*** = P ≤  0.001). 
 
 
The influence of the ratio SD 25/75 versus Ca(OH)2 (90/1, 90/10, 90/20 and 90/30) on 
bioavailability was also investigated. After nasal delivery of these powders to rabbits a 
gradual increase in absorption of insulin was observed when the Ca(OH)2 content increased. 
A maximum was seen for the ratio 90/10. A further increase in Ca(OH)2 content to a ratio of 
90/30 resulted in a sudden drop of nasal insulin absorption (Figure 2, Table 3). Furthermore a 
linear relationship was obtained (P < 0.001, Linear Contrast Analysis) between Ca(OH)2 
concentration and tmax, this parameter decreased at higher calcium concentration. The ratio of 
Amioca starch/Carbopol 974P versus Ca(OH)2 had an important influence on the extent of 
absorption enhancement of insulin. 
 
In order to evaluate if a similar absorption enhancement could be obtained using another 
calcium salt, CaCO3 was incorporated in the carrier containing SD 25/75 at a ratio 90/10. For 
this formulation a similar (P > 0.05) absolute bioavailability (26.1 ± 9.8 %), Cmax                   
(1288 ± 670 µIU/ml) and tmax (28.7 ± 4.6 min) was obtained compared to the formulation 
with Ca(OH)2. 
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Figure 2. Insulin serum concentration-time profiles after nasal delivery to rabbits of powder formulations         
(1 IU insulin/mg) containing SD 25/75 physically mixed with Ca(OH)2 at different ratios: (90/1 (▲), 90/10 (■), 
90/20 (●) and 90/30 (-). The formulation based on SD 25/75 without Ca(OH)2 (◆) was used as reference. 
 
 
It is known that poly(acrylates) have the potential to bind calcium ions. They were able to 
prevent denaturation of proteins by enzymes that are thermodynamically stabilised by 
calcium (e.g. trypsin or α-chymotrypsin), through deprivation of the enzyme-bound calcium 
(Lueβen et al., 1995; Ameye et al., 2001). It has also been demonstrated that poly(acrylates) 
are able to deplete extracellular Ca2+ whereby the paracellular permeability through the 
epithelium is increased by opening the tight junctions (Borchard et al., 1996). However,  
Ca2+-poly(acrylates) exhibit different characteristics compared to Na+-poly(acrylates). 
Complexation of calcium by poly(acrylic acid) derivates decreased the particle size of 
dispersed swollen particles of these polymers as calcium acts as cross-linking agent between 
polymer chains (Kriwet et al., 1996). Madsen and Peppas (1999) demonstrated that calcium 
decreased the swelling ratio of gels containing grafted copolymer networks of 
poly(metacrylic acid-g-ethylene glycol) significantly compared to the swelling ratio obtained 
in buffers containing NaCl. This phenomenon is pH-dependent: in acid media (below pH 4.4) 
monovalent nor divalent cations affect the swelling ratio as the protonated carboxylic acid 
groups are not available for sodium or calcium binding. At increasing pH, the acid groups are 
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ionised whereby sodium or calcium ions can interact with the polymer. Sodium ions 
(monovalent cations) can move freely in the poly(acrylate) network, whereas calcium ions 
(divalent cations) promote aggregation of polymer chains by intermolecular bridge formation 
(Horkay et al., 2001). The electrostatic repulsion between the negatively charged carboxylic 
acid groups is lower for calcium poly(acrylates), resulting in a decrease of the swelling force 
and consequently a much lower equilibrium swelling ratio (Madsen and Peppas, 1999). 
This explained the decrease in tmax at higher Ca(OH)2 content. At a ratio of 90/20 and 90/30 a 
weaker gel was obtained after dispersion in simulated nasal fluid compared to the formulation 
without Ca(OH)2 (Table 4). The formulation at a ratio of 90/30 was even not able to form a 
homogeneous hydrated network, hence the viscosity and elasticity after dispersion in the 
nasal fluid could not be measured. This may result in a faster clearance of the formulations 
from the nasal cavity resulting in a decreased tmax.  
 
From Table 4 it can also be observed that specifically the formulation based on                  
(SD 25/75)/Ca(OH)2 90/10 exhibited a higher elasticity after dispersion in the nasal fluid 
compared to the reference formulation without Ca(OH)2. Although this can provide an 
explanation for the enhanced absorption observed for the formulation, it does not explain the 
shorter tmax. The highest absorption observed for this formulation is probably due to an 
optimal balance between Na+- and Ca2+-carboxylate groups on the poly(acrylate) chains. 
 
 
Table 4. Elasticity (G’) and viscosity (G”) of 10 % (w/w) dispersions 
into simulated nasal fluid. 
Formulation G’ 
(Pa) 
G” 
(Pa) 
 
SD 25/75 
 
1699 ± 31 
 
142 ± 4 
(SD 25/75)/Ca(OH)2 90/1 1673 ± 49 136 ± 3 
(SD 25/75)/Ca(OH)2 90/10 1822 ± 26 152 ± 6 
(SD 25/75)/Ca(OH)2 90/20 1412 ±176 113 ±15 
(SD 25/75)/Ca(OH)2 90/30 - - 
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Through the strong interaction between Ca2+ and the carboxylate groups, only a minimal 
concentration of free Ca2+-ions will be present in the formulation. It is improbable that 
dissociated free Ca2+-ions enhanced the paracellular absorption of insulin through the 
epithelium via the tight junctions. The integrity of the intercellular junctions can be 
modulated by divalent cations (e.g. Ca2+ and Mg2+): a reduction of extracellular calcium as 
well as increased intracellular calcium levels can improve paracellular absorption by opening 
of the tight junctions (Bhat et al., 1993; Brown and Davis, 2002). Therefore, loading the nasal 
cavity with additional free Ca2+-ions should rather reduce the nasal absorption of insulin. As 
for the formulations based on the ratio 90/1, 90/10 and 90/20 a higher Cmax was observed in 
comparison with the reference formulation without Ca(OH)2, it is demonstrated indirectly 
that Ca2+ is fixed on the carboxylate groups. On the other hand after dispersion of these 
formulations in nasal fluid, a progressive dissociation of Ca2+ from Ca2+-carboxylate might be 
responsible for their shorter tmax due to the closing of the tight junctions in response to the 
dissociated Ca2+-ions.  
 
This hypothesis was also suggested in a preliminary study wherein the mechanism of 
absorption enhancement of the SD 25/75 and (SD 25/75)/Ca(OH)2 90/10 powders was 
investigated using TEER measurements. Assessment of the transepithelial electrical 
resistance (TEER) was used as direct method to estimate the opening of the tight junctions. 
It was observed that hydrated SD 25/75 or (SD 25/75)/Ca(OH)2 90/10 particles had no effect 
on the TEER of the Caco-2 monolayers. In a second experiment, dry SD 25/75 or              
(SD 25/75)/Ca(OH)2 90/10 powder particles were spread on the apical side of the monolayers 
and after an incubation time of 2 or 5 min 500 µl calcium-free transport medium was added. 
After exposure of the epithelial cells to the dry powders a decrease in TEER was observed 
(Figure 3). This can be explained by the water absorbing capacity of the particles which 
dehydrated the epithelial cells causing a hydrostatic pressure within the paracellular space 
and opening of the tight junctions. A similar observation was made by Bjork et al. (1995) 
who found that only dry degradable starch microspheres were able to enhance the 3H-
mannitol transport across the Caco-2 cell monolayers. 
 
After the incubation period the formulation (SD 25/75)/Ca(OH)2 90/10 induced a slightly 
higher decrease in TEER compared to SD 25/75. This suggested that the former had a higher 
water absorbing capacity. Evaluation of SNF uptake of both formulations demonstrated that 
(SD 25/75)/Ca(OH)2 90/10 had a slightly higher and faster absorption of SNF what correlated  
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with the TEER data (Figure 4). As the decrease in TEER is a measure for opening the tight 
junctions a slightly higher paracellular transport may be obtained for                        
(SD 25/75)/Ca(OH)2 90/10, explaining the higher and faster absorption of insulin when this 
formulation was used as carrier. 
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Figure 3. Influence of powder formulations SD 25/75 (▲) and (SD 25/75)/Ca(OH)2 90/10 (●) on the TEER 
values of Caco-2 cells after an incubation period of 2 (closed symbols) and 5 min (open symbols). 
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Figure 4. Simulated nasal fluid uptake by SD 25/75 (▲) and (SD 25/75)/Ca(OH)2 90/10 (●)  
powders (n = 2, mean ± SD).  
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Using transmission electron microscopy it was observed that 15 min after nasal 
administration of SD 25/75 and (SD 25/75)/CaCO3 90/10 to rabbits the tight junctions were 
opened (Figure 5). However, no difference in the extent of opening between both 
formulations could be observed 
 
 
 
 
 
 
 
 
 
 
Figure 5. Transmission electron microscopy pictures of the closed tight junctions before nasal administration 
(A) (magnification 30000 x) and of the opened tight junctions 15 min after nasal administration of SD 25/75 (B) 
(magnification 30000 x) and (SD 25/75)/CaCO3 90/10 (C) (magnification 20000 x) to rabbits. 
 
 
 
 
A 
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After addition of calcium-free transport medium the TEER was followed in function of time. 
Calcium-free transport medium was used to allow detection of a possible effect of dissociated 
calcium ions on membrane integrity. For the (SD 25/75)/Ca(OH)2 90/10 formulation a 
progressive increase in TEER was observed in function of the time (after 60 min the TEER 
values were ± 15 % lower than the initial values), while for the SD 25/75 powder formulation 
a further decrease in TEER was found (after 60 min the TEER values were ± 80 % lower than 
the initial values) (Figure 3). This suggested that calcium ions gradually dissociated from the 
Ca2+-carboxylates. In Madin Darby canine kidney epithelial cells, a decreased transepithelial 
resistance due to decreased extracellular calcium levels was restored by calcium replacement 
(Balda et al., 1991). In primary pulmonary endothelial cultures, chelation of extracellular 
calcium increased the permeability of albumin, decreased the transepithelial resistance and 
caused retraction of adjacent cells. The normal barrier function was restored by repletion of 
calcium (Sasby and Sasby, 1986). Junctional resealing was also observed in native 
oesophageal epithelium when changing from calcium-free medium to calcium-containing 
solutions (Tobey et al., 2004). The increase in TEER observed for (SD 25/75)/Ca(OH)2 90/10 
after hydration might be contributed to repletion of extracellular calcium via dissociated 
calcium ions, thus closing the tight junctions. This can explain the low tmax seen for the 
formulations containing Ca2+-poly(acrylates). The further decrease in TEER after hydration 
of the SD 25/75 formulation could not be contributed to the calcium-free transport medium as 
medium compatibility with the Caco-2 monolayers has been demonstrated in preliminary 
tests. A further water absorption of the polymers in function of time might be a possible 
explanation. The prolonged decrease in TEER indicated that the tight junctions were opened 
for a longer period what may explain the higher tmax observed for this formulation. 
As some problems were reported concerning quantitative transfer of the powder formulations 
to the Caco-2 cells and homogeneous spreading of the particles over their surface, the results 
of this TEER experiment have to be considered as preliminary and have to be confirmed in an 
additional experiment.  
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4.1.3.2 Insulin versus salmon calcitonin 
 
The next experiment was performed to evaluate if a similar trend in bioavailability was 
observed when insulin (MW 5808 Da) was substituted by the smaller peptide salmon 
calcitonin (MW ± 3500 Da). Salmon calcitonin was used as it is more potent than human 
calcitonin in mammals, especially in man (Guttman, 1980). 
 
In Figure 6 the salmon calcitonin concentration versus time profile after intravenous 
administration of 10 IU salmon calcitonin to rabbits is shown. The basal levels of calcitonin 
were determined in untreated rabbits and varied between 14 and 17 pg/ml (Figure 7). As 
these concentrations were not negligible in comparison with the concentrations obtained after 
nasal delivery of salmon calcitonin, the basal levels were taken into account for the 
calculation of the absolute bioavailability. 
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Figure 6. Salmon calcitonin serum concentration-time profiles after intravenous administration of 10 IU salmon 
calcitonin to rabbits (n = 2). 
 
 
The salmon calcitonin serum concentration-time profiles obtained after nasal delivery of    
SD 25/75 and (SD 25/75)/Ca(OH)2 90/10 are given in Figure 7. It can be observed that 
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incorporation of salmon calcitonin into the carriers resulted in a similar trend as for insulin. 
Although the differences were not significant (P > 0.05), the absolute bioavailability and Cmax 
were higher while tmax was lower when SD (25/75)/Ca(OH)2 90/10 was used as carrier   
(Table 5). 
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Figure 7. Basal serum levels (●) and serum concentration-time profiles of salmon calcitonin after nasal delivery 
to rabbits of powders (2 IU salmon calcitonin/mg) based on SD 25/75 with CaCO3 (■) and without CaCO3 (▲). 
 
 
Table 5. Absolute bioavailability, Cmax and tmax (mean ± SD) of salmon calcitonin formulated in 
nasal powder formulations (2 IU salmon calcitonin/mg) containing SD 25/75 or                            
(SD 25/75)/Ca(OH)2 90/10.  
Formulation BA 
(%) 
Cmax 
(pg/ml) 
tmax 
(min) 
 
n 
 
SD 25/75 
 
5.8 ± 4.1 
 
56.5 ± 18.3 
 
15.8 ± 4.1 
 
4 
(SD 25/75)/Ca(OH)2 90/10 7.6 ± 2.7 81.3 ± 23.2 10.8 ± 3.2 4 
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Although the nasal bioavailability of hydrophilic molecules generally decreased with 
increasing molecular weight (Pontiroli and Pozza, 1990; Behl et al., 1998), the nasal 
bioavailability of salmon calcitonin was dramatically lower compared to equivalent 
formulations with insulin. This may be due to the different enzyme specificity as well as to 
the concentration and activity of both proteins (Hayakawa et al., 1989; Gizurarson and 
Bechgaard, 1991; Ishikawa et al. 2001). 
 
 
4.1.3.3 Spray-drying versus physical mixing 
 
The importance of using a spray-dried mixture of Amioca® starch and Carbopol® is 
emphasised in Figure 8 and Table 6. Nasal delivery of powders based on a physical mixture 
of Amioca® starch and Carbopol® 974P resulted in a significant (P < 0.001) lower absorption 
of insulin. Cmax was significantly (P = 0.001) lower, while a similar (P > 0.05) tmax was 
obtained. 
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Figure 8. Insulin serum concentration-time profiles after nasal delivery to rabbits of powders (1 IU insulin/mg) 
based on SD 25/75 (▲) and PM 25/75 (●) with Ca(OH)2 (closed symbols) and without Ca(OH)2 (open 
symbols). 
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Table 6. Absolute bioavailability, Cmax and tmax (mean ± SD) of insulin after nasal delivery to rabbits 
of powders (1 IU insulin/mg) based on SD 25/75 and PM 25/75 with and without the addition of 
Ca(OH)2. 
Formulation BA 
(%) 
Cmax 
(µIU/ml) 
tmax 
(min) 
n 
 
a SD 25/75 
 
    19.2 ± 5.3 *** 
 
     681 ± 247 *** 
 
50.9 ± 7.4 
 
8 
(SD 25/75)/Ca(OH)2 90/10 29.0 ± 11.4 1813 ± 828 27.3 ± 3.4 8 
b PM 25/75 4.9 ± 1.6 228 ± 178 47.8 ± 8.3 8 
c (PM 25/75)/Ca(OH)2 90/10 8.2 ± 4.3 385 ± 217      24.1 ± 3.4 *** 8 
Seta was compared to setb using Contrast Analysis (Significantly higher: *** = P ≤ 0.001). 
Setb was compared to setc using Contrast Analysis (Significantly lower: *** = P ≤ 0.001). 
 
 
The reduced absorption of the formulation based on the physical mixture can be attributed to 
the slower and lower hydration of the formulation compared to the equivalent spray-dried 
mixture (Figure 9). The uptake of insulin incorporated in PM 25/75 started 15 min after 
administration, while the onset of insulin absorption using the carrier SD 25/75 was within 5 
min after nasal delivery. 
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Figure 9. Simulated nasal fluid uptake by SD 25/75 (▲) and PM 75/25 (●) powder (n = 2, mean ± SD). 
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Creating a Ca2+-poly(acrylate) starting from a physical mixture of PM 25/75 and Ca(OH)2 in 
a ratio 90/10, the absorption of insulin was promoted compared to the equivalent formulation 
without Ca(OH)2: the absolute nasal bioavailability and Cmax were increased (P > 0.05) and 
tmax was decreased (P < 0.001) (Figure 8, Table 6).  
 
 
4.1.4 Conclusions 
 
Freeze-drying neutralised (using NaOH) aqueous dispersions containing Amioca starch, 
Carbopol 974P and Ca(OH)2 (or CaCO3) yielded powders containing a mixture of sodium 
and calcium carboxylate. There was an optimal balance between sodium and calcium 
carboxylate to enhance the absorption of insulin which was obtained for a formulation 
containing 10 % Ca(OH)2 or CaCO3. After nasal peptide delivery using these formulations a 
higher Cmax but lower tmax was observed in comparison with the equivalent formulations 
without Ca(OH)2. The mechanism of absorption enhancement was possibly due to the higher 
water absorbing capacity of the Ca-containing powder and to its higher elasticity after 
dispersion into the nasal fluid. The decrease in tmax when the calcium concentration in the 
formulation increased was possibly due to the progressive dissociation of calcium from the 
Ca2+-carboxylate after hydration of the powder, inducing a closure of the tight junctions. 
The importance of using a spray-dried starch/Carbopol mixtures instead of a physical 
mixture was also demonstrated as this contributed to the water absorbing capacity. 
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Chapter 4.2 Mucosal irritation testing on rabbits and slugs 
 
 
4.2.1 Introduction 
 
A very important issue in the development of nasal formulations is the irritating potential of 
the active ingredient as well as the non-active components. Formulations for protein and 
peptide delivery are mostly indicated for chronic therapies whereby their safety is as essential 
as their effectiveness. For nasal delivery four areas of toxicity can be distinguished: local 
irritation of the mucosa, effect on mucociliary clearance, epithelial damage and rate of 
recovery of the damaged epithelium (Agu et al., 2002). Different in vitro and in vivo methods 
have been developed to assess the toxicological effects of nasal formulations. An erythrocyte 
model has been used to demonstrate the membrane activity of different absorption enhancers 
such as bile salts, surfactants (Longenecker et al., 1987) and fatty acids (Mishima et al., 
1987). Histopathological examination of the nasal mucosa gives a qualitative assessment of 
morphological damage caused by the formulation (Merkus et al., 1993). As mucociliary 
clearance is a local defence mechanism protecting the respiratory tract from invading 
microorganisms, a nasal formulation should not adversely affect the normal mucociliary 
clearance mechanism. Agu et al. (1999) used human nasal epithelial cell cultures to predict 
the nasal cilio-toxicity of pharmaceutical compounds in humans by measuring the ciliary beat 
frequency. The mucociliary clearance can also be followed in vivo by gamma scintigraphy or 
using a saccharin clearance test (Schipper et al., 1991). 
 
The present study was performed to evaluate if the enhanced nasal bioavailability of insulin 
after administration of a powder formulation containing (SD 25/75)/CaCO3 90/10              
(cfr. Chapter 4.1) is due to mucosal damage. In literature it has been reported that enhanced 
bioavailability is frequently associated with a disruption of the integrity of the mucosal 
epithelium. 
The possible toxicological effects after multiple administration of the powders were 
evaluated using a non-invasive in vivo method in rabbits (Callens et al., 2001). After 
administration of the formulations the nasal cavity was washed with phosphate buffered 
saline to determine the release of lactate dehydrogenase (LDH) and alkaline phosphatase 
(ALP), which are biochemical markers for membrane damage. 
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This method was compared with the Slug Mucosal Irritation (SMI) assay developed by 
Adriaens and Remon (1999). The use of invertebrates as model organism for screening 
toxicological effects of chemicals on mucosal surfaces is preferred based on ethical and 
financial considerations. The hermaphroditic slug Arion Lusitanicus was selected as the body 
wall of the slug is covered with a single-layered epithelium containing ciliated cells, cells 
with microvilli and mucus-producing cells. Mucus secretion is essential for locomotion of the 
slug and protects its body wall against mechanical and chemical damage (South, 1992). The 
amount of mucus produced by the slugs during repeated contact with a chemical substance is 
a measure for irritation, while tissue damage can be estimated from the release of proteins 
and enzymes from the body wall (Adriaens and Remon, 1999, 2002; Callens et al., 2001; 
Ceulemans et al., 2001; Adriaens et al., 2003; Dhondt et al., 2004, 2005;                     
Weyenberg et al., 2004). 
 
In the past a similar comparison showed a good correlation between the non-invasive in vivo 
method in rabbits and the SMI assay (Callens, 2002). A formulation containing                   
Drum Dried Waxy Maize starch/Carbopol® 974P 90/10 (DDWM/C 974P 90/10) was 
administered nasally to rabbits during 28 consecutive days. Histological examination of the 
nasal epithelium at the end of the experiment revealed only a slight increase in the number of 
granulocytes. In the SMI test the same formulation was classified mildly irritating without 
causing membrane damage. For the negative control (untreated rabbits or slugs) an intact 
membrane in the nasal cavity of the rabbits was found after 28 days, which was in agreement 
with the results of the SMI assay where no irritation or membrane damage was seen. The 
positive control (DDWM/benzalkonium chloride 95/5), on the other hand, resulted in severe 
irritation and membrane damage in rabbits and slugs. Microscopic examination of the nasal 
epithelium of rabbits after daily treatment during only 5 days with the positive control 
showed a squamous epithelium with many granulocytes and ulcerations. Contact of the 
positive control with the foot mucosa of slugs induced severe irritation and irreversible 
damage of the mucosal tissue. 
 
The present study describes the optimisation of the SMI procedure for the evaluation of 
viscosity-enhancing and/or bioadhesive polymers. Upon contact between dry powders 
containing viscosity-enhancing and/or bioadhesive polymers and the body wall of slugs, the 
powder absorbs water from the mucosal epithelium whereby a polymer film is formed over 
the foot mucosa of the slug. After a contact period of 30 min with the powder, the slugs are 
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transferred to a Petri dish containing phosphate buffered saline (PBS) solution. The PBS 
samples are analysed for the presence of proteins, LDH and ALP released from the body wall 
to evaluate the membrane damage. When the polymer film on the foot mucosa is not 
completely removed, it may form a barrier to the release of proteins and enzymes from the 
mucosa into the PBS solution, possibly underestimating the toxicological effects induced by 
the formulation. As a consequence the SMI procedure was modified to ensure complete 
removal of the polymer film from the foot mucosa of the slug. This was done by washing the 
foot mucosa with 2 ml PBS and cautiously drying with absorbent paper or by cleaning the 
foot mucosa with paper moistened with PBS before the slugs were transferred to the Petri 
dish containing PBS. The effect of these modifications on the protein and enzyme release and 
the prediction of the mucosal tolerance of the powders were evaluated. 
 
 
4.2.2 Materials and methods 
4.2.2.1 Materials 
 
Phosphate buffered saline (PBS, pH 7.4) and sodium lauryl sulphate (SLS) were obtained 
from Sigma Diagnostica (Bornem, Belgium). The spray-dried mixture of Amioca starch and 
Carbopol 974P (ratio: 25/75, w/w) (SD 25/75) (batch number: 10851: 141-1) was prepared 
by National Starch and Chemical Company (Bridgewater, New Jersey, USA). Drum Dried 
Waxy Maize starch (DDWM) was obtained from Eridania-Béghin Say-Cerestar (Vilvoorde, 
Belgium). Calcium carbonate (CaCO3) (density: 0.30 g/ml) was purchased from Federa 
(Brussels, Belgium). All other chemicals were of analytical grade. 
 
 
4.2.2.2 Preparation of powder formulations 
 
1.0 g SD 25/75 or 1.0 g of a physical mixture of SD 25/75 and CaCO3 (ratio: 90/10, w/w) was 
dispersed in 40.0 ml distilled water and neutralised with 2.0 M NaOH to pH 7.4. Water was 
removed from the formulation by freeze-drying: the dispersion was frozen to 228 K within 
175 min at 1000 mbar. Primary drying was performed at 258 K and at a pressure varying 
between 0.8 and 1 mbar during 13 h, followed by secondary drying at elevated temperature 
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(283 K) and reduced pressure (0.1 - 0.2 mbar) for 7 h. After freeze-drying the powders were 
sieved (63 µm) at low relative humidity (20 %) and ambient temperature. The fractions below 
63 µm were stored in a desiccator at 4 - 8 °C until use.  
 
 
4.2.2.3 Irritation test on rabbits 
4.2.2.3.1 Experimental procedure 
 
During 5 consecutive days 10.0 mg of the nasal powders SD 25/75 or                        
(SD 25/75)/CaCO3 90/10 was sprayed into each nostril of New Zealand white rabbits (n = 6, 
3.0 ± 0.5 kg). The powders were administered using polyethylene tubes (Medisize, Hillegom, 
The Netherlands) connected to a syringe containing 1 ml compressed air (± 2.5 bar). This 
device was based on a system developed by Sørensen (1991). 
1 and 23 h after administration each nostril was washed with 600 µl PBS (pH 7.4) using a 
micropipette to quantify the amount of proteins, lactate dehydrogenase (LDH) and alkaline 
phosphatase (ALP) released from the mucosa into the nasal cavity. During these 
manipulations the rabbits were in supine position, their back lifted to an angle of 45° and 
their head was kept horizontally to prevent drainage of the PBS into the nasopharynx. After  
5 s PBS was collected in a test tube by returning the rabbits to their normal upright position. 
Release of the nasal epithelial cytosolic enzyme LDH served as an indicator for leakages 
caused by membrane damage or cell lysis, while the release of membrane-associated ALP 
gave an indication of membrane damage (Krishnamoorthy et al., 1995). 
 
 
4.2.2.3.2 Analytical procedures 
4.2.2.3.2.1 Determination of protein concentration 
 
The total protein concentration in the PBS samples was determined with a NanoOrange 
protein quantitation kit (Molecular Probes, Leiden, The Netherlands) (Harvey et al., 2001). 
The NanoOrange reagent allowed accurate detection of proteins in solutions at 
concentrations between 10 ng and 10 µg/ml. Bovine serum albumin was used as a standard. 
The fluorescence measurements were carried out on a fluorometer (Wallac 1420 multilabel 
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counter, PerkinElmer, Turku, Finland) using excitation/emission wavelengths of 485/590 nm. 
The protein concentration was expressed as µg/ml.  
 
 
4.2.2.3.2.2 Determination of LDH and ALP activity 
 
The lactate dehydrogenase activity (LDH, EC 1.1.1.27) and alkaline phosphatase activity 
(ALP, EC 3.1.3.1) were measured with an enzyme kit (LDH/HBDH 2.8 and ALP 6, ABX 
diagnostics, Montpellier, France). The enzyme activity measurements were conducted on a 
Cobas Plus analyser (ABX, Brussels, Belgium) at 37°C. The enzyme activity was expressed 
as U/l. 
 
 
4.2.2.3.3 Statistical analysis 
 
Per sampling point the mean protein concentration, LDH activity and ALP activity of both 
nostrils were calculated.  
Statistical analysis of the data was performed using SPSS version 11.0. To evaluate the effect 
of multiple powder administration on protein, LDH and ALP release from the nasal mucosa 
of rabbits a Repeated Measures Univariate Variance-Analysis was performed. The sphericity 
of the data was tested using the Mauchly’s test. If sphericity of the data was not fulfilled, a 
correction was made with the Huyn-Feldt test. The homogeneity of the variances was tested 
using the Levene’s test. To compare the nasal washings between the different powders and 
within one powder formulation a Bonferroni test was used with P < 0.05 as significance level. 
 
 
4.2.2.4 Slug Mucosal Irritation test 
4.2.2.4.1 Experimental procedure of Slug Mucosal Irritation test 
 
The mucosal irritation test according to the methodology described by Adriaens and     
Remon (1999) was modified for viscosity-enhancing and/or bioadhesive powders       
(Callens et al., 2001) and will be described briefly. Slugs weighing between 2.5 and 4.5 g 
were used. The experiment contained five negative control slugs (placed on 20 mg DDWM), 
five positive control slugs (placed on 20 mg DDWM/sodium lauryl sulphate                      
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Daily during 5 successive days 
30’ Contact Period with 
20 mg of the test substance 
Transfer slug to new Petri
dish. Add 1 ml PBS and
remove this after 1 h. 
Transfer slug to new Petri
dish. Add 1 ml PBS and
remove this after 1 h. 
Test procedure (5-day) 
Sample 1 
Sample 2 
30’ CP 
n=5 
Measure Mucus 
production 
Irritation 
Tissue damage 
Measure Protein, 
LDH & ALP release 
in samples 
Calculate Total Mucus
production 
Calculate Mean Protein,
Mean LDH release and
count number of slugs
inducing ALP release 
Endpoints Calculations Prediction Model 
Cut-off values for the Total Mucus
production are used to classify the
compounds into non-irritants, mild,
moderate and severe irritants 
A decision tree combining the results
of the Mean Protein, Mean LDH and
number of slugs showing ALP release
is used to convert the results into
tissue damage grades: minimal, mild,
moderate and severe tissue damage 
(ratio: 80/20, w/w) (DDWM/SLS)) and per test formulation five slugs (placed on 20 mg      
SD 25/75 or (SD 25/75)/CaCO3 90/10). The slugs were placed daily on the powder 
formulations during 30 min for 5 successive days. The amount of mucus produced during 
each contact period was determined. After the 30-min contact period, the slugs were 
transferred to a Petri dish containing 1 ml PBS (pH 7.4). After 1 h PBS was collected with a 
micropipette and the slugs were placed for another 1 h on a new Petri dish containing 1 ml 
PBS after which PBS was again collected. PBS samples were analysed for proteins, LDH and 
ALP released from the body wall. After sampling the slugs were placed on a membrane filter 
(cellulose acetate 0.45 µm, Sartorius, Goettingen, Germany) moistened with 2 ml PBS until 
the next contact period (Experiment I). A schematic overview of the procedure is given in 
Figure 1. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of the Slug Mucosal Irritation test procedure, this procedure was repeated during 5 
successive days. 
 
 
Two modifications of the procedure as described above were examined. For those 
experiments the same procedure was used, however before transferring the slugs to a Petri 
dish after the 30-min contact period with the formulation, the foot mucosa of the slugs was 
washed with 2 ml PBS and dried with absorbent paper (Experiment II) or the foot mucosa 
was cleaned with paper moistened with PBS (Experiment III). 
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4.2.2.4.2 Determination of endpoints 
4.2.2.4.2.1 Mucus production 
 
The amount of mucus produced during each contact period was measured by weighing the 
Petri dishes with the test item before and after each 30-min contact period. The mucus 
production was expressed as % of the body weight. The slugs were weighed before and after 
each 30-min contact period. 
 
 
4.2.2.4.2.2 Determination of protein concentration 
 
The protein concentration was determined as described in 4.2.2.3.2.1, but the protein 
concentration was expressed as µg/ml per g body weight. 
 
 
4.2.2.4.2.3 Determination of LDH and ALP activity 
 
The LDH and ALP activity were determined as described in 4.2.2.3.2.2, but the enzyme 
activity was expressed as U/l per g body weight. 
 
 
4.2.2.4.3 Interpretation of the results 
 
The irritation potency and tissue damaging effect of the test substances were estimated using 
a classification prediction model based on the endpoints of the SMI assay. The irritation 
potency was estimated by the total mucus production (4 classes: non-irritant, mild, moderate 
and severe irritant). The cut-off values for solids were used for classification. The total mucus 
production was calculated by averaging the mucus production of all slugs measured during 
each 30-min contact period. 
The tissue damage was predicted by the mean protein and LDH release and by the number of 
slugs showing ALP release (4 classes: minimal, mild, moderate and severe membrane 
damage). The overall mean protein release was calculated from the samples collected 
between day 2 until day 5 for each slug. For the LDH release the overall mean of the samples 
was calculated from all data points collected for each slug. The classification prediction 
model is depicted in Figure 2. 
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Figure 2. The Slug Mucosal Irritation prediction model that distinguishes between irritation potency and tissue 
damage. 
 
 
4.2.2.4.4 Acceptance criteria 
 
Before the results of the conventional set-up of the SMI assay (Exp. I) are considered valid, 
the following criteria had to be met: 
- the negative control (DDWM) should be classified as non-irritant (total mucus 
production < 7 %) and should induce minimal tissue damage (mean protein 
release < 25 µg/ml.g, mean LDH release < 1 U/l.g and no ALP release) 
- the positive control (DDWM/SLS 80/20) should be classified as a severe irritant 
(total mucus production > 20%) and should result in severe tissue damage (ALP 
release in 4 of the 5 slugs or mean protein release > 100 µg/ml.g)  
 
 
4.2.3 Results 
4.2.3.1 Nasal irritation study on rabbits 
 
The aim of this study was to compare the mucosal toxicity of the nasal powder formulation 
SD 25/75 with (SD 25/75)/CaCO3 90/10 after multiple administration to rabbits. Mucosal 
damage was monitored by determining the release of proteins and the two marker enzymes, 
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LDH and ALP, in the washings of the nasal cavity as described in the method developed by 
Callens et al. (2001). 
 
 
4.2.3.1.1 Preliminairy study 
 
In a preliminary study the protein concentration and the activity of LDH and ALP were 
determined in nasal washing collected 1 h before and 1 and 23 h after single nasal 
administration of SD 25/75 and (SD 25/75)/CaCO3 90/10 to rabbits. Washing 1 h after 
administration was done to investigate if an increased protein, LDH and ALP release 
occurred which is an indication of membrane damage. Washing of the nasal cavity 23 h after 
administration was performed to evaluate if the release of proteins and marker enzymes had 
returned to their basal level. This allowed to estimate the reversibility of membrane damage 
induced by the powders. The protein concentration and enzyme activity measured before 
administration were used as basal levels. 
This preliminary test was performed to evaluate the reproducibility of the method reported by 
Callens et al. (2001). The results are summarised in Table 1. 
 
 
Table 1. Protein concentration and LDH and ALP activity found in nasal washings 
performed 1 h before and 1 and 23 h after a single nasal administration of the powder 
formulations SD 25/75 and (SD 25/75)/CaCO3 90/10 to rabbits.  
 1 h before 1 h after 23 h after n 
LDH (U/l)     
SD 25/75 170 ± 172 a 750 ± 347 b 284 ± 107 a 4 
(SD 25/75)/CaCO3 90/10 253 ± 295 a 738 ± 413 b 379 ± 408 a 8 
 
ALP (U/l) 
    
SD 25/75 130 ± 166 a 236 ± 177 a 184 ± 70 a 4 
(SD 25/75)/CaCO3 90/10 90 ± 61 a 146 ± 66 a 152 ± 87 a 8 
 
PROTEINS (µg/ml) 
    
SD 25/75 1355 ± 842 a 2308 ± 792 a 1687 ± 554 a 4 
(SD 25/75)/CaCO3 90/10 1562 ± 597 a 1808 ± 563 a 1595 ± 845 a 8 
Data are presented as mean ± SD. 
Within each formulation the same subscripts are not significantly different from each 
other (P > 0.05, Bonferroni test). 
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For both formulations an increase in protein concentration and enzyme activity was measured 
in the PBS samples 1 h after administration. Only for LDH the increase was significant        
(P < 0.05). One hour after administration the differences in protein, LDH and ALP release 
between both treatments were not significant (P > 0.05), however the values for SD 25/75 
were higher than for (SD 25/75)/CaCO3 90/10. 
 
After 23 h the levels of proteins and enzymes in the nasal washings had decreased, although 
they remained slightly higher, but not significantly (P > 0.05), than the levels measured 
before administration. The decrease in protein and enzyme release 23 h after administration 
indicated that the effects of the powders on the nasal mucosa were reversible after single 
administration. 
 
Callens (2002) administered the SD 25/75 powder daily to rabbits during 28 days. Every      
3-4 days the nasal cavity was washed before and after administration to determine the protein 
concentration and enzyme activity. The results were compared to untreated rabbits (negative 
control group) and to rabbits treated with DDWM/benzalkonium chloride during                  
12 consecutive days (positive control group). The results of these experiments are shown in 
Table 2. 
 
Callens (2002) reported a similar trend after nasal delivery of SD 25/75 during 28 days as in 
the preliminary experiment after single administration: increased levels of proteins, LDH and 
ALP were found immediately after administration and these levels had decreased after 23 h. 
The protein concentration and enzyme activity after administration were clearly higher and 
lower compared to the negative and positive control, respectively. Furthermore, it was noted 
that the protein concentration and enzyme activity 1 h after administration of SD 25/75 was 
independent of the number of administrations, suggesting that the membrane damage is 
reversible. Moreover, in our preliminary experiment the levels of proteins, LDH and ALP 1 h 
after a single administration of SD 25/75 were in the same range of the values of the mean 
protein concentration and mean enzyme activity measured during multiple administration. 
This demonstrated that the non-invasive washing method described by Callens et al. (2001) is 
reproducible, therefore the negative and positive control experiments were not repeated based 
on ethical considerations and the data generated by Callens et al. (2001) will be used as 
reference values in this study. 
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Table 2. Mean protein concentration and mean LDH and ALP activity 
measured in nasal washings of untreated rabbits (negative control 
group), rabbits treated with DDWM/BAC 95/5 (positive control group) 
during 12 consecutive days and rabbits treated with SD 25/75 during 28 
days (Callens, 2002). 
 1 h before 1 h after n 
LDH (U/l)    
Negative control - 66 ± 20 3 
DDWM/BAC 95/5 - 4823 ± 1907 3 
SD 25/75 457 ± 153 810 ± 238 4 
 
ALP (U/l) 
   
Negative control - 96 ± 31 3 
DDWM/BAC 95/5 - 518 ± 194 3 
SD 25/75 215 ± 89 353 ± 151 4 
 
PROTEINS (µg/ml) 
   
Negative control - 627 ± 83 3 
DDWM/BAC 95/5 -   7086 ± 2978 3 
SD 25/75 1207 ± 262 1643 ± 310 4 
Data are presented as mean ± SD. 
 
 
4.2.3.1.2 Multiple administration during 5 days 
 
During 5 consecutive days 10.0 mg of the powder formulations SD 25/75 and                    
(SD 25/75)/CaCO3 90/10 was sprayed into each nostril of the rabbit. Each day the nasal 
cavity was washed 1 h before and 1 h after administration. The protein concentration and 
enzyme activity in the nasal washing sampled 1 h before the first powder administration were 
considered as basal levels. Three days after the last administration, an additional washing was 
performed to evaluate if the release of protein, LDH and ALP had returned to their basal 
levels. 
 
The LDH activity obtained 1 h and 23 h after nasal delivery of the powder formulations      
SD 25/75 and (SD 25/75)/CaCO3 90/10 are shown in Figure 3. The LDH activity of both 
formulations after administration was in general significantly higher (P < 0.05) compared to 
the basal LDH activity. Figure 3 also clearly illustrates that the LDH release was higher 
compared to the negative control, but lower than the positive control (Callens, 2002). 
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Although the increase for the formulation SD 25/75 was higher compared to                      
(SD 25/75)/CaCO3 90/10, this difference was only significant (P < 0.05) after the second 
administration because on days 3 to 5 a progressive decrease in LDH activity could be 
observed after nasal administration of SD 25/75. This could be due to the nasal mucosa 
adapting to the powders after multiple exposure. In case of the positive control no decrease in 
LDH activity was observed after multiple administrations. 
 
For both powder formulations a pronounced decrease in LDH release 23 h after 
administration was observed which was slightly higher than the basal LDH release and which 
decreased with increasing administrations. Moreover, the LDH activity measured on day 8 
(i.e. 3 days after the last administration) was similar (P > 0.05) to the basal LDH activity, 
indicating that any damage to the nasal epithelium induced by the powder formulations was 
reversible. 
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Figure 3. LDH activity in the nasal washings of rabbits 1 h before (open symbols) and 1 h after (closed 
symbols) administration of the powder formulations SD 25/75 (red) and (SD 25/75)/CaCO3 90/10 (blue) during 
5 consecutive days (n = 6, mean ± SD). The LDH activity in the nasal washings of the negative control 
(untreated) (-) and positive control (DDWM/BAC 95/5) (() rabbits performed 1 h after administration were 
added for comparison (n = 3, mean ± SD) (Callens, 2002). 
 
 
In Figure 4 the ALP activity in the nasal washings after nasal administration of SD 25/75 and 
(SD 25/75)/CaCO3 90/10 are shown. 1 h after nasal administration of SD 25/75 and           
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(SD 25/75)/CaCO3 90/10 an increased ALP activity was measured from day 2 and day 4, 
respectively. Only after the second administration the ALP activity induced by SD 25/75 was 
higher than for (SD 25/75)/CaCO3 90/10, although not significantly (P > 0.05). A decreased 
ALP release from the mucosa was observed after repeated nasal administrations of SD 25/75, 
whereas for the positive control an increased was seen. 
 
23 h after second and third administration of SD 25/75 and (SD 25/75)/CaCO3 90/10, 
respectively, the ALP release had decreased to levels slightly above the basal ones. For both 
formulations the ALP activity measured after 23 h decreased after repeated administrations 
and 3 days after the last administration the basal level of ALP release was detected, indicating 
a complete recovery of the nasal mucosa. 
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Figure 4. ALP activity in the nasal washings of rabbits 1 h before (open symbols) and 1 h after (closed symbols) 
administration of the powder formulations SD 25/75 (red) and (SD 25/75)/CaCO3 90/10 (blue) during 5 
consecutive days (n = 6, mean ± SD). The ALP activity in the nasal washings of the negative control (untreated) 
(-) and positive control (DDWM/BAC 95/5) (() rabbits performed 1 h after administration were added for 
comparison (n = 3, mean ± SD) (Callens, 2002). 
 
 
The protein concentration in the nasal cavity of rabbits after nasal delivery of SD 25/75 and 
(SD 25/75)/CaCO3 90/10 are shown in Figure 5. Although no statistical differences              
(P > 0.05) were detected between the protein concentration before and after nasal delivery, a 
similar trend was observed as for the release of the marker enzymes. After administration a 
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pronounced increase in protein release was observed combined with a return to the basal 
levels after 23 h. In comparison with (SD 25/75)/CaCO3 90/10 the SD 25/75 powder induced 
a higher release of proteins from the nasal mucosa, although this difference was not 
significant (P > 0.05). 
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Figure 5. Protein concentration in the nasal washings of rabbits 1 h before (open symbols) and 1 h after (closed 
symbols) administration of the powder formulations SD 25/75 (red) and (SD 25/75)/CaCO3 90/10 (blue) during 
5 consecutive days (n = 6, mean ± SD). The protein concentration in the nasal washings of the negative control 
(untreated) (-) and positive control (DDWM/BAC 95/5) (() rabbits performed 1 h after administration were 
added for comparison (n = 3, mean ± SD) (Callens, 2002). 
 
 
4.2.3.2 Slug Mucosal Irritation assay 
 
The mucosal tolerance of the powders SD 25/75 and (SD 25/75)/CaCO3 90/10 was also 
evaluated using an alternative mucosal irritation test on slugs. The irritation potency was 
evaluated based on the amount of mucus produced by the slugs, whereas tissue damage was 
assessed by the release of proteins and enzymes (LDH and ALP) from the body wall. The 
observations made during this study will be compared to the results from the non-invasive 
washing method in rabbits (cfr. paragraph 4.2.3.1). In addition, the results of preliminary tests 
performed in order to optimise the procedure of the mucosal irritation test on slugs are 
discussed. 
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The results of the mucosal irritation of powders tested according to the procedure described 
by Callens et al. (2001) (Exp. I) are shown in Table 3. 
 
 
Table 3. Effect of SD 25/75 and (SD 25/75)/CaCO3 90/10 on the endpoints of the Slug Mucosal Irritation 
test (n = 5, mean ± SD). 
 Total MP 
(%) 
Protein 
(µg/ml.g) 
     LDH 
    (U/l.g) 
ALP 
(U/l.g)         (n) 
Irritation/ 
Damage 
Exp I       
DDWM   4.5 ± 1.1    10 ± 7 - - 0/5 NI/Min 
DDWM/SLS 80/20 23.3 ± 1.4 120 ± 28 0.3 ± 0.2 0.2 ± 0.5 1/5 Sev/Sev 
SD 25/75 18.4 ± 4.2 49 ± 30 0.2 ± 0.3 - 0/5 Mo/Mild 
(SD 25/75)/CaCO3 90/10 16.1 ± 2.0 30 ± 13 - - 0/5 Mo/Mild 
 
Exp II 
      
DDWM  5.5 ± 1.8  36 ± 16 0.3 ± 0.2 - 0/5 NI/Mild 
DDWM/SLS 80/20 21.1 ± 1.0 150 ± 86 2.1 ± 1.8 0.4 ± 0.6 2/5 Sev/Sev 
SD 25/75 18.6 ± 1.1 61 ± 40 0.5 ± 0.4 - 0/5 Mo/Mo 
(SD 25/75)/CaCO3 90/10 16.8 ± 1.8 26 ± 15 0.2 ± 0.2 - 0/5 Mo/Mild 
 
Exp III 
      
DDWM  6.8 ± 1.4 19 ± 7 0.1 ± 0.1 - 0/5 NI/Min 
DDWM/SLS 80/20 19.6 ± 2.4 175 ± 46 2.5 ± 0.6 0.4 ± 0.4 5/5 Mo/Sev 
SD 25/75 17.9 ± 1.4 88 ± 32 1.2 ± 1.2 0.3 ± 0.6 1/5 Mo/Mo 
(SD 25/75)/CaCO3 90/10 16.2 ± 1.3 48 ± 21 0.4 ± 0.4 - 0/5 Mo/Mild 
MP: mucus production in % (w/w) of the body weight 
 
 
The powder formulations induced a mucus production higher than the negative control but 
lower than the positive control. After contact with SD 25/75 the slugs produced a slightly 
higher amount of mucus compared to (SD 25/75)/CaCO3 90/10. The amount of mucus 
produced per day by the positive control slugs decreased after repeated treatments, whereas 
the mucus production of the slugs treated with the test formulations remained constant. This 
indicated that the mucus-secreting cells of the positive control slugs were severely and 
irreversibly damaged after repeated contact. In contrast, the cells of slugs treated with          
SD 25/75 and (SD 25/75)/CaCO3 90/10 sufficiently recovered in between contact periods. 
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The protein release after contact with SD 25/75 and (SD 25/75)/CaCO3 90/10 was also higher 
than for the negative control. For SD 25/75 the release was slightly higher than for             
(SD 25/75)/CaCO3 90/10 and seemed to increase after repeated contact with the material. 
This indicated that SD 25/75 might have a higher membrane damaging potential. However, 
the protein concentrations in the PBS samples of the positive control slugs were clearly 
higher and the release increased after each contact period. 
 
The LDH activity of the negative control slugs and the slugs treated with                        
(SD 25/75)/CaCO3 90/10 was below the detection limit. In case of SD 25/75 LDH was only 
detected on the last day of the experiment for 3 slugs. After contact with the positive control 
all slugs released LDH, three of them already after the third treatment. ALP release was only 
detected in samples of the positive control slugs. 
 
Based on the endpoints of the SMI assay summarised in Table 3 and the prediction model 
which is shown in Figure 2, the powder formulations SD 25/75 and (SD 25/75)/CaCO3 90/10 
are classified according to their irritation potency and membrane damaging capacity. Despite 
the higher mucus production, protein concentration and LDH activity after contact with      
SD 25/75, both formulations were considered to be moderately irritating and mildly 
membrane damaging. The negative control was classified as a non-irritant inducing minimal 
damage to membranes. In contrast, the positive control was a severe irritant causing severe 
damage of mucosal tissue after contact. 
 
The following experiments were performed in order to evaluate if incomplete removal of the 
polymer film formed during the 30-min contact period between mucus and the test 
formulation may act as a barrier to protein and enzyme release from the mucosal tissue of the 
slug into the PBS solution. Therefore, the procedure of the SMI assay was modified. A first 
experiment was performed wherein the foot mucosa of the slug was washed with 2 ml PBS 
and cautiously dried with paper immediately after the 30-min contact period (Exp. II). In a 
second experiment the foot mucosa was carefully cleaned with paper moistened with PBS 
(Exp. III). The results of both experiments are shown in Table 3. 
 
Using the procedure of Exp. II and III a similar total mucus production was measured 
compared to Exp. I, resulting in the same classification for irritation according to the 
prediction model. Using the procedure of Exp. III the positive control was classified as 
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moderate irritating instead of severe irritating as was concluded in Exp. I and II. However, it 
should be mentioned that the positive control in Exp. III (19.6 % mucus production) was a 
borderline case as the upper limit of moderate irritation for mucus production was 20 %. 
 
The protein concentration in the PBS samples using the protocol of Exp. II was higher 
compared to the concentrations measured in Exp. I, even for the negative control. Protein 
concentrations in the PBS samples obtained using Exp. III were higher compared to Exp. II 
(except for the negative control). 
 
Using the modified test set-ups (Exp. II and III) LDH release was detected for all 
formulations. For the negative control samples LDH was measured earlier and in higher 
activities in Exp. II compared to Exp. III. This observation was in contradiction with the 
results of the positive control and the two test formulations. For the positive control and     
SD 25/75 higher LDH activities were detected at an earlier stage when the modified protocols 
were used. During Exp. III LDH was detected in all slugs treated with the positive control 
released from the third contact period, whereas in Exp. II there was still one slug for which 
LDH activity was found only after the last contact period. In case of SD 25/75 LDH activities 
were found after the fourth contact period in two and four slugs during Exp. II and III, 
respectively. Also for (SD 25/75)/CaCO3 90/10 LDH release occurred earlier and in higher 
activities in Exp. III: three slugs produced LDH after four days in Exp. III, whereas in Exp II 
only two slugs released LDH after the fifth contact period. 
 
The ALP release of the positive control slugs showed a similar trend between the different 
procedures as the LDH release: an earlier detection, in higher quantities and by a higher 
number of slugs in the following rank order Exp. III > Exp. II > Exp. I. The ALP release seen 
for SD 25/75 in Exp III. was produced by one slug from the third contact period.  
 
Due to the higher protein concentrations in the PBS samples of Exp. II, the membrane 
damaging potential of the negative control formulation was classified in a higher scale 
compared to Exp. I: mild tissue damaging (Exp. II) versus minimal (Exp. I). Using the 
procedure of Exp. III the same prediction was made for the negative control as in Exp. I: 
minimal membrane damage. 
Changing the protocol of the SMI test had no influence on the prediction of the positive 
control: severe tissue damage in all cases.  
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Despite the higher protein concentration and LDH activity measured in Exp. II and III for 
(SD 25/75)/CaCO3 90/10, this material was classified in the same class as in Exp. I: mild 
tissue damaging. On the other hand the SD 25/75 formulation, was more membrane 
damaging following the modified procedures compared to Exp I: moderate (Exp. II and III) 
versus mild tissue damage (Exp. I). However, it should be noted that SD 25/75 in Exp. I was 
a borderline case for its membrane damaging potential: a mean protein release of                 
49 ± 30 µg/ml.g was measured, whereas the lower limit of the moderate irritation class was 
50 µg/ml.g.  
 
 
4.2.4 Discussion 
 
It has been demonstrated that the non-invasive washing technique in rabbits                
(Callens et al., 2001) is a reproducible method to evaluate the toxicity of nasal formulations. 
The simplicity of the experimental set-up is in contrast with other in vivo methods described 
in literature. Hirai et al. (1981) and Huang et al. (1985) developed an in-situ perfusion 
technique whereby the trachea of anaesthetised rats was cannulated to maintain respiration. A 
second cannula was inserted through the oesophagus to the posterior part of the nasal cavity. 
This cannula served to perfuse the nasal cavity with the test solution, which was recirculated 
during 1.5 to 6 h using a peristaltic pump. Furthermore, the passage of the nasopalatine tract 
was sealed with an adhesive agent to prevent drainage of the solution from the nasal cavity to 
the mouth. This method was adapted by Marttin et al. (1995) in order to better mimic the 
physiological conditions. However, cannulation of anaesthetised rats was still required. 
Moreover, in perfusion tests the mucus layer is progressively washed away, hence the nasal 
epithelium is in direct contact with the test solutions (Merkus et al., 1999). 
 
Using the non-invasive washing technique in rabbits it was shown that both powder 
formulations SD 25/75 and (SD 25/75)/CaCO3 90/10 caused mucosal irritation and membrane 
damage after nasal administration as an increased protein, LDH and ALP release from the 
nasal mucosa was observed. A higher membrane damaging potential was observed for        
SD 25/75 compared to (SD 25/75)/CaCO3 90/10. For both powders the effects on the 
epithelium were reversible as the protein concentrations and enzyme activities decreased 
within 24 h, returning to their basal levels within 3 days.  
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A progressive decrease in protein and enzyme release was observed after repeated 
administrations to rabbits. This might be related to adaptation of the nasal mucosa to the 
powders after multiple exposure. This might also be attributed to incomplete clearance of the 
formulation from the nasal cavity within 24 h (Callens et al., 2003). As a result a polymer 
film covering the nasal mucosa would prevent contact between the nasal epithelium and 
powder particles after the next powder administration. In addition a polymer film would also 
prevent the release of protein or marker enzymes into the nasal cavity. Therefore, the 
toxicological effects induced by the formulation may be underestimated. However, the non-
invasive washing technique in rabbits allowed a good prediction of the membrane damaging 
potential of the powders as the conclusions correlated with those drawn with the SMI assay.  
 
Using the Slug Mucosal Irritation test the formulations SD 25/75 and                        
(SD 25/75)/CaCO3 90/10 induced a higher mucus production and release of proteins 
compared to the negative control formulation, indicating that the formulations had a 
membrane irritating and damaging potential, although considerably lower compared to the 
positive control. Only for SD 25/75 LDH release was detected in Exp. I. In the modified 
procedures, LDH release was observed for both formulations, but the activities measured for 
SD 25/75 were the highest. Using the prediction model SD 25/75 was also classified as 
having a higher membrane damaging potential compared to (SD 25/75)/CaCO3 90/10.  
 
The protocols of the SMI assay had a pronounced influence on the protein concentration and 
LDH and ALP activity found in the PBS samples: the results obtained using the modified 
protocols (Exp. II and III) suggested that the procedure of Exp I may underestimate the tissue 
damaging potency of the formulations, especially for test substances on the borderline 
between the mild and moderate class. This might be explained by a partial removal of the thin 
polymer film covering the foot mucosa of the slug, hampering the release of proteins and 
enzymes from the epithelial cells. In Exp II the negative control (DDWM) was classified as 
mild instead of minimal damaging for the membranes. However, the non-irritating properties 
of DDWM have clearly been demonstrated by several authors (Bottenberg et al., 1991; 
Bouckaert et al., 1993, 1996; Callens et al., 2001; Ceulemans et al., 2001; Weyenberg et al., 
2004), suggesting that the results obtained with Exp. II overestimate the mucosal toxicity 
induced by dry powder formulations.  
Although the same conclusions were drawn for the test formulations with Exp. II and       
Exp. III, the procedure of Exp. II is considered to be more aggressive as the protein release 
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for the negative control slugs was higher than the results in Exp. I and LDH release was 
detected in higher number of slugs in comparison with Exp. III.  
Consequently, the procedure of Exp III will be further optimised and validated to allow a 
more accurate prediction of the mucosal toxicity of dry powder formulations using slugs as 
test organism. 
 
The moderate irritating potential and mild to moderate membrane damage of the powders   
SD 25/75 and (SD 25/75)/CaCO3 90/10 is probably due to poly(acrylic acid) incorporated in 
the formulation as Carbopol® has been reported to cause membrane damage when used in 
high concentrations. Buccal bioadhesive tablets containing ≥ 50 % Carbopol® 934P induced 
mucosal injuries in humans (Bottenberg et al., 1991). Nasal delivery of Carbopol® 971P to 
rabbits resulted in severe inflammation of the nasal epithelium (Ugwoke et al., 2000). 
However, in the present study the spray-dried mixture of Amioca®starch and Carbopol® 974P 
was neutralised, thus reducing the irritating and membrane damaging potential of    
Carbopol® 974P. Previous experiments have shown (Adriaens et al., 2003) that slugs exposed 
to a non-neutralised mixture of starch/Carbopol® 974P (ratio: 60/40, w/w) produced a similar 
amount of mucus after multiple contact periods compared to slugs treated with a neutralised 
mixture of starch/Carbopol® 974P containing 75 % Carbopol®. In addition, the non-
neutralised mixture containing 40 % Carbopol® 974P induced a cytosolic LDH release    
(0.70 ± 0.85 U/l.g). Under the same experimental conditions only a minimal LDH release 
(0.2 ± 0.3 U/l.g) was seen for the neutralised mixture containing 75 % Carbopol®. According 
to the prediction model a neutralised mixture of starch/Carbopol® 974P at a ratio of 25/75 has 
a similar mucosal toxicity as a non-neutralised starch/Carbopol® 974P mixture containing   
40 % Carbopol®: moderate irritation and mild membrane damage.  
 
 
4.2.5 Conclusions 
 
A good correlation was found between the non-invasive nasal washing technique in rabbits 
and the Slug Mucosal Irritation assay during the toxicological evaluation of the nasal powder 
formulations SD 25/75 and (SD 25/75)/CaCO3 90/10. As a slightly higher mucosal tolerance 
was obtained for the formulation containing CaCO3, the absorption enhancement of insulin 
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observed with the carrier (SD 25/75)/CaCO3 90/10 was not due to a higher disruption of the 
integrity of the mucosal tissue. 
Both formulations were classified as substances which cause moderate membrane irritation 
and mild to moderate membrane damage, hence they are not recommended for chronic drug 
therapies, but are rather indicated for single use drug delivery (e.g. nasal vaccination). 
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Chapter 5 Stability of spray-dried Amioca 
starch/Carbopol powder 
 
 
5.1 Introduction 
 
Stability testing was performed on a spray-dried mixture of Amioca starch/Carbopol 974P 
(ratio: 25/75, w/w) stored during 9 months as bulk powder in an open container at different 
temperatures and relative humidities. The moisture content, simulated nasal fluid uptake rate 
and rheological properties of the powder as well as the pharmacokinetic parameters of insulin 
after nasal delivery to rabbits were determined in function of time. 
 
 
5.2 Materials and Methods 
5.2.1 Materials 
 
Actrapid HM 100 (100 IU/ml) (human monocomponent insulin) was obtained from Novo-
Nordisk (Bagsvaerd, Denmark). The spray-dried mixture of Amioca starch and      
Carbopol 974P (ratio: 25/75, w/w) (SD 25/75) (batch number: 12621: 14F) was prepared by 
National Starch and Chemical Company (Bridgewater, New Jersey, USA). Carbopol 974P 
was supplied by Noveon (Cleveland, Ohio, USA). All other chemicals were of analytical 
grade. 
 
 
5.2.2 Storage conditions 
 
SD 25/75 was stored as bulk powder in an open container at three different storage 
conditions: at room temperature (25 ± 2 °C) in a sealed box containing silica particles to 
obtain a relative humidity of 10 ± 5 %, at room temperature (25 ± 2 °C) in a sealed box 
containing a saturated sodium bromide solution to obtain a relative humidity of 60 ± 5 % and 
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in an oven (40 ± 2 °C) in a sealed box containing a saturated sodium chloride solution to 
obtain a relative humidity of 75 ± 5 %. 
 
 
5.2.3 Insulin formulations 
5.2.3.1 Insulin solution for intravenous administration 
 
An insulin solution of 0.8 IU/ml was prepared by diluting Actrapid HM 100 in a phosphate 
buffered saline solution (PBS, pH 7.4) (2.38 g Na2HPO4.2H2O, 0.19 g KH2PO4 and 8.0 g 
NaCl per liter distilled water) of which 0.5 ml was administered intravenously to rabbits       
(n = 10). 
 
 
5.2.3.2 Nasal powder formulations 
 
After dispersion of 0.5 g SD 25/75 in 15 ml distilled water, 2.0 M NaOH was added until   
pH 7.4 was reached. Then the insulin solution (Actrapid® HM 100) was added in order to 
obtain a final concentration of 1 IU insulin per mg powder, taking the moisture content of the 
powder formulation into account. 
To obtain a powder, the aqueous dispersion was freeze-dried using an Amsco-Finn Aqua 
GT4 freeze-dryer (Amsco, Germany). The dispersion was frozen to 228 K within 175 min at 
1000 mbar. Primary drying was performed at 258 K and at a pressure varying between       
0.8 and 1 mbar during 13 h, followed by secondary drying at elevated temperature (283 K) 
and reduced pressure (0.1 - 0.2 mbar) for 7 h. 
After freeze-drying the powder was sieved (63 µm) at low relative humidity (20 %) and 
ambient temperature. The fraction below 63 µm was stored in a desiccator at 4 - 8 °C until 
use. 
 
 
5.2.4 Measurements 
 
The nasal bioavailability, the simulated nasal fluid uptake rate, the moisture content and the 
rheological properties were determined before storage and after 3, 6 and 9 months storage  
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(25 °C - 10 % RH; 25 °C - 60 % RH and 40 °C - 75 % RH). A freeze-dried formulation    
(cfr. paragraph 5.2.3.2) was used to determine the nasal bioavailability, liquid uptake rate and 
rheological properties, whereas the moisture content of the bulk powders was determined. 
 
 
5.2.5 Moisture content 
 
The moisture content was determined using a Mettler DL 35 Karl Fischer titrator (Mettler-
Toledo, Beersel, Belgium). Hydranal-Composite 2 (Riedel-de Haën Laborchemicalien, 
Seelze, Germany) was used as titrant and anhydrous methanol (Riedel-de Haën 
Laborchemicalien, Seelze, Germany) as reaction medium. Calibration and verification of the 
titrant (theoretical 2 mg H2O/ml) was performed with distilled water.  
 
 
5.2.6 Liquid uptake rate 
 
The liquid uptake rate was studied hydrodynamically. 50 mg powder formulation was placed 
on the upper side of a filter connected to a reservoir filled with simulated nasal fluid (SNF) 
(7.45 mg/ml NaCl, 1.29 mg/ml KCl and 0.32 mg/ml CaCl2, Melon, 1968). The measurements 
were performed at 32 ± 0.5 °C. The amount of SNF absorbed was determined volumetrically 
in function of time. 
 
 
5.2.7 Rheological properties 
 
The elasticity (G’) and viscosity (G”) of the powder formulations were determined on a      
TA Instruments AR 1000-N Rheometer (Zellik, Belgium) after dispersion (10 %, w/w) in 
simulated nasal fluid. The measurements were performed at 32 ± 0.5 °C using a cone of 4 cm 
having an angle of 1° and applying an oscillation stress of 25 Pa and a frequency of 0.1 Hz. 
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5.2.8 Nasal bioavailability  
 
New Zealand white rabbits (3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was 
available ad libitum. They were sedated with an intramuscular injection of 0.05 ml/kg 
Placivet (Codifar, Florida, USA). The rabbits received 0.4 IU insulin intravenously. 10 mg 
powder formulation (equivalent to 10 IU insulin) was administered in each nostril using 
polyethylene tubes (Medisize, Hillegom, The Netherlands). The powder was released from 
the tubes using a syringe containing 1 ml compressed air (2.5 bar). This device was based on 
a system developed by Sørensen (1991). The tubes were filled under conditions of low 
relative humidity (20 %) and ambient temperature. Blood samples were collected from the 
ear veins at -5, 1, 5, 10, 15, 20, 30, 40, 50 and 60 min after intravenous administration and at 
-5, 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 90, 120, 150 and 180 min after nasal delivery of the 
powder formulations. The samples were centrifuged (700g, 5 min) and the sera were frozen at 
–20 °C until RIA-analysis (Coat-A-Count kit, DPC, Humbeek, Belgium). The radioactivity 
of the samples was quantified using a Cobra gamma counter (Canberra Packard Benelux, 
Zellik, Belgium). The individual serum concentration-time profiles were analysed using 
MW/Pharm version 3.15 (Medi-ware, Utrecht, The Netherlands). For calculation of the 
absolute biovailability (BA) the weight of the rabbits and the concentration of insulin in the 
powder formulations were taken into account. The maximum insulin serum concentrations 
(Cmax) and tmax values were determined from the individual serum concentration-time 
profiles.  
 
¾  Statistical analysis 
 
Statistical analysis was performed on the absolute bioavailability, Cmax and tmax values of the 
different powder formulations using a one-way Anova followed by post hoc Scheffé test with 
P < 0.05 as significance level. The data and residuals were tested for normal distribution 
using the Kolmogorov-Smirnov test and the homogeneity of variances was tested using the 
Levene’s test. If the distribution of the data or residuals was not normal or the variances were 
not homogeneous, the data were transformed to their power. The computer software SPSS 
version 11.0 was used for statistical analysis. 
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5.3 Results and Discussion 
5.3.1 Moisture content 
 
In Figure 1 the moisture content of the SD 25/75 powder in function of storage time and 
storage conditions is shown.  
 
SD 25/75 stored at 10 % RH resulted in a lower moisture content compared to the initial 
spray-dried powder due to the water absorbing capacity of the silica particles. Storage at      
60 % and 75 % RH increased the water content from 4 % (t = 0) to 10 and 12 % (w/w), 
respectively.  
 
Storage time had no influence on the moisture content at each storage condition. 
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Figure 1. Influence of storage time and storage conditions on moisture content (% (w/w)) of SD 25/75        
(mean ± SD, n = 3). 
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5.3.2 Liquid uptake 
 
The uptake of simulated nasal fluid (SNF) by the freeze-dried nasal powders based on        
SD 25/75 stored at different conditions is given in Figure 2. 
A higher relative humidity and temperature induced a fast hydration rate: at 40 °C – 75 % RH 
a fast and complete hydration of the polymer chains (SNF uptake: ± 7.7 ml/g) was observed 
within 45 s. Storage at 25 °C – 10 % RH and 25 °C – 60 % RH resulted in nasal powder 
formulations having a slower SNF uptake: ± 12.6 ml/g and ± 16.0 ml/g over a period of 1 h, 
respectively. The hydration rate of powder stored at 25 °C – 10 % RH was similar to the 
hydration rate prior to storage and was slightly lower than the powder stored at                     
25 °C – 60 % RH. Storage time had no influence on the hydration rate of the formulation. 
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Figure 2. Influence of storage time (0m (●), 3m (▲), 6m (■) and 9m (◆)) and storage conditions                    
(25 °C – 10 % RH (red), 25 °C – 60 % RH (green) and 40 °C – 75 % RH (blue)) on uptake of simulated nasal 
fluid by SD 25/75 (mean ± SD, n = 2). 
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5.3.3 Rheological properties 
 
The viscosity and elasticity after dispersion in simulated nasal fluid of SD 25/75 powders 
stored at different conditions are shown in Table 1. 
The elasticity (G’) and viscosity modulus (G”) of the SD 25/75 powders stored at                 
25 °C - 10 % RH did not alter during storage and was slightly lower compared to the data 
obtained after storage at 25 °C - 60 % RH. The differences in G’ and G” between the sample 
time points were minimal. 
On the other hand, storage at elevated temperature (40 °C) and relative humidity (75 %) 
resulted in a high viscosity and elasticity after dispersion into SNF. After 6 months the 
elasticity modulus was strongly decreased, while the viscosity modulus remained similar. 
After 9 months it was not possible to define G’ and G” due to problems of homogeneity of 
the gel. 
 
 
Table 1. Influence of storage time and storage conditions of       
SD 25/75 on elasticity (G’) and viscosity (G”) after dispersion 
into simulated nasal fluid (mean ± SD, n = 3). 
Formulation G’ (Pa) G” (Pa) 
 
reference (t = 0) 
 
25 °C – 10 % RH  (3 m) 
 
2962 ± 64 
 
2815 ± 68 
 
249 ± 26 
 
258 ± 27 
25 °C – 10 % RH  (6 m) 2378 ± 75       260 ± 4 
25 °C – 10 % RH  (9 m) 2078 ± 84 235 ± 13 
 
25 °C – 60 % RH  (3 m) 
 
3346 ± 203 
 
295 ± 13 
25 °C – 60 % RH  (6 m) 3078 ± 214 284 ± 14 
25 °C – 60 % RH  (9 m) 
 
    3387 ± 82       293 ± 7 
40 °C – 75 % RH  (3 m) 20315 ± 1151 3695 ± 273 
40 °C – 75 % RH  (6 m) 7897 ± 455 3577 ± 128 
40 °C – 75 % RH  (9 m) - - 
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5.3.4 Nasal bioavailability 
 
The influence of storage time and storage conditions on the absolute bioavailability, Cmax and 
tmax of insulin obtained after nasal delivery to rabbits is shown in Table 2. The insulin serum 
concentration-time profiles are depicted in Figure 3. 
 
It can be observed that the absorption of insulin was not influenced after storage at               
25 °C – 10 % RH as similar serum insulin concentration-time profiles were obtained during 
the entire test period (P > 0.05). As described earlier (cfr. paragraph 5.3.2 and 5.3.3) the 
physical characteristics of the powder did not change during storage under these conditions.  
 
 
Table 2. Influence of storage time and storage conditions of SD 25/75 on the 
pharmacokinetic parameters of insulin after nasal delivery to rabbits (mean ± SD). 
Formulation BA 
(%) 
Cmax 
(µIU/ml) 
tmax 
(min) 
n 
 
reference (point t = 0) 
 
25 °C – 10 % RH  (3 m) 
 
12.4 ± 2.0 
 
11.4 ± 5.0 
 
441 ± 125 
 
389 ± 176 
 
36.9 ± 5.6 
 
  44.4 ± 10.9 
 
8 
 
8 
25 °C – 10 % RH  (6 m) 10.2 ± 5.2 334 ± 192 38.9 ± 7.2 8 
25 °C – 10 % RH  (9 m) 11.6 ± 4.3 398 ± 191 40.1 ± 6.5 7 
 
25 °C – 60 % RH  (3 m) 
 
17.0 ± 5.6 
 
677 ± 244 
 
39.1 ± 5.1 
 
8 
25 °C – 60 % RH  (6 m) 16.4 ± 4.4 781 ± 321 35.6 ± 7.3 8 
25 °C – 60 % RH  (9 m) 
 
17.9 ± 7.0 741 ± 420 41.6 ± 6.3 6 
40 °C – 75 % RH  (3 m)        20.9 ± 7.7    1354 ± 383 ***    23.2 ± 8.2 ** 7 
40 °C – 75 % RH  (6 m)        3.7 ± 1.1 ***       201 ± 97 *     14.6 ± 3.1 *** 8 
40 °C – 75 % RH  (9 m)    5.2 ± 2.6 *       301 ± 164     13.6 ± 2.5 *** 8 
Significantly different from reference formulation (* = 0.05 ≥ P > 0.01;                      
** = 0.01 ≥ P > 0.001 and *** = P ≤ 0.001) 
 
 
Increasing the relative humidity from 10 to 60 % resulted in a higher absorption of insulin: an 
absolute bioavailability of 12.4 ± 2.0 % and 17.0 ± 5.6 % before storage and after 3 months, 
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respectively. This can be explained by the higher viscosity and elasticity of the formulation 
after dispersion into the nasal cavity and its slightly higher water absorbing capacity          
(cfr. paragraph 5.3.2 and 5.3.3). After 6 and 9 months the absorption of insulin was similar to 
the values obtained after 3 months. 
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Figure 3. Influence of storage time (before (●), 3m (▲), 6m (■) and 9m (◆)) and storage conditions of           
SD 25/75 (25 °C – 10 % RH (red), 25 °C – 60 % RH (green) and 40 °C – 75 % RH (blue)) on the serum insulin  
concentration-time profiles after nasal delivery to rabbits. 
 
 
Nasal delivery of SD 25/75 exposed to 75 % RH at 40 °C during 3 months resulted in a 
higher absorption rate of insulin. Cmax increased significantly (P ≤ 0.001) from                   
441 ± 125 µIU/ml to 1354 ± 383 µIU/ml, while tmax significantly (P ≤ 0.01) decreased from 
36.9 ± 5.6 min to 23.2 ± 8.2 min. Storage at these conditions during 6 and 9 months resulted 
in a dramatic decrease of the nasal bioavailability of insulin (P ≤ 0.001). 
 
SD 25/75 particles stored at 40 °C - 75 % RH absorbed water during storage                      
(cfr. paragraph 5.3.1) whereby the polymers become in a relaxed state. As freeze-drying is 
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required to prepare the nasal formulations, it is hypothesised that after freeze-drying the 
dehydrated polymers preserve their relaxed structure. This would allow fast hydration upon 
contact with water (cfr. paragraph 5.3.2), thereby creating a kind of super slurper. The 
increased absorption observed after 3 months storage at 40 °C - 75 % RH can be explained by 
the fast hydration of the powder upon contact with the nasal mucosa, thereby shrinking the 
epithelial cells and opening the tight junctions (Edman et al., 1992; Illum et al., 1994).  
Although SNF absorption of the powders stored at 40 °C - 75 % RH was independent of 
storage time (cfr. paragraph 5.3.2) there was a significant decrease of nasal bioavailability   
(P ≤ 0.001) after 6 and 9 months storage. This is an indication that conformational changes in 
the polymer structure occurred in function of storage time at these conditions. Those 
structural changes seemed to influence the elastic properties of SD 25/75 as the elasticity 
decreased after dispersion of the powder stored during 6 months at 40 °C - 75 % RH, while 
the viscosity did not change compared to a sample stored during 3 months at the same 
conditions (cfr. paragraph 5.3.3). Based on these data the elasticity of the formulation can 
also be considered an important factor in drug absorption. However, the exact mechanism of 
how the elasticity modulus of the carrier can modulate the absorption of insulin remains 
unclear. On the one hand the decreased elasticity of SD 25/75 after 6 months storage at        
40 °C - 75 % RH (compared to storage during 3 months) may result in a faster clearance of 
the formulation from the nasal cavity. As a result the residence time in the nasal cavity would 
decrease, possibly contributing to the lower nasal bioavailability of insulin. On the other hand 
it should be noticed that the same formulation had a higher elasticity compared to the 
reference (cfr. paragraph 5.3.3), whereas its nasal bioavailability in rabbits was significantly 
(P < 0.05) lower. Thus, further investigations are needed to elucidate the relevance of the 
elasticity modulus on nasal drug absorption. 
Furthermore, in Chapter 4 (cfr. paragraph 4.1.3.1) a similar observation was made: after nasal 
delivery using the powder (SD 25/75)/Ca(OH)2 90/10 a higher absorption of insulin was 
observed in comparison with the SD 25/75 formulation. Besides the higher and faster SNF 
uptake of (SD 25/75)/Ca(OH)2 90/10, a higher elasticity but comparable viscosity was 
obtained after dispersion in SNF in comparison with SD 25/75.  
 
Although water absorption of the SD 25/75 powder during storage at 25 °C - 60 % RH was 
slightly lower than during storage at 40 °C - 75 % RH (cfr. paragraph 5.3.1) a slower liquid 
uptake rate was observed (cfr. paragraph 5.3.2). This indicates that storage at elevated 
relative humidity and temperature is required to transform the polymers to a relaxed state and 
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to form a super slurper. At higher temperature the flexibility of the hydrated polymer chains 
will increase and it is suggested that at 40 °C – 75 % RH the polymer chains of        
Carbopol 974P have the potential to uncoil whereby their functional groups are 
preferentially directed towards the surface of the particles. As a consequence the functional 
groups are immediately available for hydration upon contact with water.  
 
Furthermore, it was observed that after nasal delivery of the reference formulation (batch 
number 12621: 14F) at t = 0 a bioavailability of only 12.4 ± 2.0 % was observed in 
comparison with 19.2 ± 5.3 % obtained after nasal delivery of SD 25/75 powder (batch 
number 10851: 141-1) used in Chapter 3 and 4. To verify the batch variability a third batch of 
SD 25/75 (batch number 13724: 4A) was prepared, resulting in an even lower bioavailability 
(7.5 ± 1.8 %) (Table 3).  
 
 
Table 3. Absolute bioavailability, Cmax and tmax (mean ± SD) after nasal delivery to 
rabbits of different batches of powder (1IU insulin/mg) containing SD 25/75.  
Batch number (SD 25/75) BA 
(%) 
Cmax 
(µIU/ml) 
tmax 
(min) 
n 
 
10851: 141-1 
12621: 14F 
 
19.2 ± 5.3 
12.4 ± 2.0 
 
681 ± 247 
  441 ± 125 * 
 
50.9 ± 7.4 
36.9 ± 5.6 
 
8 
8 
13724: 4A       7.5 ± 1.8 ***    352 ± 120 **      31.2 ± 13.0 ** 8 
Significantly different from original batch (10851:141-1) (* = 0.05 ≥ P > 0.01;                      
** = 0.01 ≥ P > 0.001 and *** = P ≤ 0.001) 
 
 
Future work must certainly elucidate the factors which are causing this variability as this is 
essential for the further development of these carriers for nasal delivery. Several parameters 
might contribute to this variability as they could have an influence on the characteristics of 
the final product:  
-  quality of raw materials (starch and Carbopol) 
- manipulations prior to spray-drying (temperature at which the Amioca® starch and 
Carbopol mixture is stirred after jet cooking, stirrer speed and time) 
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- spray-drying parameters (e.g. inlet temperature, feed rate, solids concentration, aspirator 
flow and spray air flow) 
 
 
5.4 Conclusions 
 
Storage of a spray-dried mixture of Amioca® starch and Carbopol® 974P 25/75 at                
40 °C – 75 % RH induced structural modifications of the polymers which had an influence on 
the bioavailability of insulin after nasal delivery to rabbits. 
In order to maintain the powder characteristics obtained immediately after spray-drying the 
mixture of Amioca® starch and Carbopol® 974P 25/75 should be stored at                        
25 °C and 10 % RH.  
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Chapter 6 Spray-dried Amioca starch/Carbopol 
as carrier for nasal delivery of 
oxymetazoline HCl 
 
 
6.1 Introduction 
 
Within the scope of this thesis powders were evaluated as a nasal platform for the systemic 
delivery of high molecular weight drugs. However, as the nasal route can also be used for 
local drug therapy, this chapter evaluates the potential of powders containing viscosity-
enhancing polymers as local drug delivery systems. It was decided to evaluate the carrier 
consisting of Amioca starch and Carbopol 974P as a potential delivery system for the local 
treatment of nasal congestion via oxymetazoline hydrochloride.  
Nasal congestion is a major symptom in patients suffering from a common cold, rhinitis and 
sinusitis, causing discomfort to the patient and impairing the quality of life (Guarderas, 
1996). To relieve the symptoms an oral or topical sympathomimetic decongestant can be 
used. The latter has the advantage of a selective site of action and a rapid onset of action 
(Jackson et al., 1997; Stübner et al., 2001). 
Long-lasting use of topical sympathomimetic agents is not recommended as they are 
associated with rebound swelling of the nasal mucosa, possibly caused by down regulation of 
the α-adrenergic receptors on the nasal vasculature (Jackson et al., 1997). Healthy volunteers 
treated daily with an oxymetazoline nasal spray developed rhinitis medicamentosa within    
10 days, confirming that only short-term use of these agents is indicated (Graf and Juto, 
1994). Nasal administration of a decongestant generally induces a maximal vasoconstriction 
leading to a nutrition deficiency of the mucosa. As a consequence, when the effect of the 
decongestant has worn off excessive vasodilatation occurs whereby an additional dose of 
decongestant is required. In order to reduce the administration frequency and thus to reduce 
the risk of this rebound phenomenon, a full vasoconstriction must be avoided. A mixture of 
Amioca starch and Carbopol 974P might increase the residence time of the formulation in 
the nasal cavity, aiming to smoothen and prolong the decongestive effect of oxymetazoline 
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HCl compared to a common nasal spray. As a result one could reduce the administration 
frequency and the medication dose using these formulations, reducing habituation and the 
risk on the rebound phenomenon. 
Furthermore, most nasal sprays and drops contain a preservative such as benzalkonium 
chloride, which is membrane damaging (Berg et al., 1995) and can worsen rebound nasal 
congestion (Graf et al., 1995). As nasal powder formulations do not require any preservative, 
an additional advantage is offered when a drug for local treatment is incorporated in a dry 
carrier. 
 
The following clinical study was performed in collaboration with Dr. Joke Huyghe and Prof. 
Dr. Claus Bachert (Department of Oto-Rhino-Laryngology, Faculty of Medicine and Health 
Sciences, Ghent University). 
 
 
6.2 Materials and methods 
 
Spray-dried mixtures of Amioca starch and Carbopol 974P (ratios: 25/75 and 85/15, w/w) 
(SD 25/75 (batch number: 10851: 141-1) and SD 85/15 (batch number: 12206: 141A)) were 
prepared by National Starch and Chemical Company (Bridgewater, New Jersey, USA). 
Carbopol 974P was supplied by Noveon (Cleveland, Ohio, USA). Oxymetazoline HCl was 
obtained from Sigma (Bornem, Belgium). Nesivine® spray (0.05 % (w/v) oxymetazoline 
HCl) was purchased from Merck (Darmstadt, Germany). All other chemicals were of 
analytical grade.  
 
 
6.2.1 Preparation of powder formulations 
 
After dispersion of a physical blend of SD 25/75 and oxymetazoline HCl in distilled water, 
2.0 M NaOH was added until pH 7.4 was reached. To remove the water the aqueous 
dispersion was freeze-dried using an Amsco-Finn Aqua GT4 freeze-dryer (Amsco, 
Germany). The dispersion was frozen to 228 K within 175 min at 1000 mbar. Primary drying 
was performed at 258 K and at a pressure varying between 0.8 and 1 mbar during 13 h, 
followed by secondary drying at elevated temperature (283 K) and reduced pressure          
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(0.1 - 0.2 mbar) for 7 h. After freeze-drying the powder was sieved (63 µm) at low relative 
humidity (20 %) and ambient temperature. The fraction below 63 µm was stored in a 
desiccator at 4 - 8 °C until use. 
In addition a physical blend of SD 85/15 and oxymetazoline HCl was dispersed in distilled 
water. This dispersion was not neutralised prior to freeze-drying.  
Both powder formulations were prepared in order to obtain a final concentration of           
0.09 % (w/w) oxymetazoline HCl. 
 
 
6.2.2 Nasal delivery devices 
 
The Monopowder (Valois, Marly-le-Roi, France) and Pfeiffer system (Pfeiffer, Radolfzell, 
Germany) were used as nasal delivery devices for the powders (Figure 1). 
The Monopowder device is a single-dose delivery system. By actuation of the system, a 
pressure (compression of air) is generated inside the system, this releases the valve sealing 
the powder container and sprays the powder into the nasal cavity.  
The Pfeiffer system is a bi-dose disposable device having a dual storage chamber for the 
nasal powder. The powder formulation is deposited into the nasal cavity by inhalation. 
 
 
   
 
Figure 1. Monopowder device (left) and Pfeiffer system (right). 
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6.2.3 Quantification of oxymetazoline hydrochloride 
 
Oxymetazoline HCl was quantified using a validated HPLC method with UV-VIS detection. 
Analysis was performed with a HPLC system consisting of a HPLC pump (LC-10AD-VP, 
Shimadzu, Antwerp, Belgium), a UV-VIS detector (SPD-10A, Shimadzu, Antwerp, Belgium) 
and an integrator (C-RSA, Shimadzu, Antwerp, Belgium). The column was a Lichrospher® 
60 RP-Select B (125 mm x 4 mm). The mobile phase, used as an isocratic eluent, consisted of 
60 % (v/v) 31 mM ammonium sulphate in distilled water and 40 % (v/v) acetonitrile. The 
eluate was monitored at 220 nm. The retention time of the oxymetazoline HCl peak was     
3.5 min at a flow rate of 1.0 ml/min. The analysis was performed at room temperature. 
Calibration samples from 2.64 µg/ml to 52.8 µg/ml were prepared in the mobile phase. To 
500 mg powder formulation, mobile phase was added until a volume of 10.0 ml was 
obtained. This dispersion was put in an ultrasonic bath for 5 min and centrifuged (2500g,     
10 min). 20 µl supernatant was injected onto the HPLC column. 
 
 
6.2.4 Study protocol 
6.2.4.1 Study design 
 
The study protocol was approved by The Ethics Committee of the Ghent University Hospital. 
A written informed consent was obtained from each patient. 
The study consisted of 3 parts: 2 experiments were designed as a single-blind, cross-over 
double-treatment test (Exp. I and II), whereas one experiment was a non-blind single-
treatment test (Exp. III) in healthy volunteers (n = 6 for Exp. I, n = 4 for Exp. II and n = 5 for 
Exp. III). Before nasal delivery of Nesivine and the test formulation the subjects 
acclimatised to room temperature and relative humidity during 1 h and after administration 
they stayed during 8 h in the same room. A wash-out period of minimum 2 weeks was 
respected between successive experiments. 
 
 
6.2.4.2 Subjects 
 
Four to six healthy volunteers aged between 18 and 50 years, extremes included, participated 
into the study. The subjects included in the study were healthy as proven by medical history 
and physical examination. 
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Patients suffering from chronic diseases such as asthma, diabetes mellitus, hyperthyroid, 
epilepsy, cardiovascular diseases or liver or renal disorders were excluded from the study. 
Subjects with an increased intraocular pressure, urinary retention or known alcohol, 
barbiturate, amphetamine or narcotic abuse were also not selected.  
Nasal congestion or obstruction, acute or chronic rhinosinusitis, pharyngeal erythema, fungal 
infection of the nose, mouth or throat, clinically relevant bronchospasm, primary ciliar 
dyskinesy or cystic fibrosis were also exclusion criteria. 
Volunteers with perennial allergic rhinitis (PAR) or seasonal allergic rhinitis (SAR) could 
also not participate. Skin prick tests were performed if an allergy was supposed. Individuals 
having an allergy or hypersensitivity to antihistamines, decongestives or intranasal 
corticosteroids were also excluded. 
Included subjects had no anatomic abnormalities (deviated nasal septum, nasal polyps, 
atrophic rhinitis or sinusitis, …) of the nasal cavity as determined by anamnesis and clinical 
examination (rhinoscopy anterior and nasal endoscopy). 
With the exception of oral contraceptives, concomitant use of medication during the 
experiment was not allowed. Administration of an oral, parenteral or nasal short or long 
acting corticosteroid or nasal cromolyn was prohibited within one month before enrollment in 
the study, MAO-inhibitors within 2 weeks before and an antihistamine or leukotriene 
modifier within 5 days before. Subjects with a habitual use of nasal decongestants were also 
excluded. 
Pregnant, lactating females or females with childbearing potential without adequate 
contraception were excluded from the study. Only non-smokers were included. 
During the experiment food containing tyramine (e.g. cheese, wine, herring, …) or 
tryptophan (e.g. beans) were not allowed. 
 
 
6.2.4.3 Study medication 
6.2.4.3.1 Experiment I 
 
Nesivine® (0.05 % oxymetazoline HCl) was used as reference formulation. One dose (≈ 45 µl 
or 22.5 µg oxymetazoline HCl/actuation) was sprayed into each nostril. As test formulation a 
powder containing SD 25/75 (neutralised) and 0.09 % oxymetazoline HCl was used. In order 
to compensate for the amount of powder remaining into the device after actuation, the 
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Monopowder device was filled with 25.3 mg of powder. One dose (≈ 25 mg or 22.5 µg 
oxymetazoline HCl/actuation) was sprayed into each nostril. 
 
 
6.2.4.3.2 Experiment II 
 
Nesivine® (0.05 % oxymetazoline HCl) was used as reference formulation. One dose (≈ 45 µl 
or 22.5 µg oxymetazoline HCl/actuation) was sprayed into each nostril. As test formulation a 
powder containing SD 85/15 (non-neutralised) and 0.09 % oxymetazoline HCl was used. In 
order to compensate for the amount of powder remaining into the device after actuation, the 
Monopowder device was filled with 25.3 mg of powder. One dose (≈ 25 mg or 22.5 µg 
oxymetazoline HCl/actuation) was sprayed into each nostril. 
 
 
6.2.4.3.3 Experiment III  
 
Nesivine® (0.05 % oxymetazoline HCl) was used as reference formulation. One dose (≈ 45 µl 
or 22.5 µg oxymetazoline HCl/actuation) was sprayed into each nostril. As test formulation a 
powder containing SD 85/15 and 0.09 % oxymetazoline HCl was used. In order to 
compensate for the amount of powder remaining into the device after inhalation, each 
chamber of the Pfeiffer system was filled with 12.7 mg of powder. Two doses (≈ 12.5 mg or 
11.25 µg oxymetazoline HCl/actuation) were inhaled into each nostril. 
 
 
6.2.5 Efficacy evaluation 
6.2.5.1 Nasal airflow 
 
Before rhinomanometry the volunteers needed to avoid major physical activities               
(e.g. climbing stairs). Rhinomanometry was conducted in sitting position. The subject was 
asked to blow his/her nose prior to measurement, if necessary. First, a nasal adapter of 
appropriate size was inserted into the left nostril when measuring the airflow resistance of the 
right nostril. Subsequently, a mask was pressed on the face for an exact fit, but without 
distortion of the nostril. The patient had to breathe normally with closed mouth. After a few 
breaths, data logging was started. After 3 to 5 further breaths the result (nasal volume stream 
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at 150 Pa) was displayed. The nasal volume stream of the left side was measured accordingly. 
To ensure correct measurement, baseline adjustment to zero was done without inserted nasal 
adapter and without putting on the mask. The nasal airflow was recorded 30 min before and 
0.25, 0.5, 1, 2, 3, 4, 5, 6 and 8 h after administration of the formulations. 
  
¾ Statistical analysis 
 
The data of nasal airflow are represented as the sum of nasal volume stream of both nostrils 
(corrected for baseline). The area under the curve (AUC) of the individual nasal airflow 
versus time profiles was calculated using the trapezoidal method. Statistical analysis of the 
data was performed using SPSS version 11.0. The data were tested for normal distribution 
with a Kolmogorov-Smirnov test. To detect statistical differences in nasal airflow between 
Nesivine® spray and the nasal powder formulation used in Exp. I or II a paired t-test with      
P < 0.05 as significance level was used. To detect a statistical difference in nasal airflow 
between the nasal powder formulation used in Exp. III and Nesivine® spray administered 
during Exp. I a one-way Anova was done with P < 0.05 as significance level. 
 
 
6.2.5.2 Nasal symptoms 
 
The severity of nasal symptoms (nasal obstruction, itching and sneezing) was rated 30 min 
before and 0.25, 0.5, 1, 2, 3, 4, 5, 6 and 8 h after challenge using a visual analogue scale 
(VAS). Nasal obstruction was assessed on a scale from -10 to 10 (-10 = extremely increased, 
0 = normal and 10 = extremely decreased nasal patency). Itching and sneezing were classified 
on a scale from 0 to 10 (0 = no symptoms and 10 = severe discomfort). For nasal obstruction 
and itching the right and left nostril were scored individually, but for analysis of the data the 
mean values were used. 
 
 
6.2.5.3 Saccharine test 
 
The mucociliary function was evaluated in Exp. II using the indigocarmine saccharin liquid 
test. After administration of the solution the time interval was determined until the patient 
perceived a sweet taste or until the physician saw a bluish colour in the oropharynx. The 
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mucociliary clearance was evaluated 3.5 h after nasal administration of the powder 
formulation. 
 
¾  Statistical analysis 
 
The computer software SPSS version 11.0 was used for statistical analysis of the data. The 
data were tested for normal distribution with a Kolmogorov-Smirnov test. A paired t-test with 
P < 0.05 as significance level was used to detect a statistical difference in mucociliary 
clearance between before and after nasal administration of the powder formulation. 
 
 
6.2.6 Dialysis experiment 
 
A 10 % (w/w) dispersion of powders containing SD 25/75 or SD 85/15 (cfr. paragraph 6.2.1) 
was made in simulated nasal fluid (SNF) (7.45 mg/ml NaCl, 1.29 mg/ml KCl and 0.32 mg/ml 
CaCl2, Melon, 1968). 10 g dispersion was dialysed using a Spectra/Por® 7 membrane with a 
molecular weight cut off of 2000 Da (Spectrum Laboratories, Breda, The Netherlands). The 
filled dialysis membrane was submerged in 200 ml SNF, which was stirred using a magnetic 
stirrer at room temperature. The dispersion was dialysed during 12 h to ensure equilibration 
of free oxymetazoline HCl between the internal and external medium. 
The concentration of oxymetazoline HCl in the extern medium was quantified using the 
method described in paragraph 6.2.3. Calibration samples in a concentration range between 
0.063 and 1.00 µg/ml were prepared in SNF. After dilution of the extern medium, 20 µl was 
injected onto the HPLC column (n = 2). 
 
 
6.3 Results and discussion 
 
Prior to start with the in-vivo experiments, the oxymetazoline HCl concentrations in the 
powders based on SD 25/75 and SD 85/15 and in the Nesivine® spray were quantified at 
0.090 ± 0.009 % (w/w), 0.094 ± 0.008 % (w/w) and 0.051 % (w/v), respectively. 
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6.3.1 Experiment I 
 
In a first experiment the efficacy of the nasal spray (Nesivine®) was compared to the nasal 
powder containing SD 25/75. The powder was filled into the Monopowder device (Valois). 
This delivery system was selected based on the results of a nasal deposition and 
bioavailability study (Callens, 2002). This study compared the Monopowder with the Pfeiffer 
system: the absolute nasal bioavailability in rabbits after administration of a powder 
containing Drum Dried Waxy Maize starch and Carbopol® 974P (ratio: 90/10) using the 
Monopowder system (6.6 ± 2.7 %) was slightly higher than the Pfeiffer system (3.6 ± 1.4 %). 
By gamma-scintigraphy it was shown that a powder administered with the Pfeiffer device 
was cleared from the nasal cavity at a faster rate compared to the Monopowder device. These 
observations combined with a higher depletion of the Monopowder system (1 % of the 
powder remained in the Monopowder device after actuation compared to 30 % in the Pfeiffer 
system) were the main reasons for selecting the Monopowder system. Moreover, the 
operating principle of the Monopowder device is similar to the experimental delivery device 
used for the in-vivo experiments in rabbits. 
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Figure 2. Nasal airflow versus time profile obtained after nasal delivery of a commercial oxymetazoline HCl 
spray (Nesivine®) (closed symbols) and a powder containing SD 25/75 (neutralised) and oxymetazoline HCl 
(open symbols) delivered with the Monopowder device to healthy volunteers. Data are presented as mean ± SD 
(n = 6). 
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After nasal delivery of the formulations to the volunteers, the evolution of nasal congestion 
was followed by measuring the nasal airflow through the nostrils using a rhinomanometer. 
The results are depicted in Figure 2. After nasal delivery of Nesivine® a fast onset of action of 
oxymetazoline HCl was observed: 15 min after administration a higher nasal airflow was 
measured, reaching a maximum of 294 ± 170 ml/s after 30 min. The effect was maintained 
for at least 6 h. In contrast oxymetazoline HCl formulated in the nasal powder based on      
SD 25/75 induced a lower nasal decongestion compared to Nesivine®. Statistical analysis of 
the area under the curve demonstrated a significant difference (P < 0.05) between both 
formulations (Table 1). The reduced effect after administration of the powder might be due to 
an ionic interaction between oxymetazoline HCl and the negatively charged carboxylic acid 
groups of Carbopol® 974P, preventing drug release from the carrier. 
 
 
Table 1. Area under curve of nasal airflow versus time 
profiles obtained after nasal delivery of a commercial 
oxymetazoline HCl spray (Nesivine®) and of powders 
containing SD 25/75 (neutralised) or SD 85/15          
(non-neutralised) in combination with 0.09 % 
oxymetazoline HCl. 
  
AUC (h.ml/s) 
 
Exp. I 
 
Nesivine® spray  1532 ± 1005 
SD 25/75 (Monopowder)       75 ± 1015 a 
Exp. II  
Nesivine® spray 1524 ± 768 
SD 85/15 (Monopowder)     205 ± 663 a 
Exp. III  
SD 85/15 (Pfeiffer) 1486 ± 477 
Data are presented as mean ± SD. 
a Significantly lower than Nesivine® spray (P < 0.05, 
paired t-test) 
 
 
Subjective evaluation of the nasal patency using VAS showed that only some volunteers 
experienced a slight improvement of nasal airflow after administration of Nesivine®      
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(Table 2). However, it should be stressed that this experiment was performed on healthy 
volunteers already having a normal nasal airflow. In contrast a decrease of nasal patency was 
reported by some volunteers after application of the powder formulation. 
 
In Table 3 and 4 the median, minimum and maximum score for the nasal side effects (itching 
and sneezing) are given for both nasal formulations. It was observed that Nesivine® was well 
tolerated by all volunteers. On the other hand, treatment with the nasal powder formulation 
induced itching in most volunteers. This occurred immediately after application of the 
formulation and was often accompanied by stinging or even watering eyes. Nasal itching 
lasted until approximately 4 h after administration. Three volunteers reported a slight 
headache and two of them feeling a pressure at the maxillary sinuses.  
As nasal itching occurred immediately after spraying the powder into the nostrils, the 
pressure under which the powder is released from the device might be too high, whereby the 
particles are deposited in the lower as well as in the upper parts of the nasal cavity. 
Scintigraphic research revealed that a bioadhesive powder (DDWM/Carbopol® 90/10) 
sprayed with the Monopowder device into the nasal cavity of a silicon human nose model, 
was mainly deposited on the upper wall of the superior turbinate (Callens, 2002). Once 
powder particles are deposited in the nasal cavity, they absorb water from the nasal mucosa to 
form a gelatinous network. Swelling of hydrated particles in the narrow cavities of the upper 
parts of the nose might create a maxillary pressure and induce headache. It has to be 
elucidated if the side effects reported by the volunteers are related to the formulation itself 
and/or to the nasal delivery system. 
 
 
6.3.2 Experiment II 
 
A second experiment was performed to evaluate if an interaction between oxymetazoline HCl 
and the ionised carboxylic acid groups of the neutralised starch/Carbopol® mixture prevented 
oxymetazoline HCl to be released from the carrier. 
  
 
 
 
Table 2. The median, minimum and maximum score for nasal obstruction after nasal delivery of the different formulations to healthy volunteers. 
     
Exp I 
       
Exp II 
      Exp III  
    
 
Nesivine® spray 
    
SD 25/75 
(neutralised) 
Monopowder device 
    
 
Nesivine® spray 
    
SD 85/15 
(non-neutralised) 
Monopowder device 
    
SD 85/15 
(non-neutralised) 
Pfeiffer device 
 
 
Time (h) 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
-0.5  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0 
0.25  0 -3 0.5  0.5 0 1  -2 -2.5 -0.5  0 -2 3.5  0 -2 1.5 
0.5  0 -3 0.5  0.5 0 2  -1.75 -3.5 -1.5  0.5 -3 3.5  -1 -2 0.5 
1  0 -3.5 0  1 0 2  -1.5 -3.5 -1  0.25 -5 3  0 -2 0 
2  0 -3.5 0.5  0 0 1  -0.75 -2 -0.5  0.25 -2 2  0 -2 0 
3  0 -3 0  0.5 0 1.5  -0.75 -2.5 0  0 -1 0.5  0 -2 0 
4  0 -2 0  0 0 2.5  -0.5 -1 0  0 -1 1.5  0 -2.5 0 
5  0 -2.5 0  0 0 2.5  -0.25 -1 0  0.25 -1 1.5  0 -2.5 0 
6  0 -2 0  0 0 3.5  -0.25 -1 0  0 -1 0.5  0 -1.5 0 
8  0 -2 0  0 0 4.5  -0.5 -1.5 0  0 -1.5 2.5  0 0 0 
 
 
 
  
 
 
 
Table 3. The median, minimum and maximum score for nasal itching after nasal delivery of the different formulations to healthy volunteers. 
     
Exp I 
       
Exp II 
      Exp III  
    
 
Nesivine® spray 
    
SD 25/75 
(neutralised) 
Monopowder device 
    
 
Nesivine® spray 
    
SD 85/15 
(non-neutralised) 
Monopowder device 
    
SD 85/15 
(non-neutralised) 
Pfeiffer device 
 
 
Time (h) 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
-0.5  0 0 0  0 0 1  0 0 0  0 0 0  0 0 0 
0.25  0 0 0.5  1.75 0 3.5  1.5 0 5.5  4 4 10  0 0 1 
0.5  0 0 0.5  2 0 3  1.25 0 3  2.75 2 10  0 0 1 
1  0 0 0  1 0 3.5  0.75 0 1  1.5 1 10  0 0 0 
2  0 0 0  0.25 0 1.5  0 0 0.5  0.5 0 8  0 0 0 
3  0 0 0  0.25 0 1  0 0 0  0 0 1  0 0 0 
4  0 0 0  0.25 0 0.5  0 0 0  0 0 0.5  0 0 0 
5  0 0 0  0 0 0.5  0 0 0  0 0 0  0 0 0 
6  0 0 0  0 0 0.5  0 0 0  0 0 0  0 0 0 
8  0 0 0  0 0 0  0 0 0  0 0 2  0 0 0 
 
 
 
  
 
 
 
Table 4. The median, minimum and maximum score for nasal sneezing after nasal delivery of the different formulations to healthy volunteers. 
     
Exp I 
       
Exp II 
      Exp III  
    
 
Nesivine® spray 
    
SD 25/75 
(neutralised) 
Monopowder device 
    
 
Nesivine® spray 
    
SD 85/15 
(non-neutralised) 
Monopowder device 
    
SD 85/15 
(non-neutralised) 
Pfeiffer device 
 
 
Time (h) 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
  
Median 
 
Min 
 
Max 
-0.5  0 0 1  0 0 1  0 0 0  0 0 0  0 0 0 
0.25  0 0 1  0.5 0 4  0 0 0  1.5 0 5  0 0 0 
0.5  0 0 0  0 0 1  0 0 0  1.5 0 5  0 0 0 
1  0 0 0  0 0 4  0 0 0  2 0 3  0 0 0 
2  0 0 0  0 0 1  0 0 0  1 0 3  0 0 0 
3  0 0 1  0 0 0  0 0 0  0 0 1  0 0 0 
4  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0 
5  0 0 0  0 0 1  0 0 0  0 0 0  0 0 0 
6  0 0 0  0 0 0  0 0 0  0 0 0  0 0 0 
8  0 0 0  0 0 0  0 0 0  0 0 1  0 0 0 
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A non-neutralised SD 85/15 powder has been reported to exhibit bioadhesive capacities when  
used as a buccal bioadhesive tablet for systemic delivery of testosterone in dogs (Ameye et 
al., 2005). This mixture was also used as a platform for vaginal controlled release tablets of 
metronidazole in humans (Ameye, 2004) and for ocular mini tablets having a sustained 
release of sodium fluorescein in healthy human volunteers (Weyenberg et al., 2005). 
As the bioadhesive properties of SD 85/15 have clearly been demonstrated, it was decided to 
incorporate oxymetazoline HCl in non-neutralised SD 85/15 in order to reduce the risk of 
ionic interactions between drug and carrier. Furthermore, SD 85/15 is a safe mucosal carrier 
for drug delivery as it has no irritating or membrane damaging properties (Adriaens et al., 
2003). 
 
The nasal airflow versus time profiles of the cross-over study wherein the efficacy of the 
nasal spray Nesivine® was compared to the nasal powder containing SD 85/15 are shown in 
Figure 3. 
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Figure 3. Nasal airflow versus time profile obtained after nasal delivery of a commercial oxymetazoline HCl 
spray (Nesivine®) (closed symbols) (n = 4) and a powder containing SD 85/15 (non-neutralised) and 
oxymetazoline HCl (open symbols) delivered with the Monopowder device to healthy volunteers (n = 4 () and 
n = 3 (i.e. the data of the volunteer complaining of pain after nasal administration were omitted) (---)). Data are 
presented as mean ± SD. 
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In this experiment a distinct difference between the profile of Nesivine® and the nasal powder 
formulation could be observed. For Nesivine® a similar profile was seen as in the first 
experiment: a maximum nasal airflow of 227 ± 162 ml/s was obtained after 30 min, the effect 
lasting for 6 to 8 h. For the nasal powder formulation SD 85/15 a slower onset of action of 
oxymetazoline HCl was observed compared to Nesivine®. In case of the powder, the powder 
must hydrate before the drug can dissolve and become effective. Besides, after hydration of 
the particles a bioadhesive gel is formed whereby its polymer chains may interpenetrate into 
the mucus macromolecules, forming a physically entangled network. Also non-covalent 
bonds between the entangled chains may occur. As a result the diffusion rate of dissolved 
oxymetazoline HCl molecules through the hydrated Amioca® starch/Carbopol® 974P network 
could be slower. 
These elements may contribute to the delayed onset of action of oxymetazoline HCl after 
powder administration. For this formulation a maximum nasal airflow of 133 ± 164 ml/s was 
reached after 3 h. Afterwards the nasal airflow decreased immediately, indicating that the 
effect could not be maintained using this formulation. This can be explained by the fact that 
part of the oxymetazoline HCl is cleared from the nasal cavity before the drug molecules can 
reach their site of action as they remain entrapped in the gel. 
 
Furthermore, the formation of a bioadhesive gel could have prolonged the absorption of 
oxymetazoline HCl, but assessment of the mucociliary clearance using the saccharine test 
demonstrated that if there was an initial delay in mucociliary clearance, the normal 
mucociliary clearance rate had recovered 3.5 h after nasal administration of the SD 85/15 
powder formulation as no statistical difference (P > 0.05) was found between the mucociliary 
clearance before administration (20.3 ± 8.2 min) or 3.5 h after administration                    
(18.4 ± 6.6 min). 
 
A significant difference (P < 0.05) in AUC-values of the nasal airflow versus time profiles of 
Nesivine® and SD 85/15 powder was observed (Table 1). However, it should be mentioned 
that one of the volunteers was complaining of pain after nasal delivery of the powder 
formulation, causing itching, stinging and watering eyes, pressure at the maxillary sinuses 
and severe headache. Only in case of this volunteer a decrease in nasal airflow was observed 
after administration of the powder formulation. Hereby the efficacy reported for SD 85/15 
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might be underestimated, especially since only 4 volunteers participated in the study    
(Figure 3). 
 
When comparing the powder formulations containing neutralised SD 25/75 and                
non-neutralised SD 85/15, a slightly increased nasal airflow was observed for the latter. This 
might hint at an ionic interaction between oxymetazoline HCl and the carboxylic acid groups 
of Carbopol® 974P. However, after dialysis of SD 25/75 and SD 85/15 in simulated nasal 
fluid similar equilibrium concentrations of oxymetazoline HCl in the external medium were 
obtained: 3.37 ± 0.09 µg/ml and 3.37 ± 0.22 µg/ml, respectively, indicating a release of         
± 79 %. So if any interaction occurred between SD 25/75 and oxymetazoline HCl, it is a 
weak one whereby oxymetazoline HCl is able to dissociate from the ionic complex. 
However, even a weak interaction may be relevant in nasal in-vivo studies as the formulation 
may be cleared before the drug was dissociated from the carrier. 
 
 
6.3.3 Experiment III 
 
To investigate the influence of the delivery system on the nasal patency induced by 
oxymetazoline HCl formulated in a powder formulation, a third experiment was performed 
with the disposable system of Pfeiffer. The nasal airflow versus time profile obtained after 
nasal delivery of SD 85/15 to five healthy volunteers is shown in Figure 4. For comparison 
the results obtained after administration of the Nesivine® spray (Exp. I) are also shown. 
 
It can be observed that using the Pfeiffer system a similar maximum nasal airflow             
(227 ± 97 ml/s) was reached compared to the Nesivine® spray. However, the onset of action 
of oxymetazoline HCl formulated in the SD 85/15 powder was not as steep as in the 
Nesivine® spray. This can be explained by the fact that oxymetazoline HCl had to diffuse 
through the hydrated gel formed in the nasal cavity. Furthermore, the effect of oxymetazoline 
HCl was maintained during 6 to 8 h. The similar efficacy of SD 85/15 after deposition with 
the Pfeiffer system and the Nesivine® spray was reflected in their AUC of the nasal airflow 
versus time which were not significantly different (P > 0.05) (Table 1). 
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As already mentioned in literature, the deposition of a formulation in the nasal cavity has an 
important influence on the efficacy of nasally administered drugs. Also in this experiment it 
is demonstrated that the delivery system is a critical parameter in the development of nasal 
formulations as a higher response was obtained with the Pfeiffer device compared to the 
Monopowder system. 
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Figure 4. Nasal airflow versus time profile obtained after nasal delivery of a powder formulation based on     
SD 85/15 (non-neutralised) (open symbols) delivered with the Pfeiffer device to healthy volunteers (n = 5). The 
nasal airflow versus time profile obtained after nasal delivery of a commercial spray Nesivine® obtained in   
Exp. I is added for comparison. Data are presented as mean ± SD. 
 
 
Callens (2002) compared the deposition of a powder (DDWM/Carbopol® 974P 90/10) using 
the Monopowder and Pfeiffer device in a silicone human nose model and determined that    
22 % left the nose model via the pharynx using the Monopowder device compared to only     
2 % with the Pfeiffer device. Moreover, 21 % of the powder was deposited at the nasal 
pharynx with the Monopowder system and only 4.8 % with the Pfeiffer system. The Pfeiffer 
system distributed the powder homogenously over the turbinates, whereas with the 
Monopowder device the powder was mainly situated on the upper wall of the superior 
turbinate. As a result one can assume that less powder will be deposited posteriorly and a 
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larger fraction will deposite in the absorptive region (inferior and middle turbinates) when 
using the Pfeiffer device, enhancing and prolonging the decongestive effect. 
Only two volunteers reported some nasal itching immediately after administration with the 
Pfeiffer system, while no sneezing was reported. As the nasal side effects were minimal with 
the Pfeiffer system it might be concluded that the side effects reported in Exp. I and II are 
probably related to the nasal delivery system. 
 
The major disadvantage of the Pfeiffer delivery system is the incomplete depletion of the 
delivery system. As the volunteers were asked to sniff up the entire content of the powder 
chamber, multiple inhalations were needed to deplete the delivery device. 
 
 
6.4 Conclusions 
 
In this study it has been demonstrated that the selection of an appropriate delivery system is a 
critical issue in the development of nasal powder formulations. Incorporation of 
oxymetazoline HCl in a powder formulation based on non-neutralised SD 85/15 and using 
the Pfeiffer delivery system resulted in similar pharmacological effect in healthy volunteers 
as the commercial Nesivine® spray (0.05 % w/v), although the onset of action of 
oxymetazoline HCl was not as steep when the powder formulation was administered. Longer 
measurements (> 8 h) are required to verify if a powder formulation based on spray-dried 
Amioca® starch and Carbopol® 974P offers an advantage (such as longer decongestion, dose 
reduction) compared to conventional sprays used in the treatment of nasal congestion.  
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Summary 
 
 
 
As peptides are not suitable for oral administration, they are generally administered 
parenterally. Due to the disadvantages associated with parenteral delivery alternative routes 
of administration (buccal, nasal, pulmonal, ocular, transdermal, rectal and vaginal route) have 
been investigated. In the present work, the nasal route was selected as an alternative route for 
peptide delivery. Despite the advantages related to nasal administration, the bioavailability 
remains low. In Chapter 1 the barriers to nasal absorption of peptides are described. The 
strategies which have been described in literature to circumvent the nasal barriers are also 
mentioned.  
 
This research project focused on powder formulations as carriers for the nasal delivery of 
peptides, aiming to improve the nasal bioavailability by enhancing the residence time of the 
drug in the nasal cavity by incorporating viscosity-enhancing excipients in the formulation. 
As carrier for the nasal delivery of insulin and salmon calcitonin (used as model peptides) 
mixtures of Drum Dried Waxy Maize starch and Carbopol® 974P (ratio: 95/5, w/w) 
(DDWM/C 974P 95/5) and of spray-dried Amioca® starch and Carbopol® 974P (ratio: 25/75 
and 85/15, w/w) (SD 25/75 and SD 85/15) were used. In Chapter 2 the characteristics of the 
components of the nasal powders were described in detail.  
 
In Chapter 3 the influence of powder bulk density on the nasal bioavailability of insulin was 
investigated in rabbits as in a previous study it was shown that the density of the formulation 
determined the spray pattern from the device. The powder bulk density of the nasal 
formulations was modified by changing the solid fraction of the dispersion (prior to      
freeze-drying) and by changing the freezing rate during the freeze-drying cycle. The bulk 
density was mainly determined by the solid fraction of the dispersion: the bulk density of the 
powders increased when the solid fraction of the freeze-dried dispersion was higher. 
However, no influence of powder bulk density on the nasal bioavailability of insulin in 
rabbits was seen.  
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In Chapter 4 it was demonstrated that freeze-drying of aqueous dispersions containing   
spray-dried Amioca starch/Carbopol 974P (ratio: 25/75) and Ca(OH)2 neutralised with 
NaOH yielded powders containing a mixture of sodium and calcium carboxylate. In    
Chapter 4.1 the absorption enhancement of those powders was compared with equivalent 
powders containing only sodium carboxylate.  
An optimal balance between sodium and calcium carboxylate was required to maximise the 
absorption of insulin. The highest absorption of insulin was observed at a ratio of 90/10 
between SD 25/75 and Ca(OH)2, obtaining a bioavailability of ± 29 % and 19 % for 
equivalent formulation with and without Ca(OH)2. This increase in nasal delivery was 
possibly due to the higher water absorbing capacity of the formulation (enhancing the 
paracellular transport by opening of the tight junctions) and to the higher elasticity after 
dispersing this formulation in nasal fluid. Furthermore, after nasal delivery of                     
(SD 25/75)/Ca(OH)2 90/10 or (SD 25/75)/CaCO3 90/10 a decrease in tmax was observed, 
possibly due to a progressive dissociation of Ca2+-ions from the Ca2+-carboxylate after 
hydration of the powder which resulted in the closing of the tight junctions. 
Incorporation of salmon calcitonin in the (SD 25/75)/CaCO3 90/10 formulation resulted in a 
similar trend: a higher Cmax but lower tmax was observed compared to the equivalent 
formulation without CaCO3.  
The importance of using a spray-dried mixture of starch and Carbopol 974P instead of a 
physical mixture was also highlighted in this chapter. A physical mixture of starch and 
Carbopol induced a lower absorption of insulin, possibly due to its lower and slower water 
absorbing capacity. A similar observation was made after addition of Ca(OH)2 to this 
mixture: Cmax increased and tmax decreased in comparison with the mixture without Ca(OH)2. 
 
As an enhanced bioavailability is frequently associated with a disruption of the integrity of 
the mucosal epithelium, in Chapter 4.2 it was investigated if the enhanced nasal 
bioavailability of insulin after administration of the powder formulation containing            
(SD 25/75)/CaCO3 90/10 was due to mucosal damage. The possible toxicological effects after 
multiple administration of the powders SD 25/75 and (SD 25/75)/CaCO3 90/10 were 
evaluated using a non-invasive washing technique in rabbits and using a mucosal irritation 
assay on slugs.  
Both powder formulations induced mucosal damage after nasal administration to rabbits as an 
increased protein, LDH and ALP release from the nasal mucosa after administration was 
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observed. A higher membrane damaging potential was observed for SD 25/75 compared to 
(SD 25/75)/CaCO3 90/10. For both powders the effects on the epithelium were reversible as 
the protein and enzyme concentrations decreased within 24 h, returning to their basal levels 
within 3 days. 
Using the Slug Mucosal Irritation test, a lower mucosal tolerance was also observed for      
SD 25/75 as the mucus production and protein and LDH release after repeated 
administrations were higher in comparison with (SD 25/75)/CaCO3 90/10. However, 
according to the Slug Mucosal Irritation prediction model both formulations were classified 
as moderate membrane irritating and mild to moderate membrane damaging. Hence they are 
not recommended for chronic drug therapies. 
Two modifications of the Slug Mucosal Irritation test were also described in Chapter 4.2, 
which were performed in order to optimise the procedure for screening of formulations 
containing viscosity-enhancing and/or bioadhesive polymers. The results obtained using the 
modified protocols suggested that the present procedure might underestimate the tissue 
damaging potential of these formulations, especially for those test formulations at the 
borderline between a mild and moderate classification. The modified procedure wherein the 
foot mucosa of the slug was carefully cleaned with paper moistened with PBS after the       
30-min contact period with the formulation allowed the best prediction of those test 
substances. Consequently, this procedure will be further optimised and validated. 
 
The stability of the spray-dried Amioca® starch/Carbopol® 974P 25/75 mixture stored during 
9 months at different relative humidities (RH) and temperatures (10% RH – 25°C,            
60% RH –25°C, 75% RH – 40°C) was investigated in Chapter 5. Storage of a spray-dried 
mixture of Amioca® starch and Carbopol® 974P 25/75 at 40°C – 75% RH induced structural 
modifications of the polymers which had an influence on the bioavailability of insulin after 
nasal delivery to rabbits. In order to maintain the powder characteristics obtained 
immediately after spray-drying the mixture should be stored at 25°C and 10 % RH. 
 
In Chapter 6 the efficacy of oxymetazoline HCl formulated in a starch/Carbopol® powder 
formulation was compared to a commercial nasal spray (Nesivine®) in healthy human 
volunteers by measuring the nasal airflow during 8 h after administration and by scoring the 
nasal side effects (nasal obstruction, itching and sneezing) using a visual analogue scale. 
Powder formulations based on neutralised Amioca® starch/Carbopol® 974P 25/75 and non-
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neutralised Amioca® starch/Carbopol® 974P 85/15 were used as carriers for oxymetazoline 
HCl and two systems (Monopowder and Pfeiffer) were used as delivery devices. Nasal 
delivery of the neutralised SD 25/75 powder using the Monopowder device hardly improved 
the nasal airflow, possibly due to an ionic interaction between drug and carrier. In contrast, an 
increase in nasal airflow was seen for the non-neutralised SD 85/15 powder. The delivery 
device had an important influence on the pharmacological response. Spraying SD 85/15 with 
the Pfeiffer device resulted in higher pharmacological effect in healthy volunteers, the 
response being similar to the effect of the Nesivine® spray. However, the onset of action of 
oxymetazoline HCl was not as steep when the powder was administered. Longer 
measurements (> 8 h) are required to verify if a powder formulation based on Amioca® starch 
and Carbopol® 974P induced a longer nasal decongestion compared to the conventional 
sprays. 
Furthermore, the side effects reported following powder administration were possibly related 
to the nasal delivery system: using the Pfeiffer system the nasal side effects were minimal, 
whereas with the Monopowder device stinging and watering eyes were reported immediately 
after administration. Possibly the pressure at which the powder particles are released from the 
device is too high. 
 ___________________________________________________________________________ 
Samenvatting                                                                                                                                                        139                        
Samenvatting 
 
 
 
Aangezien peptiden niet geschikt zijn voor orale toediening, worden ze gewoonlijk 
parenteraal toegediend. Door de nadelen verbonden aan parenterale toediening werden 
alternatieve toedieningsroutes (de buccale, nasale, pulmonale, oculaire, transdermale, rectale 
en vaginale route) onderzocht. In de huidige studie werd de nasale route geselecteerd als 
alternatieve route voor peptidentoediening. Ondanks de voordelen van de nasale 
toedieningsweg, blijft de biologische beschikbaarheid laag. In Hoofdstuk 1 worden de 
barrières voor de nasale absorptie van peptiden besproken. De strategieën die in de literatuur 
beschreven zijn om deze nasale barrières te omzeilen worden eveneens vermeld.  
 
Dit onderzoeksproject focuste zich op poederformulaties die gebruikt werden als drager voor 
de nasale toediening van peptiden, met als doel de nasale biologische beschikbaarheid te 
verbeteren door het verlengen van de verblijftijd van het geneesmiddel in de nasale holte door 
incorporatie van viscositeitsverhogende excipientia in de formulatie. Als drager voor de 
nasale toediening van insuline en zalmcalcitonine (gebruikt als modelpeptiden) werden 
mengsels gebruikt van Drum Dried Waxy Maize zetmeel en Carbopol® 974P                  
(ratio: 95/5, g/g) (DDWM/C 974P 95/5) en van gesproeidroogde Amioca® zetmeel en 
Carbopol® 974P (ratio: 25/75 en 85/15, g/g) (SD 25/75 en SD 85/15) gebruikt. In     
Hoofdstuk 2 werden de karakteristieken van de componenten van de nasale poeders in detail 
beschreven. 
 
In Hoofdstuk 3 werd de invloed van de poeder bulkdensiteit op de nasale biologische 
beschikbaarheid van insuline onderzocht in konijnen aangezien in een voorgaande studie 
aangetoond was dat de poederverneveling bepaald werd door de densiteit van de formulatie. 
De poeder bulkdensiteit van de nasale formulaties werd gewijzigd door het veranderen van de 
fractie aan vaste stof van de dispersie (alvorens te vriesdrogen) en door het veranderen van de 
invriessnelheid tijdens de vriesdroogcyclus. De bulkdensiteit werd hoofdzakelijk bepaald 
door de fractie aan vaste stof van de dispersie: de bulkdensiteit van de poeders nam toe 
wanneer de fractie aan vaste stof in de te vriesdrogen dispersie hoger was. Hoewel, geen 
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invloed van de poeder bulkdensiteit op de nasale biologische beschikbaarheid van insuline 
werd waargenomen in konijnen. 
 
In Hoofdstuk 4 werd aangetoond dat vriesdrogen van waterige dispersies die gesproeidroogd 
Amioca zetmeel/Carbopol 974P (ratio: 25/75) en Ca(OH)2 geneutraliseerd met NaOH 
bevatten, resulteerden in poeders bestaande uit een mengsel van natrium en calcium 
carboxylaat. Het absorptieverhogend vermogen van deze poederformulaties werd in 
Hoofdstuk 4.1 vergeleken met de equivalente poeders die enkel een natrium carboxylaat 
bevatten. 
Een optimale balans tussen natrium en calcium carboxylaat was noodzakelijk om een 
verhoging in absorptie van insuline te bekomen. De hoogste absorptie van insuline werd 
waargenomen voor een ratio 90/10 tussen SD 25/75 en Ca(OH)2, waarbij een biologische 
beschikbaarheid van ± 29 % en 19 %  bekomen werd voor equivalente formulaties met en 
zonder Ca(OH)2. Deze stijging in nasale toediening was mogelijks te wijten aan de hogere 
waterabsorberende capaciteit van de formulatie (verhoging van het paracellulair transport 
door het openen van de tight junctions) en aan de hogere elasticiteit na dispersie van deze 
formulatie in neusvocht. Verder werd na nasale toediening van (SD 25/75)/Ca(OH)2 90/10 of 
(SD 25/75)/CaCO3 90/10 een daling in tmax waargenomen, mogelijks te wijten aan een 
progressieve dissociatie van Ca2+-ionen van het Ca2+-carboxylaat na hydratatie van het 
poeder resulterend in het sluiten van de tight junctions. 
Incorporatie van zalmcalcitonine in de (SD 25/75)/CaCO3 90/10 formulatie resulteerde in een 
vergelijkbare trend: een hogere Cmax maar lagere tmax werd waargenomen in vergelijking met 
de equivalente formulatie zonder CaCO3.  
Het belang van het gebruik van een gesproeidroogd mengsel van zetmeel en Carbopol 974P 
in plaats van een fysisch mengsel werd ook belicht in dit hoofdstuk. Een fysisch mengsel van 
zetmeel en Carbopol induceerde een lagere absorptie van insuline, mogelijks te wijten aan 
zijn lager en trager waterabsorberend vermogen. Een vergelijkbare observatie werd 
waargenomen na toevoeging van Ca(OH)2 aan dit mengsel: Cmax nam toe en tmax daalde in 
vergelijking met het mengsel zonder Ca(OH)2. 
 
Aangezien een verhoogde biologische beschikbaarheid frequent geassocieerd wordt met het 
verbreken van de integriteit van het mucosale epitheel, werd in Hoofdstuk 4.2 onderzocht of 
de verhoogde nasale biologische beschikbaarheid van insuline na toediening van de 
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poederformulatie die (SD 25/75)/CaCO3 90/10 bevatte te wijten was aan mucosale 
beschadiging. De mogelijke toxicologisch effecten na multipele toediening van de poeders 
SD 25/75 en (SD 25/75)/CaCO3 90/10 werden geëvalueerd gebruik makend van een niet-
invasieve spoeltechniek in konijnen en gebruik makend van een mucosale irritatie test op 
slakken. 
Beide poederformulaties induceerden mucosale beschadiging na nasale toediening aan 
konijnen aangezien een verhoogde vrijgave van proteïnen, LDH en ALP vanuit de nasale 
mucosa werd waargenomen na toediening. Een hoger membraanbeschadigend vermogen 
werd waargenomen voor SD 25/75 in vergelijking met (SD 25/75)/CaCO3 90/10. Voor beide 
poederformulaties waren de effecten op het epitheel reversiebel aangezien de concentratie 
aan proteïnen en enzymen daalde binnen de 24 h, terugkerend naar hun basale levels binnen 
de 3 dagen. 
Gebruik makend van de mucosale irritatietest op slakken werd een lagere mucosale tolerantie 
waargenomen voor SD 25/75 aangezien de mucusproductie en de vrijgave van proteïnen en 
LDH na herhaalde toediening hoger was in vergelijking met (SD 25/75)/CaCO3 90/10. 
Hoewel, volgens het predictiemodel van de mucosale irritatietest op slakken werden beide 
formulaties geclassificeerd als matig membraanirriterend en mild tot matig 
membraanbeschadigend. Bijgevolg worden ze niet aanbevolen voor chronische 
geneesmiddeltherapieën. 
Twee modificaties van de mucosale irritatietest op slakken werden ook beschreven in 
Hoofdstuk 4.2. Deze testen werden uitgevoerd met het oog op het optimaliseren van de 
procedure van de screening van formulaties die viscositeitsverhogende en/of bioadhesieve 
polymeren bevatten. De resultaten verkregen met de gewijzigde procedures gaven een 
indicatie dat de huidige procedure het weefselbeschadigend vermogen van deze formulaties 
zou onderschatten, vooral voor die testformulaties die zich bevinden op de grens van de 
milde en matige klasse. De gemodificeerde procedure waarin de voetmucosa van de slak 
voorzichtig werd schoongemaakt met PBS bevochtigd papier na de contactperiode van        
30 min met de formulatie, liet de beste predictie toe van deze testsubstanties. Bijgevolg zal 
deze procedure verder geoptimaliseerd en gevalideerd worden. 
 
De stabiliteit van het gesproeidroogde Amioca® zetmeel/Carbopol® 974P 25/75 mengsel 
bewaard gedurende 9 maanden bij verschillende relatieve vochtigheden (RV) en 
temperaturen (10% RV – 25°C, 60% RV – 25°C, 75% RV – 40°C) werd onderzocht in 
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Hoofdstuk 5. Bewaring van een gesproeidroogd mengsel van Amioca® zetmeel en  
Carbopol® 974P 25/75 bij 40°C – 75% RV induceerde structurele wijzigingen van het 
polymeer die een invloed hadden op de biologische beschikbaarheid van insuline na nasale 
toediening aan konijnen. Met het oog op het behouden van de karakteristieken van het poeder 
bekomen onmiddellijk na sproeidrogen moet het mengsel bewaard worden bij 25°C en 10 % 
RV. 
 
In Hoofdstuk 6 werd de effectiviteit van oxymetazoline HCl geformuleerd in een 
poederformulatie opgebouwd uit zetmeel/Carbopol® vergeleken met een commerciële nasale 
spray (Nesivine®) in gezonde vrijwilligers door het meten van de luchtstroom doorheen de 
neusholte gedurende 8 h na toediening en door het scoren van de nasale bijwerkingen (nasale 
obstructie, jeuk en niezen) gebruik makend van een visueel analoge schaal. 
Poederformulaties gebaseerd op geneutraliseerd Amioca® zetmeel/Carbopol® 974P 25/75 en 
op niet-geneutraliseerd Amioca® zetmeel/Carbopol® 974P 85/15 werden gebruikt als drager 
voor oxymetazoline HCl en twee systemen (Monopowder en Pfeiffer) werden gebruikt als 
toedieningsysteem. Nasale toediening van het geneutraliseerde SD 25/75 poeder gebruik 
makend van het Monopowder toedieningsysteem verhoogde de nasale luchtstroom doorheen 
de neusholte nauwelijks, mogelijks te wijten aan een ionische interactie tussen het 
geneesmiddel en de drager. Voor het niet-geneutraliseerde SD 85/15 poeder werd 
daarentegen een verhoogde nasale luchtstroom waargenomen. Het toedieningsysteem had een 
belangrijke invloed op de farmacologische respons. Verstuiving van SD 85/15 met het Pfeifer 
toedieningsysteem resulteerde in een hoger farmacologisch effect in gezonde vrijwilligers, 
een respons die vergelijkbaar was met het effect van de Nesivine® spray, hoewel de werking 
van oxymetazoline HCl niet zo snel was wanneer het poeder werd toegediend. Langere 
metingen (> 8 u) waren nodig om te verifiëren of een poederformulatie gebaseerd op 
Amioca® zetmeel en Carbopol® 974P een langere nasale congestie induceerden in 
vergelijking met de conventionele sprays. 
Verder waren de gerapporteerde bijwerkingen na toediening van de poederformulaties 
mogelijks te wijten aan het nasale toedieningsysteem: gebruik makend van het Pfeiffer 
systeem waren de bijwerkingen minimaal terwijl met het Monopowder systeem onmiddellijk 
na toediening prikkelende en tranende ogen werden gerapporteerd. De druk waaronder de 
poederpartikels worden vrijgesteld vanuit het toedieningsysteem was mogelijks te hoog. 
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Résumé 
 
 
 
Puisque les peptides ne peuvent pas être administrés par voie orale, ils sont généralement 
délivrés par voie parentérale. En raison des désavantages associés à cette administration 
parentérale, des voies d’administration alternatives (les voies buccale, nasale, pulmonaire, 
oculaire, transdermique, rectale et vaginale) ont été examinées. Dans cette étude la voie 
nasale a été sélectionnée comme voie alternative pour l’administration des peptides. Malgré 
les avantages de cette voie d’administration, la biodisponibilité nasale reste faible. Dans le 
premier Chapitre les barrières contre l’absorption nasale des peptides sont décrites. Les 
stratégies décrites dans la littérature pour éviter ces barrières nasales, sont aussi mentionnées. 
 
Ce projet de recherche s’est fixé sur les formulations de poudre qui ont été utilisées pour 
l’administration nasale des peptides, avec comme but d’améliorer la biodisponibilité en 
prolongeant le temps de résidence de la formulation dans la cavité nasale par l’incorporation 
de constituants visqueux. Pour l’administration nasale d’insuline et de calcitonine de saumon 
(utilisées comme modèles de peptides) des poudres contenant des mélanges de ‘Drum Dried 
Waxy Maize starch’ et de Carbopol® 974P (ratio: 95/5, m/m) (DDWM/C 974P 95/5) et des 
mélanges obtenus par atomisation d’un amidon Amioca® et de Carbopol® 974P (ratio: 25/75 
et 85/15, m/m) (SD 25/75 et SD 85/15) ont été employées. Dans le deuxième Chapitre les 
caractéristiques des constituants des poudres nasales ont été décrites en détail. 
 
Dans le troisième Chapitre l’influence de la densité vrac de la formulation sur la 
biodisponibilité nasale d’insuline a été examinée chez le lapin puisqu’une étude précédente a 
montré que la densité vrac de la poudre déterminait le processus de nébulisation de la 
formulation. La densité vrac des poudres a été modifiée en changeant à la fois la fraction de 
matière solide de la dispersion (avant lyophilisation) et la vitesse de congélation pendant le 
cycle de lyophilisation. La densité vrac a été principalement influencée par la fraction de 
matière solide de la dispersion: la densité vrac des poudres a augmenté quand la fraction de 
matière solide de la dispersion était élevée. Pourtant, aucune influence de la densité vrac de la 
poudre sur la biodisponibilité nasale d’insuline n’a été constatée chez le lapin. 
 ___________________________________________________________________________ 
Résumé                                                                                                                                                                 144 
Dans le quatrième Chapitre il a été établi que la lyophilisation des dispersions aqueuses 
contenant un mélange d’un amidon Amioca® et de Carbopol® 974P (atomisé) (ratio: 25/75) et 
de Ca(OH)2 neutralisé avec NaOH, a conduit à l’obtention de poudres contenant un mélange 
de carboxylates de sodium et de calcium. La capacité d’augmenter l’absorption d’insuline de 
ces poudres a été comparée avec des poudres équivalentes ne contenant que du carboxylate 
de sodium (Chapitre 4.1).  
Une balance optimale entre le carboxylate de sodium et de calcium était nécessaire pour 
obtenir une augmentation de l’absorption d’insuline. L’absorption d’insuline la plus élevée a 
été observée pour le ratio de 90/10 entre SD 25/75 et Ca(OH)2, permettant d’atteindre une 
biodisponibilité de ± 29 % et de 19 % pour les formulations équivalentes avec et sans 
Ca(OH)2. Cette augmentation était probablement due à la plus grande capacité d’absorption 
d’eau de la formulation (augmentation du transport paracellulaire par l’ouverture des 
jonctions intercellulaires) et à la plus grande élasticité après la dispersion de cette formulation 
dans le liquide nasal. Ensuite, après l’administration nasale de (SD 25/75)/Ca(OH)2 90/10 ou 
de (SD 25/75)/CaCO3 90/10 une baisse du tmax a été constatée, probablement due à une 
dissociation progressive d’ions de calcium du carboxylate de calcium après l’hydratation de 
la formulation résultant dans la fermeture des jonctions intercellulaires. 
L’incorporation de calcitonine de saumon dans la formulation (SD 25/75)/CaCO3 90/10 a 
conduit à une tendance comparable: Cmax était augmentée et tmax était descendu en 
comparaison avec la formulation équivalente sans CaCO3. 
L’importance de l’usage d’un mélange obtenu par atomisation d’un amidon Amioca® et de 
Carbopol® 974P au lieu d’un mélange physique a aussi été montrée dans ce chapitre. Un 
mélange physique d’un amidon Amioca® et de Carbopol® 974P a induit une absorption 
d’insuline plus faible probablement due à sa capacité plus basse et plus lente d’absorption 
d’eau. Une observation comparable a été constatée après l’addition de Ca(OH)2 à ce mélange: 
Cmax augmentait et tmax baissait en comparaison avec la formulation équivalente sans 
Ca(OH)2. 
 
Vu qu’une biodisponibilité augmentée est fréquemment associée à la rupture de l’intégrité de 
l’épithélium mucosal, dans le Chapitre 4.2 il a été vérifié si l’augmentation de la 
biodisponibilité nasale d’insuline après l’administration de la formulation                        
(SD 25/75)/CaCO3 90/10 était due aux dommages de la muqueuse. Les effets toxicologiques 
possibles ont été évalués après l’administration multiple des formulations de SD 25/75 et de 
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(SD 25/75)/CaCO3 90/10) en utilisant une méthode de rinçage non-invasive chez les lapins et 
en utilisant un test d’irritation mucosale sur limaces. 
Les deux formulations ont induit un dommage mucosal après l’administration nasale aux 
lapins vu l’augmentation de la sécrétion des protéines, LDH et ALP après l’administration. 
La formulation SD 25/75 a endommagé davantage les membranes que SD 25/75)/CaCO3 
90/10. Pour les deux poudres les effets sur l’épithélium étaient réversibles, vu que la 
concentration des protéines et d’enzymes a baissé dans les 24 h, revenant à leur niveau basal 
en trois jours.  
En utilisant le test d’irritation mucosale sur limaces, une tolérance mucosale plus faible a été 
constatée pour SD 25/75 vu que la production de mucus et la sécrétion des protéines et 
d’LDH après administration répétée étaient plus élevées en comparaison de                        
(SD 25/75)/CaCO3 90/10. Pourtant, selon le modèle de prédiction du test d’irritation 
mucosale sur limaces, les deux formulations ont été classées comme modérément irritantes et 
endommageant légèrement à modérément les membranes. Par conséquent ces formulations 
ne sont pas recommandées pour l’administration chronique. 
Deux modifications du test d’irritation mucosale sur limaces ont été décrites dans le    
Chapitre 4.2 qui était effectuées pour optimaliser la procédure de screening des formulations 
contenant des polymères visqueux et/ou bio-adhésifs. Les résultats obtenus avec les 
protocoles modifiés ont indiqué que la procédure actuelle sous-estimait le dommage 
histologique induit par ces formulations, surtout pour celles qui se trouvent dans la 
classification à la limite entre dommage léger et modéré. La procédure modifiée où la 
muqueuse des limaces a été nettoyée prudemment avec du papier humecté de PBS après une 
période de contact de 30 min avec la formulation, a permis la meilleure prédiction du 
comportement de ces substances. Ainsi la procédure sera optimalisée et validée. 
 
La stabilité du mélange obtenu par atomisation d’un amidon Amioca® et de Carbopol® 974P 
25/75 conservé pendant 9 mois à des humidités relatives (RH) et des températures différentes 
(10% RH – 25°C, 60% RH –25°C, 75% RH – 40°C), a été examinée dans le            
cinquième Chapitre. La conservation d’Amioca®/Carbopol® 974P 25/75 à 75% RH – 40°C a 
induit des modifications structurelles des polymères qui avaient une influence sur la 
biodisponibilité de l’insuline après administration nasale aux lapins. En vue de conserver les 
caractéristiques de la poudre obtenues immédiatement après atomisation, le mélange doit être 
conservé à 25°C et 10% RH. 
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Dans le sixième Chapitre, l’efficacité de l’oxymétazoline HCl formulée dans une poudre 
composée d’ amidon/Carbopol® a été comparée à un nébuliseur commercial (Nesivine®) chez 
des volontaires en bonne santé en mesurant le courant d’air dans le nez pendant 8 h après 
l’administration et en quantifiant les effets indésirables (l’obstruction nasale, le prurit et 
l’éternuement). Oxymétazoline HCl a été incorporée dans des formulations à base 
d’Amioca/Carbopol 974P 25/75 neutralisé et d’Amioca/Carbopol 974P 85/15 non-
neutralisé et deux systèmes (Monopowder et Pfeiffer) ont été employés comme système 
d’administration.  
L’administration nasale de la poudre SD 25/75 (neutralisé) utilisant le système de 
Monopowder n’a presque pas augmenté le courant d’air à travers la cavité nasale, 
probablement à cause d’une interaction ionique entre oxymétazoline HCl et Carbopol 974P. 
Par contre, pour la poudre SD 85/15 (non-neutralisé) une augmentation du courant d’air nasal 
à été constatée. Le système de délivrance avait une influence importante sur l’effet 
pharmacologique. L’administration de SD 85/15 avec le système de Pfeiffer a induit un effet 
pharmacologique plus élevé qui était comparable à l’effet du nébuliseur Nesivine®, bien que 
l’activité de l’oxymétazoline HCl soit moins rapide lors de l’administration de la poudre. Des 
mesures de plus longue durée (> 8 h) étaient nécessaires pour vérifier si la formulation à base 
d’amidon Amioca et de Carbopol® 974P provoquait une congestion nasale plus longue par 
rapport aux nébuliseurs conventionnels.  
Ensuite, des effets indésirables rapportés après l’administration des poudres nasales étaient 
probablement dus au système de délivrance: en utilisant le système de Pfeiffer les effets 
indésirables étaient minimaux, tandis qu’avec le système de Monopowder, immédiatement 
après l’administration, on observe un larmoiement et une irritation oculaire. La pression sous 
laquelle les particules de poudre ont été libérées du système de délivrance est probablement 
trop élevée.  
